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1 Introduction and aim of this study 
 
Animal models provide uniform experimental material and allow extensive testing of 
potential therapies (medicinal and operative therapies such as prosthetic devices). 
The osteoporosis research in particular is one of the most common areas where 
animal models are necessary. The FDA, Food and Drug Administration, recommends 
two preclinical animal models, the ovariectomised (OVX) rat and a second non-
rodent model, to demonstrate the efficiency and safety of new agents for the therapy 
of different diseases such as osteoporosis (Thompson et al., 1995). 
The goal of an animal model is to replicate the human condition as closely as 
possible. This has proved to be difficult (Turner et al., 2001). Bellino, (2000) 
described the usefulness of pig models for humans and the limitations due to the lack 
of information available on the ovariectomised mature pig in cardiovascular studies, 
bone studies and sensitivity of bone density to dietary calcium. 
Pigs can therefore be considered as appropriate animal models for the use in studies 
on osteoporosis. The most common form of osteoporosis is the post-menopausal 
osteoporosis. This condition can be simulated in animals by means of 
ovariohysterectomy or ovariectomy. The operation should cause an increased bone 
turnover, which results in a change in bone structure, due to estrogen deficiency, 
similar to the structure changes of human bones during menopause. Minipigs are not 
only useful as animal models for studying osteoporosis, but are also useful for the 
study of other diseases that influence bone metabolism. Bone metabolism, estrus 
cycle and gastrointestinal functions of the swine are positive features concerning 
them as an animal model (Turner, 2001). 
Throughout adult life the skeleton undergoes continuous renewing (bone 
remodelling). Bone remodelling is often referred to as coupling, which is a link 
between bone formation and bone resorption. Biochemical markers of bone formation 
and resorption allow the assessment of bone turnover. These may assist in the study 
of pathophysiological growth of the skeleton and in the study of diseases such as 
osteoporosis, which are characterised by disorders in bone mass and may have 
disturbances in both formation and resorption. These markers are determined in 
serum or urine and can be influenced by a number of factors such as age, cycle 
stage, weight loss, nutrition, seasonal and day- to -day changes. 
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These factors could cause misinterpretation of bone marker activity which leads to 
incorrect conclusions with reference to bone metabolism. 
The objective of this study was to examine the dependence of bone marker activity 
(osteocalcin, a bone formation marker and crosslaps, a bone resorption marker) on 
the estrous cycle of the miniature pig. Studies in human medicine have confirmed 
bone marker fluctuations during the menstrual cycle, where hormone levels vary. 
These fluctuations are also possible in the animal model minipig. 
Furthermore the behaviour of biochemical markers, osteocalcin and crosslaps were 
examined at and after ovariohysterectomy to determine the effect of OVX 
(ovariohysterectomy) on these specific bone markers in the miniature pig.  The 
present study also determined the influence of calcium ration in feed on bone 
metabolism before and after castration. 
To accomplish these objectives a pilot study is performed with 16 Dresdner minipigs. 
These are divided into three groups; control, OVX (ovariohysterectomised) group and 
a second control group. The control group receives a 0.99% calcium ration, whereas 
the OVX and second control group receive a 0.7% calcium ration. All animals are to 
be synchronised at the start of the study. The study consists of two periods; pre-
castration and post-castration. The OVX group will be ovariohysterectomised at the 
beginning of the post-castration period. Blood samples will be extracted in particular 
intervals pre-castration and post-castration. Formation marker osteocalcin, resorption 
marker crosslaps, progesterone and estradiol concentrations are to be determined 
from collected serum samples. 
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2 Literature 
 
2.1. Definition 
  
In 1993, the Consensus Development Conference reached the currently acceptable 
definition of osteoporosis: a systemic skeletal disorder characterised by low bone 
mass and micro-architectural deterioration of bone tissue, thus causing an increase 
in bone fragility and susceptibility to fracture risk (Consensus Development 
Conference, 1993). Characteristic for this disease are low- traumatic fractures.  The 
disease has become a major public health problem. The costs for fracture treatment 
are staggering and many patients everyday life are affected seriously. 
In 2000, this definition was modified to osteoporosis being defined as a skeletal 
disorder characterised by compromised bone strength that predisposes to an 
increased fracture risk. (NIH Consensus Development Panel on Osteoporosis 
Prevention and Therapy, 2001). 
In addition to this definition, two main features to bone strength were added:  
Bone density and bone quality. Bone density is expressed in grams of mineral per 
area volume. Bone quality refers to architecture, turnover, damage on bone 
(fractures) and mineralization. 
 
2.2 World Health Organisation (WHO) definition of osteoporosis 
 
Bone density correlates well with bone strength (NIH Consensus Development Panel 
on Osteoporosis Prevention and Therapy, 2001). The WHO defines osteoporosis on 
the basis of bone mineral density (BMD). It was assumed that the relative risk for 
fracture must be lowest when the BMD is highest (WHO, 1994). The lowest fracture 
risk would be between the ages of 20 and 40 in healthy people. The fracture risk in 
this group of people was set at 1.0. It was agreed to that the relative fracture risk 
doubles for each standard deviation (SD)   decrement in BMD.  
With this concept in mind, the WHO developed the following definitions: 
 
Normal is defined as BMD less than, or equal to, 1.0 SD below the mean for peak 
bone mass. 
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Low bone mass (osteopenia) is defined as more than one, but less than, or equal to, 
2.5 SD below the mean. 
. 
Osteoporosis is defined as more than 2.5 SD below the mean. 
 
These definitions are often related to in T-scores. T-score refers to amount of 
standard deviations of the mean of healthy persons between the age of 25 and 40 
years. Z-scores are scores, which are obtained from the mean bone density of 
persons in a comparative population. 
 
Table 1: WHO definition of osteoporosis, based on bone mineral density and T-scores 
using dual x-ray absorptiomerty of the proximal femur and spine (WHO, 1994) 
 
Normal T-score > -1 
Osteopenia T-score < -1 > -2.5 
Osteoporosis T-score<  -2.5 
Severe osteoporosis T-score<  -2.5 and osteoporotic 
fractures 
 
 
 
 
2.2.1 Post- menopausal osteoporosis 
 
Osteoporosis represents a bone mass loss unassociated with other chronic diseases 
and is related to an estrogen deficiency (Type I) and aging (Type II) (Gambacciani 
and Ciaponi, 2000; Riggs and Melton, 1986; Melton and Riggs, 1988). At the age of 
45-50 years woman reach the stage were the ovieran function ceases. This causes a 
decline in the estrogen concentrations in the body. In women the most frequent type 
of osteoporosis is due to estrogen deprivation after menopause (Consensus 
Development Conference, 1993).  
Many studies have shown that estrogen intervention reduces the rate of bone loss 
among postmenopausal women (Ettinger et al., 1985; Lindsey, 1989; Ham and 
Carlson, 2004; Qi et al., 2004; Carlsten, 2005; Biglia et al., 2005). Ettinger et al. 
(1985) did a retrospective study comparing subjects using estrogen replacement 
Literature 
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therapy and matched controls. Quantitive bone mineral assessments were obtained. 
Estrogen users showed significantly greater bone mineral. Lindsay, (1989) states that 
bone mass in females is fairly constant up until the 5th decade and then decline at all 
skeletal sites. Estrogen therapy prevents bone loss that follows menopause. Ham 
and Carlson, (2004) measured the trabecular bone volume in ovariectomised 
untreated, estrogen treated and soy phytestrogens treated monkeys. Estrogen 
decreased the bone turnover indices. Soy phytestrogens were protective against loss 
in bone volume. Some studies do not only measure the changes in bone, but also the 
changes in bone markers due to estrogen therapy. Watts et al. (2000) determined the 
relationships among bone mineral density changes and bone marker changes in 
post-menopausal women receiving estrogen and found that bone mineral density 
changes correlate significantly with bone marker changes at 6 months esterified 
estrogen therapy. Warming et al. (2004) evaluated the effectiveness of 17β-estradiol 
and drospirenone combination for the prevention of post-menopausal osteoporosis. 
Bone mineral density increased at lumber spine hip, and total body, while bone 
markers decreased (osteocalcin, serum bone alkaline phosphatase, serum Crosslaps 
and urinary Crosslaps) from base line.   
Type II Osteoporosis is a result of aging. This affects all skeletal sites, both cortical 
and cancellous bone. It is a result of senile decline in bone mass (Riggs and Melton, 
1986; Melton and Riggs, 1988).   
Type III Osteoporosis is an idiopathic osteoporosis, which affects pre-menopausal 
women as well as middle aged men (Riggs and Melton, 1986; Melton and Riggs, 
1988).   
 
In postmenopausal women the changes in cancellous bone structure are considered 
to be a consequence of focal imbalances in remodelling processes. This results in 
perforation and removal of trabecular structures (Boyce et al., 1995). Through the 
loss in structure the bone is less resistant to pressure and stress, causing fracturing. 
Three consequences of estrogen deficiency are discussed (Parfitt, 1987). Firstly, the 
osteoclast activity is elevated, which results in large lacuna due to resorption. 
Secondly the interplay of bone resorption and formation activity (coupling) is 
disturbed (Ivey and Baylink, 1981). Thirdly, histomorphometric analyses have given 
reason to assume that the osteoblast units in bone are insufficient (Lips et al., 1978). 
Estrogen deficiency causes bone loss. Kameda et al. (1997) was able to show that 
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17 β-estradiol directly inhibits osteoclastic bone resorption through apoptosis of 
osteoclasts. An estrogen deficiency would cause an increased generation and 
activity of osteoclasts, which perforate bone trabeculae, thus causing strength loss 
and increased fracture risk (Hughes et al., 1996). Hughes et al. (1996) also showed 
that estrogen causes apoptosis in osteoclasts. In the presence of estrogen, 
osteoblasts produce transforming growth factor-beta 1 (TGF-beta). Anti TGF-beta 
antibody inhibited TGF-beta and estrogen. This may indicate that TGF-beta might 
mediate osteoclast apoptosis. Marie et al. (2000) states that soluble factors, which 
include bone morphometric proteins, leptin and TGF-beta, can modulate 
differentiation of mesenchymal stem cells to osteoblasts, chondrocytes or adipocytes. 
Interleukin 1 is another factor that is of particular interest in the pathogenesis of 
osteoporosis. This is a protein, which is known to stimulate bone resorption and 
perhaps formation. Pacifici et al. (1987) found that monocytes in osteoporotic patients 
produced more interleukin-1 than subjects in the control group.  
Interleukin-1 released from peripheral blood monocytes, appeared to reflect bone 
formation.  
Insulin-like growth-factor (IGF-I) is a regulator of osteoblast activity. A binding protein, 
insulin-like growth factor–binding protein-4 (IGFBP-4) suppresses biological activity 
of IGF-I. Parathyroid hormone (PTH) enhances binding activity of IGFBP-4. This is 
abolished through 17β-estradiol. Kudo et al. (1996) found that IGFBP-4 protease 
activity, in SaOS-2 cells, which is responsible for cleavage of IGFBP-4, was 
suppressed in parathyroid hormone-treated (PTH) cells. This suppression was 
reversed by adding 17β-estradiol. Kudo et al. (1996) explain that the inhibitory effect 
of PTH on osteoblastic activity occurs by inhibiting PTH-induced suppression of 
IGFBP-4 protease activity.  
O´Shaughnessy et al. (2000) found that nitric oxide plays an important role in the 
stimulation of osteoblast activity through estrogen. Findings indicated that 17β-
estradiol modulates osteoblast function by nitric oxide-dependant mechanisms. 
 
A large number of people are affected by this disease. Osteoporosis causes fractures 
in more than a million Americans each year (McGarry and Kiel, 2000). Over the past 
years life expectancy has increased. Most women spend more than one third of their 
lives after menopause and therefore the consequences of estrogen deficiency have 
become a major problem for health providers (Gambacciani and Ciaponi, 2000).  
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This disease is responsible for considerable morbidity as well as deaths in many 
older women (Gambacciani and Ciaponi, 2000).  
During normal aging, the decrease in trabecular bone strength is much more 
pronounced than the decline in apparent density (Mosekilde et al., 2000). With age 
the trabecular bone declines with a factor of four, density however declines with the 
factor of two. Certain factors such as the loss of connectivity in horizontal struts of 
trabecular network, due to osteoclastic perforations, micro fractures, change in bone 
mineral quality, influence strength and density, but it is not known how the 
relationship between the two is influenced (Mosekilde et al., 2000). Furthermore the 
interplay corticalis, trabecular network, effect of bone marrow as a hydraulic and the 
effect of soft tissues such as cartilage, connective tissue and muscle on these factors 
must be investigated further (Mosekilde et al., 2000). 
 
Due to the complications occurring during the progression of the disease, high costs 
arise. In Europe, in 2000, the number of osteoporotic fractures was estimated at 3.9 
million, of which 0.89 million were hip fractures (179000 hip fractures in men and 
711000 in women). The total direct costs were estimated at €31.7 billion, which were 
expected to increase to €76.7 billion in 2050 based on the expected changes in the 
demography of Europe (Kanis and Johnell, 2005). It is estimated that in Europe, 179 
000 men and 611 000 women will suffer a hip fracture each year and that the cost of 
all osteoporotic fractures in Europe is provisionally €25 billion (Melton et al., 2003). A 
study in Switzerland showed that the annual costs of hospitalisations (duration of 
hospital visit), for osteoporotic fractures, were greater than those for myocardial 
infarction, stroke and breast cancer, and only slightly lower than those for chronic 
obstructive pulmonary diseases. For women with osteoporosis the costs for 
hospitalisation were higher than for the other mentioned diseases (Lippuner et al., 
1997). In Denmark, the estimated prevalence of osteoporosis in persons aged 50 
years or more is 40.8% among women and 17.7% among men (Vestergaard et al., 
2005).
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2.2.2 Secondary osteoporosis 
  
The National Institute of Health Osteoporosis and Related Bone Diseases- National 
Reference Centre (NIH ORBD-NRC, 2001) defines secondary osteoporosis as 
osteoporosis caused by certain medical conditions or treatments that interfere with 
the attainment of peak bone mass and / or precipitate bone loss. Cushing’s disease 
causes the body to produce excessive amounts of glucocorticoids, causing obesity, 
muscular wasting and accelerated bone loss. Effective agents that control 
inflammatory diseases, such as corticosteroids can cause osteoporosis (Sambrook 
and Lane, 2001). Glucocorticosteroids are commonly prescribed for treating a variety 
of inflammatory and allergic conditions, such as asthma, rheumatoid arthritis and 
inflammatory bowl disease. This can cause one of the most common forms of drug 
induced osteoporosis. Bone loss tends to be greater in individuals using oral forms of 
medication.  
Glucocorticoids exert their negative effects on bone through mechanisms that are not 
yet completely elucidated (Minetto et al., 2004). An indirect mechanism leading to a 
decrease in bone mass is the glucocorticoid-induced impairment of gonadal steroid 
synthesis (Boscaro et al., 2001), which counteracts bone resorption (Canalis, 1996). 
The loss of muscle mass and strength in patients with Cushing’s Syndrome and 
patients that are treated with exogenous corticosteroids, may contribute to bone loss 
due to the decrease in tropic action of the muscle contraction on the bone (Lane and 
Lukert, 1998; Frost, 1987). Corticosteroids have an inhibitory effect on osteoblasts 
and the differentiation on osteoblast precursor cells. They also decrease the mRNA 
levels that code osteoblast products such as osteocalcin (Morrison et al., 1989). 
Glucocorticoid receptors have been identified in cells that reside in the bone 
microenvironment (Peck, 1984). These cells are able to produce and release 
cytokines and growth factors that influence bone turnover (Angeli et al., 2002; Kristo 
et al., 2002). Glucocorticoids can promote osteoclastgenesis by inhibiting 
osteoprotegerin (OPG) and enhancing RANK-L production by stromal cells (Hofbauer 
et al., 1999).  
Other major effects of glucocorticosteroids are the decrease of intestinal calcium 
absorption and an increase of urinary calcium and phosphor concentrations (Klein et 
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al., 1977; Hahn et al., 1981; Morris et al., 1990; Cosman et al., 1994). This leads to a 
secondary hyperparathyroidism and therefore an increase in bone absorption.  
  
Adequate thyroid hormone levels are essential for normal bone remodelling. Elevated 
levels of these hormones, also known as thyrotoxicosis, have been linked to bone 
loss. Thyrotoxicosis can occur naturally from an overproduction by the thyroid gland 
and can also occur with extensive amounts of thyroid replacement (e.g. treating 
hypothyroidism). Thyroid hormone has an effect on osteoblasts via its specific 
nuclear receptor and thereby stimulates bone resorption (Britto et al., 1992; Kim et 
al., 1999; Allain and McGregor, 1993). The activity of osteoblasts and osteoclasts are 
both increased, whereas the osteoclast activity predominates, resulting in bone loss. 
Hyperthyroidism is thus one of the major causes of secondary osteoporosis (Riggs 
and Melton, 1986). The increased entry of calcium from the bone into the blood (due 
to increase of bone resorption) suppresses parathyroid hormone (PTH) secretion 
from the parathyroid gland. This results in a suppression of PTH-induced vitamin D 
activation in the kidneys, causing a decrease in intestinal calcium absorption and an 
increase in urinary calcium excretion, resulting in a calcium imbalance. This may 
accelerate bone loss in hyperthyroidism further (Shafer and Gregory, 1972). 
Gonadotropin-releasing hormone agonist administration can cause an increase in 
bone turnover, due to estrogen deficiency. Stroup et al. (2001) treated cynomolus 
monkeys with gonadotropin-releasing hormone agonists, and found that bone 
turnover increased as early as 4 weeks after administration. Bone turnover returned 
to control levels in two weeks after the administration of estrogen. Medical castration, 
using gonadottropin-releasing hormone agonists, is widely accepted as androgen 
deprivation therapy for prostrate cancer. Miyaji et al. (2004) studied the effects of 
gonadottropin-releasing hormone agonists on bone metabolism markers and bone 
mineral density in patients with prostate cancer. A decrease in bone mineral density 
was observed. A functional coupling of bone resorption and bone formation markers 
suggested that gonadotropin-releasing hormone agonists stimulates bone formation 
to compensate lower bone mass.  
Adults taking antiepileptic drugs have an augmented risk for osteopenia and 
osteoporosis. This is due to the abnormalities of bone metabolism associated with 
antiepileptic drugs. The hepatic enzyme-inducing antiepileptic drugs, phenytoin, 
phenobarbital and primidone have clear association with a decrease in bone mineral 
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density (Pack and Morrel, 2004). The cytochrome P450 system is induced through 
these medications, causing an increased conversion of vitamin D into polar inactive 
metabolites in liver microsomes, causing a reduced bioavailability of vitamin D 
(Gough et al., 1986; Perucca, 1987). This causes a decrease in intestinal calcium 
absorption, resulting in hypocalcaemia and an increase in circulating parathyroid 
hormone. Parathyroid hormone mobilizes calcium stores and subsequent bone 
turnover (Richens and Rowe, 1970; Hahn et al., 1972; Bouillon et al., 1975; Gough et 
al., 1986; Stamp et al., 1972; Weinstein et al., 1984). 
Rheumatoid arthritis is a systemic autoimmune inflammatory disease that causes 
osteoporosis (Inaba, 2004). This is associated with three types of bone loss: local 
subchondral and joint margin bone erosion, paraarticular osteoporosis and 
generalised osteoporosis (Deodhar and Woolf, 1996). Recently it has been reported 
that serum TNF-α has a suppressive effect on bone formation. This is increased in 
rheumatoid arthritis patients. TNF- α may have an important role in the development 
of osteoblast dysfunction in these patients (Inaba, 2004). Major factors affecting bone 
loss in rheumatoid arthritis are age, menopausal states, impairment of activity of daily 
living (Inaba, 2004). In addition, treatment of rheumatoid arthritis with drugs such as 
glucocorticoid and methotrexate (Buckley et al., 1997) and malnutrition (Inaba et al., 
2000) could have harmful effects on bone metabolism. 
Bone metabolism is also affected in anorexia nervosa, due to multiple hormonal 
endocrine and nutritional factors (Munoz and Argente, 2002). Due to amenorrhea in 
this condition, estrogen deficiency has been described as the main source for bone 
loss. The mechanisms underlying the estrogen deficiency are not completely 
understood (Grinspoon et al., 2000). These are only few of the factors that may 
cause secondary osteoporosis.  
In table 2 varies other etiological reasons for the occurrences of secondary 
osteoporosis are listed. 
Other reasons for weak bones may also be smoking, geographical location or genetic 
inheritance. The cessation of smoking seemed to decrease fracture risk. These 
findings varied geographically (Vestergaard and Mosekilde 2003). Akhter et al. 
(2005) studied the influence of smoking on biomechanical properties of bone in 
female mice and found that the ultimate load and stiffness of the femoral neck was 
lower in the smoke exposed mice. Micro-computed tomographic scanning of the 
distal femoral bone volume/total volume and trabecular thickness showed decreased 
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trends in the smoke exposed group. Mueller and Cievro, (1998) state that smoking 
has numerous health risks for women, one which includes ovulatory dysfunction and 
early menopause. Smoking is directly toxic to the ova and it decreases the estrogen 
secretion (Shulman et al., 1990). Cesar-Neto et al. (2003) found that tobacco smoke 
had more influence on bone implant contact (in terms of bone/implant contact area) 
than nicotine treatment alone in the tibiae of adult Winsar rats. This suggests that 
tobacco smoke constituents other than nicotine may be responsible for compromised 
biochemical properties of smoker skeleton.  
Some studies confirm that osteoporosis is a disease that is inherited. Carbonell Sala 
et al. (2005) state that it has a polygenetic pattern of inheritance that complicates the 
identification of genes causing osteoporosis (cytokines, calcitropic hormones, sex 
hormone pathway synthesis, bone matrix synthesis genes involved in estrogenic 
metabolism and LDL receptor related protein 5 gene). It is possible to identify 
associations between candidate gene polymorphisms and disease phenotype in 
population based and case-control studies. Bone density is an important parameter 
that is used to detect osteoporotic fracture risk. It is confounded by environmental 
influences and polygenic inheritance (Campbell et al., 2003). Li et al. (2004) did a 
study to determine the heritability of low bone mineral density (BMD), at the hip in 
Ashkenazi Jewish families and found a significant genetic determination in decreased 
BMD at the femoral neck of these people. Diez et al. (1989) conclude that fractures in 
the proximal femur due to osteoporosis are common processes in the Mediterranean 
areas. These reflect the impact of the environment. The Mediterranean areas, 
however, have a lower incidence compared to the geographical areas in the north. 
This could be due to the influences of climate and different ethnic groups.  
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Table 2: Etiology of secondary osteoporosis (Inaba et al., 2004) 
 
Endocrine/ metabolic diseases 
Hyperparathyroidism (primary, secondary) 
Thyrotoxicosis 
Cushing syndrome 
Hypogonadism 
Diabetes mellitus 
Pregnancy 
Anorexia nervosa 
 
Inflammatory diseases 
Rheumatoid arthritis 
Ankylosing spondylitis 
 
Functional 
Immobilization/weightlessness 
Chronic obstructive lung diseases 
Postgastrectomy 
Hepatic disease (particularly primary bilary cirrhosis) 
Alcohol abuse 
Following organ transplantation 
 
Haematopoietic 
Multiple myeloma 
Lymphoma/Leucemia 
Mastocytosis 
 
Congenital 
Osteogenesis imperfecta 
Menkes syndrome 
Ehlers-Donlos syndrome 
Homocysteinuria 
Marfan´s syndrome 
 
Drugs 
Corticosteroid 
Thyrotoxine 
Anticonvulsants (barbiturates, phenytion) 
Anticoagulants (heparin, cumarin), Antimetabolites (metotrexate, cyclosporine) 
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2.3 Osteoporosis imaging 
 
Osteoporotic fractures may be prevented if the disease is diagnosed soon enough. 
There are various techniques that enable assessment of osteoporotic bones. In 
human medicine certain bones have a predisposition to fracture. Important 
osteoporotic fractures are hip, vertebral and forearm fractures (Lau, 2001).The 
fracture incidence increases with age in both men and women, but remains higher in 
women throughout life (Lau, 2001). Conventional radiographs are not suited to 
diagnose early osteoporotic fractures (Link and Majumdar, 2003). Bone mass 
measurements are standard techniques in the diagnosis of osteoporosis (Link and 
Majumdar, 2003).  
 
2.3.1 Osteodensitometry 
 
Several techniques can be used to measure bone density (BMD) and bone mineral 
content (BMC). BMD measures bone density is the amount of bone tissue in a certain 
volume of bone, reflecting the amount of calcium in the bone. The strengths of bone 
mineral density are: it changes slowly, so it provides a statistic measurement of 
skeletal status; the variability within persons is very low and measurements are very 
precise; and it can be used to diagnose osteoporosis using the definitions proposed 
by the World Health Organisation (WHO) (Looker et al., 2000). BMC measures the 
mineral content in bone. In adult mammals, approximately 20% of the bone wet 
weight is water, 45% ash, 35% organic matter (Carter and Spengler, 1978). Calcium 
contributes 37% of the ash content and phosphor contributes 18.5%. On dry weight 
basis mineral content is 65-70% and organic matter is 30-35% (Keene et al., 2004). 
 
2.3.1.1 Dual X-ray Absorptiometry 
 
This is an established method of the WHO for diagnosing osteoporosis (Looker et al., 
2000). The principle behind Dual X-ray Absorptiometry (DXA), is measuring the 
transmission of x-rays of two different photon energies, through the body. Depending 
on the attenuation coefficient on the atomic number, photon energy and 
measurement of transmission factors at two energies, an “areal “density is measured 
retrospectively. Scans are taken of two tissues, bone mineral and soft tissue. The 
areal BMD is measured in mg/cm² and includes trabecular and cortical bone. 
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Accuracy is limited due to the differences in soft tissue composition in which the x-ray 
beams pass through (Blake et al., 2002). The preferred anatomic sites for DXA are 
the measurement of bone mineral in lumber spine, proximal femur and whole body. 
Peripheral sites can also be scanned (Njeh et al., 1999). 
 
The first generation of DXA scanners used pinhole collimator that produced a pencil 
beam coupled to a single scintillation detector in the scanning arm. More advanced 
systems introduced a slit collimator to generate a fan beam coupled to a linear array 
of solid-state detectors. This shortens scan time and produces a higher resolution 
(Njeh et al., 1999). The latest DXA systems have two- dimensional detector arrays 
developed for digital radiography systems. They possess a cone-beam system. 
Measurements are done within seconds (Boudousq et al., 2003).  
 
The main advantages of X- ray systems such as these are the shortened 
examination time due to an increased photon influence of the X-ray tube, greater 
accuracy and precision, which results in higher resolution and removal of errors due 
to source decay (Kelly et al., 1988). Another advantage of DXA is the low radiation 
exposure (Njeh et al., 1999). 
DXA, however, is unable to differentiate between trabecular and cortical bone. The 
effects of bone loss are more prevalent in trabecular bone, due to the much higher 
surface area. Bone mineral content is much greater in cortical bone, and can 
therefore conceal small changes in trabecular bone (Brismar et al., 2001). 
Osteoporosis is a disease where the micro-architectural deterioration of bone tissue 
takes place. This method is not able to display this accurately, because bone mineral 
content is greater in the cortical bone and conceals changes in the trabecular bone.  
 While density (quantity) does correlate with strength (Keaveny et al., 2001), about 
30% of the variability in bone strength remains unexplained (National Institutes of 
Health, 2000; Hans et al., 1997). 
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2.3.1.2 Quantitative computer tomography 
 
This technique measures volumetric measurements (mg/ml) of trabecular bone. 
Quantitative computer tomography (QCT) may be performed at any CT system. All 
that is required is a calibration phantom and dedicated software to improve precision. 
Measurements are done on spine and appendicular skeleton (spine and peripheral 
QCT). 
 
Peripheral quantitave computed tomography (pQCT) 
 
The purposes of these scanners are to measure the bone mineral content (BMC) and 
bone mineral density (BMD) of the peripheral skeleton. This is a method that enables 
true volumetric density measurements of the appendicular bone without other tissue 
overlapping. It provides exact three dimensional localisation of the target volume.  
Assessing cortical and trabecular bone separately is possible (Njeh et al., 1999). 
Peripheral scanning is used in the distal radius (Glüer et al., 1995). The patient lies 
on a phantom. Between patient and phantom, a water or gel filled cushion is placed. 
This avoids artefacts (Link and Majumdar, 2003). These are performed at one site 
with a single axial slice of 2.5 mm thickness. This is located at the level that 
represents 4% of the ulna length from the distal radial cortical endplate.  Some pQCT 
are able to incorporate multi-slice data acquisition and cover a larger amount of bone 
(Kaisel and Rüegsegger, 1991). Measuring more slices enables an accurate 
reflection of the bone status and potentially measures more representative changes 
in the distal radius. Riggs et al. (2004) did scans with a single energy CT. The 
principle of the scans is as follows: the joint space is visualized and a reference point 
is set electronically, from a digital image (scout view) of the forearm, at the 
intersection of joint space with radius-ulna junction for the forearm. From here, an 
automatic program is selected, which scans a more distal and more proximal site of 
the radius. A computerised surface detection algorithm peels the bone pixel-by-pixel 
until a certain percentage of core areas remain. The outer 10% of the bone is 
excluded to avoid partial volume effects from the bone edge. Depending on the 
program, certain areas in mg/cm3 are considered to be cortical and certain areas are 
considered as trabecular (Russo et al., 2006). 
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Spinal QCT 
 
An external bone mineral reference phantom is used to calibrate the computed 
tomography measurements of bone-equivalent values. This is used as a control 
device to characterize the scanner and to perform a quality assurance test. During 
the scanning process, the spine and phantom should appear as a single object 
(Yoganandan et al., 2006). For the regions of interest in the vertebral bodies, special 
software is required to analyse the image. The most commonly examined vertebra 
range from the first to the third lumbar vertebral bodies. 8-10 mm thick sections are 
obtained by a lateral scout image. A low-dose technique and a gantry parallel to the 
vertebral endplates are required. To improve precision, reduce acquisition and 
analysis time, the placement of the region of interest and the sagital location of mid 
vertebral slices can be automated (Njeh et al., 1999; Glüer et al., 1988, Kalender et 
al., 1988). 
 
Bone marrow fat increases with age. This may decrease BMD falsely (Glüer and 
Genant, 1989). Kuiper et al. (1996) conclude that bone mineral measurements of the 
femoral neck with QCT and DXA are highly correlated with chemically determined 
bone mineral mass. Both techniques are influenced by femoral fat content. While 
DXA is susceptible to accuracy errors, due to overlying calcified structures and 
degenerative joint diseases, other studies show that QCT are dependent on the 
status of degenerative joint diseases (Yu et al., 1995). The ease of use, the 
possibility to assess cortical and trabecular bone separately, measuring BMD and 
bone mineral content (BMC) make this method an interesting alternative to other 
methods. A comparative study using DXA and QCT was done by Angelopoulos et al., 
(2006). In comparison to DXA, QCT T-and Z-scores were higher. QCT T-scores 
correlated more closely to age than DXA T-scores. QCT T-scores correlate closely 
with osteocalcin, urinary N-telopeptide cross-links of type I collagen and 
deoxypyridinoline, without statistical significance and DXA T-scores correlated only 
with C-telopeptide cross links of type I collagen, without statistical significance. Which 
one of the two techniques determine the overall strength of vertebrae more precisely, 
must still be further investigated.  
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2.3.1.3 Micro-computed tomography 
 
Micro-computed tomography (micro-CT) is a technique for the non-destructive 
assessment and analysis of the three-dimensional trabecular bone structure (a 
network of plates and rods, arranged in a lattice-like network).  A compact miniature 
CT-scanner system has been developed by Rüegsegger et al. (1996). This CT-
scanner, also referred to as desktop µCT, allows non-invasive imaging and 
quantitative morphometry of bone specimens of various sizes. It is therefore likely 
that this technique will allow characterisation of the effects of diseases and 
therapeutic agents on trabecular bone architecture in humans and in a variety of 
animals. Eckstein et al. (2002) examined the body composition, bone mineral states 
and architecture in Growth Hormone-transgenic mice. The femora of these mice were 
examined with DXA and micro-CT. A comparison of these two methods confirmed a 
high consistency between these two methods. Abe et al., (2000) observed the 
morphological characteristics of the femur in osteopetrotic (op/op) mice, using micro-
computed tomography. The accuracy of the reconstructed 3-D images was confirmed 
by comparing an original femur. The arbitrary cross-section could be displayed on a 
screen and a detailed examination of the internal structures was possible. The 
volume percentage of the trabecular bone could be measured in three dimensions. It 
was confirmed that micro-CT can be applied to 3-D morphometric analysis. 
The effect of ovariectomy in rats on the changes in trabecular structure in alveolar 
bone was investigated by Tanaka et al. (2003), using micro-CT. The alveolar 
trabeculae in the sham operated group had network structures, whereas rats, that 
were ovariectomised, had fragmented structures. Trabecular bone volume, number 
and thickness of ovariectomised rats were significantly lower than those found in the 
sham operated rats.  
The micro-CT is capable of acquiring 3-D X-ray images made up of 20003 voxels on 
specimens up to 5 cm in extent with resolutions down to 2 µm. This allows the 3-D 
structure of tissue-engineered materials to be imaged across orders of magnitude in 
resolution. The micro structural features in regenerating bone was studied by Jones 
et al. (2004).Tissue-engineered bone material based on polycaprolactone scaffold 
and autologous marrow cells were examined. Imaging occurred at a scale of 1 cm 
and resolutions of 10 µm. The complex ingrowth of bone into polymer scaffold was 
visualised. Theoretically, the voxel data may be used to calculate expected 
mechanical properties of tissue-engineered implants. 
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The ability to evaluate fracture risk at an early point of time is essential for the 
prognostics and the treatment of osteoporosis. Mittra et al. (2005) used sheep 
femoral trabecular bone, to investigate the interrelationship of trabecular mechanical 
and micro structural properties. These were analysed using mechanical testing and 
micro-CT. Findings showed, that micro-CT indices are structural in nature, e.g. 
structural model index (SMI) (Hildebrand and Ruegsegger, 1997), which expresses 
the structure of the trabeculae, is as good as density orientated indices in predicting 
strength in the trabecular region. The analysis also showed that a loss of bone 
primarily affects the connectedness and the number of trabeculae, while increased 
strength results in an increase of thickness of trabeculae while not improving 
connectedness. 
Teo et al. (2006) studied the relationship between image intensity CT, cancellous 
bone micro-architecture (using micro-CT) and mechanical properties. It was found 
that the predictive power of bone strength and stiffness was improved with the 
combination of bone density and micro architecture information. 
Other than displaying the micro architecture of bone, micro-CT can be used to 
assess emphysema in mice. Postnov et al. (2005) induced emphysema in mice by 
intratracheal installation of different amounts of porcine pancreas elastase. This 
emphysema could be clearly detected by micro-CT seven weeks later. Watz et al. 
(2005) reconstructed terminal airspaces of lung specimens with micro-CT. This made 
virtual endoscopy of the alveolar ducts possible. Watz et al. (2005) investigated the 
appearance of lung parenchyma at the structural level of alveoli. A virtual endoscopy 
of the alveolar ducts was made possible after a 3-D reconstruction of the terminal 
airspaces.  Badea et al. (2005) demonstrated a non-invasive imaging method for the 
in vivo characterization of cardiac structure and function in mice using 4-D micro-CT.  
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2.4 Biochemical parameters 
 
Bone metabolism is a dynamic and continuous remodelling process that is normally 
maintained in a tightly coupled balance between resorption of old or injured bone and 
formation of new bone. Bone metabolism occurs on focused sites on the surface of 
the bone called bone remodelling units or bone metabolism units (BMU). Osteoclasts 
and osteoblasts are the cells that carry out bone metabolism at the specific BMU site. 
Osteoclasts resorb existing bone. Osteoblasts are responsible for bone formation. 
These replace the surfaces resorbed by the osteoclasts with a replacement bone 
matrix, termed osteoid. Some osteoblasts are entrapped in bone matrix. Here they 
become osteocytes. Osteoporosis is a condition in which an imbalance appears to be 
between bone resorption and formation, with bone resorption exceeding formation. 
Biochemical techniques have been developed to measure products of bone 
resorption and bone formation, and thus the degree of bone turnover is able to be 
measured. Markers of formation assess either osteoblastic synthetic activity or post 
release metabolism of procollagen. Resorption markers reflect osteoclast activity and 
or collagen degradation (Christenson, 1997). 
  
2.4.1 Markers of bone formation 
2.4.1.1 Bone alkaline phosphatase 
 
Alkaline phosphatase (ALP) is a membrane bound protein that is synthesized by cells 
in a variety of tissues. In humans 4 isoenzymes have been identified. 3 are 
expressed in tissue specific distributions in the intestine, placenta, and germ cells 
(Prince, 1993). The fourth isoenzyme is tissue non-specific and is distributed 
throughout the body, but especially abundant in the liver, kidney and bone (Allen, 
2003). 
This enzyme is also produced by other tissues (liver, placenta, intestine) (Moss, 
1987), which contributes to the total amount of alkaline phosphatase in the blood. 
The bone isoenzyme is situated in the membrane of the osteoblasts and is then 
released into the circulation. The condition hypophosphotasia lacks this enzyme, 
suggesting that it has a role in the mineralization of newly formed bone (Watts, 1999). 
In children and adolescents up to 80 % ALP measurable in serum, derives from 
bone, mirroring growth. In adults, however, about 50% is bone derived. The 
remainder comes mostly from the liver (Eberling and Åkesson, 2001). 
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Four variants of ALP have been identified in animals: bone alkaline phophatase, 
intestinal ALP, liver ALP and in dogs the corticosteroid induced ALP. Liver and bone 
ALP are products of the same gene. They only differ in location numbers of 
posttranslational glycosylation sites, making them isoforms, rather than isoenzymes 
(Sanecki et al., 1990). 
 
In young animals that still have an immature skeleton, the bone ALP will tend to be 
predominant. In mature and older animals, medication and disease could cause an 
increase in liver and corticosteroid- induced ALP (Saini and Saini, 1978). 
 
Different tests have been developed to differentiate between different isoenzymes. 
Bone ALP can be isolated by heat denaturation or gel electrophoresis (Saini and 
Saini, 1978). More recently radioimmunoassays  (RIA) and enzyme-linked-immuno-
asorbert-assays (ELISA) (Price et al., 1997) have been developed for human use, but 
exhibit an acceptable cross reactivity with bone ALP from a number of animal species 
(Allen et al., 2000). 
 
2.4.1.2 Osteocalcin 
 
This is a major noncollagen protein of the bone matrix. It consists of 49 amino acids 
and is rich in glutamic acid (Catherwood et al., 1985). Osteocalcin is vitamin K 
dependant and is synthesized in osteoblasts and megakaryocytes (Thiede et al., 
1994). Vitamin K is a cofactor for the synthesis of blood coagulation factors II, VII, IX, 
and X and inhibitors such as Protein C and S and bone matrix protein. Its active form 
is a coenzyme in glutamic acid carboxylation (Mijares et al., 1998; Olson, 1984). 
When vitamin K is insufficient, a small amount of uncarboxylated osteocalcin is 
released from osteoblasts into the circulation. So the serum concentration of 
uncarboxylated osteocalcin is considered as a sensitive marker of vitamin K status in 
the bone (Sokoll et al., 1997). High levels of uncarboxylated osteocalcin have been 
associated with low bone mineral density and an increased hip fracture risk (Booth et 
al., 2003, Booth et al., 2004). Benyahu et al. (1997) reports that osteocalcin mRNA 
and protein is also expressed in vitro in adipocytes. It is known, that the osteocalcin 
synthesis is regulated by vitamin D, 1, 25(OH) ² D3 (Cantatore and Pipitone, 1999). 
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The active metabolite of 1, 25(OH) ² D3 enters the cell and binds with a vitamin D 
receptor. This complex forms a heterodimer with the retinoid receptor and binds to a 
vitamin D responsive element on a responsive gene e.g. on that of osteocalcin. 
Transcription and translation follows and proteins are formed such as osteocalcin 
(Lips, 2006). 
Structurally, the mature osteocalcin peptide consists of two anti-parallel α-helical 
domains connected by a β turn. At the C-terminal end, there are two further β turns 
and a β sheet. The structure is stabilized by a Cys23-Cys29 disulphide bond. 
(Hauschka 1982, 1986).  During the matrix synthesis, some osteocalcin is released 
into the bloodstream. This has a short half-life and is determined mainly by renal 
clearance. No intact osteocalcin is released during resorption, but fragments of 
osteocalcin are released in vitro and during resorption and formation. Osteocalcin 
may serve as a site for hydroxyapatite crystals (Delmas, 1993; Gamero et al., 1994; 
Taylor et al., 1990). Ivaska et al. (2004) discovered that intact and fragmented 
osteocalcin can also be released during bone resorption. Furthermore in addition to 
the conventional use of bone formation, osteocalcin can also be used as a marker of 
bone resorption in vitro and bone matrix derived osteocalcin may contribute to the 
circulating osteocalcin levels, suggesting that serum osteocalcin should be seen as a 
marker of bone turnover, rather than a marker of bone formation. 
 
Osteocalcin in serum is susceptible to rapid enzymatic cleavage. Thus both intact 
and fragmented, N-mid-molecular fragments are found in serum. The C-terminal 
fragment is most susceptible to cleavage, while the N-terminal mid fragment shows 
apparent greater stability (Diaz Diego et al., 1994).  In addition to this, degradation 
occurs rapidly at room temperature. If the analysis of intact osteocalcin is wanted, 
specimens should be frozen as soon as possible after collection (Blumsohn et al., 
1995). Takahashi et al. (2000) found that the variability of N-mid osteocalcin was less 
than that of intact osteocalcin. For stability of osteocalcin after storage, the mean 
value of N-mid osteocalcin was 94.3% of the initial value after 7 days at 4°C whereas 
intact osteocalcin was 73.4%. The reduction of intact osteocalcin values was 
significantly larger than N-mid osteocalcin after 2.5 and 7 days. Furthermore at 
-30°C, N-mid values did not change up to 10 weeks. Blood samples should be 
collected on ice, and plasma or serum should be kept at -20°C for short term storage, 
and at -70°C for long term storage (Lee et al., 2000). Samples should only be thawed 
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once to prevent degradation and generation of fragments. Osteocalcin is also 
reduced in lipemic serum, because it binds with lipids (Delmas et al., 1990). 
  
 A number of sensitive RIA and ELISA kits have been developed for measuring 
osteocalcin in humans. These assays may be used in some animals (these include 
pigs, goats, sheep, cows, horses, rabbits and primates). These are not appropriate 
for others such as dogs, rats, and mice. Sensitive and specific RIAs are now 
available commercially for rats and mice (Allen, 2003).  
 
Carter et al. (1996), suggests that serum osteocalcin and 1, 25 dihydroxyvitamine D3 
are better predictors of bone mineralization and or bone turnover in pigs than serum 
alkaline phosphatase. Brown et al. (1984) suggested that there are three different 
groups of postmenopausal osteoporotic women, those with normal, high and low 
bone formation. In support to this, osteocalcin concentrations have been reported to 
be similar, higher or lower than the normal age-match controls. 
 
2.4.1.3 Propeptides of collagen type I 
 
During the formation of new bone, collagen type I is synthesized by osteoblasts. The 
collagen molecule is synthesized as a much larger precursor procollagen molecule. 
This is secreted into the extra cellular space, where it is attacked by extra cellular 
protease, releasing free peptide sequences, amino-and carboxy termini of the 
procollagen type I molecule (Allen, 2003).  
 
The serum concentrations of carboxy-terminal propeptide of type I collagen (PICP), 
reflect the synthesis of new collagen, not only by osteoblasts in bone, but also by 
fibroblasts in other connective tissues (Melkko et al., 1990). PICP as a marker of 
bone formation is appealing, since the synthesis should be directly proportional to the 
amount of type I collagen produced. PICP, however, appears to lack sensitivity for 
identifying subtle alterations in bone turnover (Charles et al., 1994). PICP is stable in 
serum and can be reliably measured with an immunoassay, in specimens which have 
been frozen and thawed a number of times. It has also been shown that the 
molecules are stable at room temperature for 15 days (Swaminathan, 2001). 
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The serum concentrations of amino-terminal propeptide of type I collagen (PINP) also 
reflect changes in the synthesis of new collagen, by both osteoblasts in bone and by 
fibroblasts in other connective tissues (Eberling et al., 1992; Melkko et al., 1996). 
Unlike PICP, a portion of non-dialyzable hydroxyproline is incorporated into bone. 
This component of the measured fragment may represent bone resorption. PINP, 
however appears to be a more dynamic and sensitive marker for changes in bone 
formation, than PICP (Eberling and Åkesson, 2001).  
Commercial RIA and ELISA kits are available for both PINP and PICP in humans. 
Some of these kits show cross reactivity in animals e.g. in sheep and pigs (Allen, 
2003). 
 
Palmieri et al. (2000) found that in the second phase of osteogenesis in vitro, rat 
osteoblasts secrete inducers of chemo taxis and chemo invasion of endothelcells and 
tumors cells. The protein was isolated and identified. It had two sequences coincident 
with amino-terminal amino acids, of the α1 and of the α2carboxyl propeptides of type I 
collagen, as physiologically produced by procollagen C proteinase. This could 
illustrate the unknown function for the carboxyl-terminal trimer as possibly relevant in 
promoting endothelial cell migration and vascularisation of tissue producing collagen 
type I. 
Hernandez et al. (2004) studied the effects of glucocorticosteroids on DNA synthesis 
and cellular function in human osteoblastic cells by using indirect peroxidase staining 
with type I anti procollagen antibodies and by measuring PICP and PINP. 
Supraphysiological doses of glucocorticsteroids caused a direct inhibition on 
osteoblastic function through their effect on type I procollagen synthesis.  
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2.4.2 Markers of bone resorption 
 
The organic matrix of bone consists of up to 90% collagen type I. Type I collagen is 
rich in the amino acid hydroxyproline and has a triple helix structure. The strands of 
the triple helix are connected by cross-links between lysine or hydroxylysine 
residues, which join the non-helical amino-and-carboxy-terminal ends of one collagen 
molecule to the helical portion of an adjacent molecule (Eyre, 1987). The amino-and-
carboxy-terminals of these collagen type I molecules are linked to the helical region 
of the adjacent collagen molecules through pyridinium cross-links, deoxypyridinoline 
(Dpd) and pyridinoline (Pyd). During bone resorption, hydroxyproline and pyridinium 
cross-links can be released with or without fragments of the collagen molecule. 
These are not reutilised.  
 
2.4.2.1 Telopeptides of collagen type I 
 
Collagen type I break down is mediated by acid proteases. This is an enzyme derived 
from osteoclasts. The break down leads to a release of free and peptide bound 
metabolites of collagen type I (Coleman, 2002). Fragments released from amino-and-
carboxy-terminals of collagen type I molecules are termed N-terminal telopeptides 
(NTX) and C terminal telopeptides (CTX). These consist of short peptide sequences 
from helical region of the collagen type I molecule and the telopeptide region of the 
adjacent collagen molecule linked to the pyridinium cross-link (Pyridinoline (Pyd) or 
deoxypyridinoline (Dpd)). A portion of the telopeptides released from the bone is 
excreted in the urine, the remaining portion is metabolised in the liver and kidney 
(Hanson et al., 1992). These markers can be measured in the urine and serum.  
A third telopeptid, pyridinoline cross-linked carboxy-terminal-telopeptide of type I 
collagen (ICTP), can be measured in serum. This is a peptide, which is bound by 
hydroxypyridinium bridge proteins. These pyridinoline cross-links bind two telopeptid 
regions of one collagen molecule to another collagen molecule. When collagen is 
broken down, ICTP is set free into the circulation (Charles et al., 1994). This marker 
is not significantly affected by renal clearance in healthy individuals (Risteli et al., 
1993). 
Eriksen et al. (2004) isolated and characterised carboxy-terminal telopeptide 
structures of collagen type I from human bone. Analysis of collagen cross-links within 
purified structures indicated the presence of trivalent ICTP structures, divalently 
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cross-linked peptides and uncross-linked telopeptide chains. Estimations suggest 
that more than half of the trivalently cross-linked pool of carboxy-terminal 
telopeptides represent cross-linked structures other than pyridinolines and pyrroles. 
This suggests the presence of unknown, uncharacterised mature trivalent cross-links. 
 
CTX, NTX and ICTP are commonly used to monitor skeletal effects of biphosphonate 
therapy for osteoporosis. All three markers have been used in animals. Different 
species have variable cross reactivity. NTX is measured by an immunoassay using 
an antibody to the α-2 chain of the NTX fragment (Hanson et al., 1992). CTX 
concentrations are also measured with an immunoassay. There is a cross reactivity 
for ICTP in commercial assays for dogs, cats, horses, pigs, rats and primates (Allen, 
2003). NTX measurements have been done in growing minipigs kept in metabolic 
cages (Bollen et al., 1997). As shown in human studies, the reliability of 
measurements in urine is lower than those in plasma. It is of importance to choose 
appropriate biochemical markers to demonstrate effects of calcium on bone 
resorption. Guillemant et al. (2003) discovered that, for this purpose, CTX was more 
sensitive than NTX, while ICTP was not sensitive to acute changes in osteoclastic 
activity due to calcium intake.   
 
2.4.2.2 Pyridinium cross links (Pyridinoline and deoxypyridinoline) 
 
The modification of lysine and hydroxylysine produces non reducable pyridinium 
cross-links, pyridinoline (Pyd) and deoxypyridinoline (Dpd). These stabilize mature 
collagen. Both markers are released from bone in an approximate ratio of 3:1. Dpd is 
relatively specific for bone. Pyd is found in articular cartilage and soft tissue 
(ligaments and tendons). About 60% of the cross-links are bound to proteins. The 
rest are non protein bound. Pyridinium cross-links are not metabolised or absorbed 
from the diet (Colwell et al., 1993). 
 Urinary concentrations of Pyd can be measured using high performance liquid 
chromatography. Sensitive and specific ELISAs have now replaced this technique. 
These assays measure free Dpd in urine specimens. Pyd can be measured in both 
serum and urine. All commercially available kits have wide spread cross-reactivity 
with animal specimens. The cross-reactivity for Pyd measured in serum is found in 
dogs, horses, cows, sheep, pigs rabbits and primates (Allen, 2003).   
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The elevation of pyridinoline is caused by hydroxylation of lysine residues within the 
collagen telopeptides. Not only processes in bone, but also fibrosis processes can 
cause an increase in hydroxylation. Cytokines such as transforming growth factor-ß 
induce substantial increase in lysyl hydroxylase 2b mRNA levels, which induces the 
hydroxylation of lysine residues and therefore an increase in pyridinoline. Similar 
effects were observed for Interleukin-4, activine A, and Tumor Necrosis Factor-α (van 
der Slot et al., 2005). 
2.4.2.3 Osteopontin 
 
Osteopontin is a non-collagenous protein. It is very abundant in bone matrix and is 
synthesised by osteoblast, osteoclasts and osteocytes (Yoshitake et al., 1999). 
Osteoclasts express αvβ3 integrin, which is a receptor for osteopontin (Flores et al., 
1992). Yamate et al. (1997) reported that the expression of osteopontin by osteoclast 
and osteoblast progenitors in murine bone marrow increased after ovariectomy, and 
that osteopontin stimulated the interaction between osteoclast progeniters and 
stromal/osteoblastic support cells that generated tartrate-resistant acid phosphatase-
positive cells. Yoshitake et al. (1999) report that osteopontin knock-out mice are 
resistant to ovariectomy-induced bone resorption compared to wild-type mice. It is 
speculated that the bone loss observed may be related to the requirement of efficient 
signalling through the αvβ3 integrin for optimal osteoclast function. So if osteopontin 
is deficient, as it is in knock-out mice, there is no high-affinity interaction between 
osteopontin and αvβ3 integrin and therefore less bone resorption activity by 
osteoclasts. Other non-collagenous proteins such as bone sialoprotein (BSP) can 
interact with αvβ3 integrin, but with less affinity. Whether osteopontin is required for 
human postmenopausal osteoporosis requires further investigation.  
Parathyroid hormone (PTH) is often used to increase bone mass in osteoporosis 
patients. It has, however, diverse effect on cortical bone mass. PTH regulates the 
expression of osteopontin in osteoblasts and therefore osteopontin could be one of 
the targets of PTH in bone. Kitahara et al. (2003) examined the role of osteopontin in 
PTH actions and found that osteopontin deficiency induced PTH enhancement of 
whole-bone bone mineral density as well as cortical bone mass. 
 Bone osteopontin has properties of an extra cellular matrix protein promoting 
osteoblast and osteoclast attachment via αvβ3 integrin. The attachment of 
osteoclasts, but not osteoblasts requires that the protein be appropriately 
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phosphorylated (Katayama et al., 1998). In a recent study were bone discs (wild-type, 
osteopontin-null) were implanted subcutaneously or intramuscularly in mice (wild-
type, osteopontin-null), revealed the involvement of osteopontin in bone angiogenisis 
and osteoclast recruitment. The vascularisation and bone resorption were 
significantly impaired in the absence of osteopontin (Asou et al., 2001). As a 
molecule that mediates the attachment of bone cells to the bone matrix, osteopontin 
is poised to tranceduce any stress that would move the cell relative to the matrix 
(Denhardt et al., 2001). It can bind to hydroxylapitite, to osteocalcin (Ritter et al., 
1992), and to type I collagen, especially after being cross-linked by tissue 
transglutaminase (Kaartinen et al., 1999). It is speculated that osteopontin released 
by the osteocytes and delivered to the bone surface, might attract osteoclast 
precursor cells and promote osteoclast mobility and that it could stimulate osteoclast 
differentiation in marrow, possibly by synergizing with a RANK/RANKL-generated 
signal (Denhardt et al., 2001). 
Substances such as nicotine can regulate the expression of osteopontin. Walker et 
al. (2001) presented evidence that the nicotinic receptor α4 subunit is present in 
primary bone cells. To determine the in situ bone cell responses within their 
trabecular matrix, cores of human bone were isolated and perfused with different 
dosages of nicotine. An increase in osteopontin was found, suggesting that nicotine 
has direct effect on the synthesis of osteopontin. Sakamoto et al. (2005) investigated 
the effect of homocystein on the expression of osteocalcin and osteopontin in 
MC3T3-E1 preosteoblastic cells and found that osteocalcin decreased in the 
presence of homocystein and osteopontin was activated, compared to the control 
levels. This suggests that hyperhomocysteinenmia appears to be a risk factor for 
osteoporosis by disturbing osteoblast function. 
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2.4.3 Markers of bone turnover 
2.4.3.1Receptor activator of nuclear factor kappa B, receptor activator of nuclear   
factor kappa B ligand, osteoprotegerin 
 
RANK, Receptor Activator of Nuclear factor Kappa B, is a protein, which is crucial for 
all calciumtropic hormones and proresorptive cytokines, to increase calcemia and 
multiplication of osteoclasts in bone. This is found in the membrane of cells in 
osteoclast line and in dendritic cells (Suda et al., 1999). RANK is seen as a 
hematopoietic surface receptor controlling the calcium metabolism and the 
osteoclastgenesis (Kaneda et al., 2000). RANK ligand (RANKL), is a protein 
produced by the osteoblasts, cells of bone stroma and by activated T lymphocytes. 
This protein may promote osteoresorption by induction of cathapsin K gene 
expression (Suda et al., 1999; Corisdeo et al., 2001). It binds on the surface of 
preosteoclasts and stimulates their differentiation into mature osteoclasts, thus 
resulting in osteoabsorption.  RANKL is a member of the Tumour Necrosis Factor 
(TNF) family. It is a crucial cytokine for the differentiation, activation and survival of 
the osteoclasts. It also acts as a regulator between osteoblasts and osteoclasts 
(Lacey et al., 1998). Osteoprotegerin or OCIF (OsteoClastogenesis InhibitingFactor) 
is a protein, which also belongs to the TNF family. Osteoprotegerin inhibits 
differentiation of progenitors into osteoblasts through binding with RANKL, thus 
inhibiting maturation of osteoclasts. It therefore competes with RANK. It displays 
hypocalcemic and antiresorptive effects (Suda et al., 1999). Osteoprotegerin is 
expressed by a variety of other organs and tissues such as the heart, lungs, kidney, 
bone and vessel wall (Simonet et al., 1997). 
 
Imbalances in the ratio between Osteoprotegerin and RANKL or RANK underlie the 
pathology of many skeletal disorders which exhibit excessive bone loss, excessive 
bone formation or bone remodelling disorders, e.g. rheumatoid arthritis, periprosthetic 
osteolysis, tumour associated osteolysis, various osteopetosis or Paget´s disease 
(Hofbauer and Heufelder, 2001; Walsh and Choi, 2003; Sattler et al., 2004; Hofbauer 
and Schoppet 2004; Schoppet et al., 2002). 
RANKL is up regulated by a number of substances .i.e.1α25-dihydroxyvitamin D3 , 
parathyroid hormone, glucocorticoids, prostaglandin E2, Interleukin(IL)α, TNFα, 
IL6,11,17,calcium and immunosuppressants (Cyclosporin A). A down regulation 
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occurs through Transforming Growth Factor (TGF) β. Osteoprotegerin is stimulated 
by some of the same factors, such as vitamin D3, ILα, TNFα, IL6,11,17, calcium and 
estrogen ,TGF β and decreased by PTH, glucocoticoids, prostaglandin E2, insulin-
like-growth factor 1 and immunosuppressants (Collin-Osdoby, 2004). 
 
In vascular diseases, alterations in the RANK, RANKL, Osteoprotegerin system, have 
been implicated. Bone loss caused by osteoporosis has been prevented through 
blocking RANKL. Osteoprotegerin, RANK fusion proteins or RANKL antibodies may 
be used as a blockage. Other conditions such as chronic inflammatory disorders and 
malignant tumours in animal models have been prevented through a RANKL 
blockade. This may emerge as a therapy in humans for postmenopausal 
osteoporosis, myoloma and osteolytic metastasis (Hofbauer and Schoppet, 2004).  
  
Up to now some studies have been performed that have produced contradictory 
results. Bone remodelling parameters showed only sporadically clear association with 
osteoprotegerin e.g. deoxypyridinoline and osteoprotegerin, C-terminal collagen I 
propeptide (Browner et al., 2001). While in other studies no correlations between 
bone markers and osteoprotegerin were found (Szulc et al., 2001). Browner et al. 
(2001) proved a slight negative correlation between calcium and osteoprotegerin and 
slight positive correlations between osteoprotegerin and parathyroid hormone. 
Osteoprotegerin has, however, had a favourable effect in individuals with 
osteoporosis or destructive bone diseases. It minimised the development of 
osteoporosis caused by ovariectomy and reduced development of experimental bone 
metastasis (Kostenuik and Shalhoub, 2001). These results indicate that the RANK, 
RANKL, Osteoprotegerin system can be used in diagnostics and therapy in 
osteoporosis and other conditions such as vascular diseases and tumours. 
2.4.3.2 Bone Sialoprotein (BSP) 
 
 Bone Sialoprotein is a major constituent of bone matrix. It accounts for 
approximately 10% of the non-collagenous proteins. BSP mRNA is almost 
exclusively synthesised in mineralised tissues by osteoblasts, osteoclasts and 
osteocytes (Franzen and Heinegard, 1985). It therefore appears to be involved in the 
process of bone formation and resorption. BSP is a highly sulphated, 
phosphorylated, and glycosylated protein, which is characterised by its ability to bind 
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hydroxyapatite through polyglutamic acid, sequences (Oldberg et al., 1988). The 
deposition of BSP into the extra cellular matrix (Chen et al., 1991, 1992) and the 
ability to nucleate hydroxylapatite crystal formation indicate a potential role in the 
initial mineralization of bone (Hunter and Goldberg, 1993). BSP has been reported to 
be able to promote the differentiation of pre-osteoblasts into osteoblasts (Zhou et al., 
1995). Valverde et al. (2005) suggest that BSP contributes to RANKL mediated bone 
resorption, by inducing osteoclastgenesis and osteoclast survival and deceasing 
osteoclast apoptosis.  
Studies have been performed and have demonstrated that BSP is a specific 
biochemical marker of bone metabolism in post-menopausal women and valuable for 
the quantitative monitoring of the skeletal response to hormone replacement therapy 
in postmenopausal women (Störk et al., 2000). Ruf, (2001) studied the value of 
sialoprotein as a biochemical marker related to screening and diagnosing 
osteoporosis. The study showed that bone sialoprotein reacted the same way as the 
known bone formation parameters (BAP, osteocalcin, PICP) and concluded that BSP 
is a sound and convincing supplement parameter for diagnosing osteoporosis. BSP 
is expressed in breast, thyroid and prostate cancers (Ibrahim et al., 2000; Waltregny 
et al., 2000).  Recently scientists have, however, recognised that BSP is elevated in 
the tumours and blood of people that are developing certain other cancer forms. 
The National Institute of Dental and Craniofacial Research ( NIDCR) reports for the 
first time (2004) that BSP forms a complex with two other proteins, and therefore 
possibly enables cancer cells to degrade the tissue that surrounds them and break 
free from the tumour, causing metastasis. This could mark the protein complex as a 
potential target to prevent metastasis. Therefore, the regulation of the BSP gene 
expression is potentially important for the regulation of osteoblast differentiation, 
bone matrix mineralization and in the tumour metastasis. Kato et al. (2006) showed 
that lipopolysaccharides (LPS) suppressed BSP gene transcription through protein 
kinase A and tyrosine kinase-dependant pathways. LPS effects were mediated 
through cAMP response elements and fibroblast growth factor response elements in 
the proximal BSP gene promoter. The studies of Shimizu et al. (2006) indicate that 
the combination of fibroblast growth factor and forsolin act through protein kinase, 
tyrosine kinase and mitogen-activated protein kinase dependent pathways and  
target certain elements of the BSP gene, to synergistically increase the BSP 
expression. Nakajima et al. (2006) showed that chlorpromazine suppresses the BSP 
Literature 
 33
transcription. This occurs through tyrosine and mitogen-activated protein kinase 
dependent pathways.  
2.4.3.3 Osteonectin 
 
Osteonectin is also known as Secreted Protein, Acidic and Rich in Cysteine 
(SPARC), which is a phosphorylated, acidic, glycine-rich protein, which binds 
calcium. It may, however, be involved in cell proliferation processes such as 
modelling of extracellular matrix. Osteonectin binds selectively to hydroxyapatite and 
to collagen fibrils at distinct sites in bone. It is responsible for the calcification of bone 
collagen (Termine et al., 1981). SPARC belongs to the matricellular group of 
proteins. It modulates cellular interaction with an extra- cellular matrix by binding 
structural matrix proteins such as collagen and vitronectin. It inhibits cellular 
proliferation by stopping cells of the G1 phase of the cell cycle. Other functions of this 
protein are regulating the activity of growth factors such as platelet-derived growth 
factor (PDGF), fibroblast growth factor (FGF)-2 and endothelial growth factor (VEGF). 
In adult animals, osteonectin is expressed largely in remodelling tissue such as bone, 
gut mucosa, healing wounds, tumours and disorders associated with fibrosis 
(Brekken and Sage, 2000). It is also secreted by human osteoblasts (Hunzelmann et 
al., 1998). 
Osteonectin can be expressed by endothelium, in response to certain injuries. As a 
result of certain studies, it appears to regulate endothelial barrier functions, through 
F-actin-dependent changes in cell shape. The appearance of intercellular gaps 
changes and a paracellular pathway for extravasation of macromolecules is provided 
(Goldblum et al., 1994). 
Fujita et al. (2002), suggest that SPARC may play an important role in the 
remodelling and repair of periodontal tissue by promoting proliferation and matrix 
metallopproteinase-2 production. It may also regulate osteoclast formation through a 
osterprotegerin/ osteoclastgenesis inhibitory factor in periodontal ligament cells. 
In particular, it is clear that although matricellular proteins are not required for bone 
development and function, the proteins act to modulate post-natal bone structure in 
response to aging, ovariectomy, mechanical loading and bone regeneration (Alford 
and Hankensen, 2006). 
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2.4.4   Bone marker variability 
 
Bone remodelling is often referred to as coupling, which is a link between bone 
formation and bone resorption. The resorption process takes approximately 7-10 
days, whereas the formation process takes 2-3 months. Resorption markers respond 
to therapy faster (2-12 weeks) than formation markers (3-6 months) (Bernardi et al., 
2004). Serum and urinary markers are used as diagnostic and prognostic indicators 
of skeletal health and disease. The utility of these markers is critically dependent on 
the ability of the assay to detect significant variation from the normal (healthy) state. 
The variability within the assay technique (analytical variability) and the variability that 
is inherent within the study population (biological variability) determine the 
expressiveness of individual assays. Factors affecting biological variability include 
age, sex, nutrition, exercise, and systemic diseases (Watts, 1999; Souberbielle et al., 
1999). In addition to these, pre-analytical variability can be caused by marked diurnal, 
day-to-day and seasonal variation or incorrect storage. 
 
Pre-analytical and biological factors 
 
Diurnal variation 
 
The underlying basis for these temporal rhythms has not been explained, but links to 
activity, food and water intake, renal function and hormonal changes have been 
implicated (Mühlbauer and Fleisch, 1995; Nielson et al., 1991). 
In humans bone alkaline phosphatase has been showed to increase in the morning 
to the afternoon. Osteocalcin increases at night (Nielson et al., 1990a). NTX, Pyd, 
Dpd increase at midnight (Schlemmer et al., 1994). 
Osteocalcin and bone alkaline phosphatase showed the same patterns in miniature 
pigs as in humans (Tsutsumi et al., 2004a). Many studies in human medicine have 
concluded that osteocalcin has a large diurnal variation. Peaks were found in the 
early morning 0400h (Grundberg et al., 1985; Tracy et al., 1990).  Seasonal 
variations have also been seen. Bone marker concentrations decline from January to 
July and then increase in winter (Thomsen et al., 1989; Nielsen et al., 1990b). 
Jackson et al. (2003) studied the circadian variation in biochemical markers of bone 
cell activity in two year old horses. He found no circadian variation in the analysed 
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markers, but implied that the circadian variation may come at a later age when the 
skeleton has reached maturity. 
Ostrowska et al. (2003) found that lighting conditions can influence daily fluctuations 
of biochemical bone markers in rats. The mechanism seems to be dependant on the 
changes of endogenous melatonin concentrations. Woitge et al. (2000) suggested 
that biochemical markers BAP, Pyd, Dpd, NTX and PTH, 25(OH) D3, 1.25(OH)2 D3 
showed significant seasonal variation. Levels of biochemical markers and of PTH 
were highest in winter and most predominant in premenopausal women under fifty 
years of age and in subjects who showed a significant individual rhythm in 25(OH)D3. 
These changes are related directly to variations in the hormonal regulation of skeletal 
homeostasis. 
 
Age, size, gender 
 
Intra-individual variation is related to age. High values occur in childhood (2-10 fold) 
of that in adulthood. The metabolism is very active in infants and slows down at the 
age of 3 years. Bone markers stabilise their activity in prepubertal children and 
increase at the beginning of the pubertal growth spurt. After a final height is reached 
marker levels decrease to the levels seen in adulthood (Szulc et al., 2000). Nielson et 
al. (1990c) discovered that the osteocalcin concentrations reached their highest 
levels during the luteal phase of the menstrual cycle. High values occur again in the 
postmenopausal period. Tsutsumi et al. (2004a) studied the age-related changes in 
bone markers in Göttinger minipigs. The ages 3-76 months, corresponded roughly to 
the period of childhood to adulthood. Tsutsumi et al. (2004a) discovered that bone 
alkaline phosphatase, osteocalcin, NTX, Pyd and Dpd followed the same patterns in 
minipigs as they did in humans at the same hypothetical age. Chailurkit et al. (2005) 
followed the progression of serum bone alkaline phosphatase (BAP) and serum 
osteocalcin in boys and girls and found that BAP levels increased with age,   peaking 
at about 12-13 years. There was a progressive decline in BAP levels with advancing 
age in girls older than 9 years. Serum osteocalcin levels also increased with age and 
reached a peak at the ages 12 and 13 in girls and boys. Serum BAP and osteocalcin 
levels varied with pubertal stages. Van der Sluis et al. (2002) did a cross-sectional 
study on biochemical parameters of bone turnover in healthy Dutch children and 
young adults and found peak concentrations for collagen type I cross-linked N-
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telopeptides, cross-linked telopeptide of type I collagen, carboxy-terminal propeptide 
of type I procollagen, N-terminal propeptide of type I procollagen, alkaline 
phosphatase and osteocalcin during puberty. In girls this is approximately 2.5 years 
earlier than in boys. Children with growth hormone deficiency have reduced bone 
marker concentrations. These increase with the administration of growth hormone. 
Federico et al. (2003) showed that there were no changes in serum osteocalcin, 
carboxy-terminal propeptide of type I procollagen, and cross-linked carboxy-terminal 
telopeptide of type I collagen during puberty in growth hormone treated, growth 
hormone deficient children in a longitudinal study. The study, however, failed to 
demonstrate an association between short and long term changes in bone markers 
and the long term rate of growth or final height of individuals. Baroncelli et al. (2000) 
showed that children with a growth hormone deficiency had reduced bone turnovers 
at baseline. Long-term growth hormone therapy stimulated bone turnover. 
Osteocalcin, PICP, and ICTP, however, do not predict growth rate during long term 
treatment in children with growth hormone deficiency. 
The larger or bulkier skeleton of a man may increase the levels of bone markers 
(Bernardi et al., 2004). Breur et al. (2004) investigated the markers of bone 
metabolism in dog breeds of different size. The results of this study showed that 
serum bone alkaline phosphatase and ICTP concentrations in larger breeds and toy 
breeds do not differ from those of the concentrations found in beagles. A lot of 
studies show a higher concentration of osteocalcin in adult males than in adult 
females (Duda et al., 1988; Epstein et al., 1984). Zanze et al. (1997) found age and 
sex related differences in the urinary excretion of collagen degradation markers, 
suggesting that unlike boys, girls maintain a high degree of collagen degradation up 
to the age of 24 months despite a decrease in their rate of collagen formation. 
Gundberg et al. (2002), found that mean values of serum osteocalcin and BAP were 
lower in women than in men <50 years old. In individuals ≥ 50 years of age, 
osteocalcin was significantly higher in women than in men. Fares et al. (2003) 
examined the effect of gender, puberty, and vitamin D status on biochemical markers 
of bone remodelling and found that they were most affected by gender. 
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Nutrition 
 
Bone metabolism is dependent on nutritional status. Malnutrition causes a disturbed 
bone metabolism, therefore causing changes in bone marker concentrations.  
With the exception of hydroxyproline, substances contained in diet do not affect 
serum and urinary levels of bone markers (Bernardi et al., 2004). Extreme fasting 
over 4 days had no significant effect on pyridinium cross-link concentrations 
(Grinspoon et al., 1995). In severely malnourished children, however, concentrations 
were decreased by approximately one-third of those after recovery from 
malnourishment (Branca et al., 1992).  
A cross-sectional study considered the influence of diets in women between the ages 
of 45-55 with regard to fruit and vegetable intake. The potassium, magnesium and 
phosphate intake correlated negatively with pyridinoline excretion. Potassium, 
magnesium, ß-carotine and fibre intake were negatively correlated with 
deoxypyridinoline excretion. Statistical calculations indicated that magnesium intake 
accounted for 12% of the variability (New et al., 2000). Vitamin D deficient diets or 
malabsorption reportedly caused an increase in pyridinium cross-links excretion. 
Concentrations were two to three times higher in deficient postmenopausal women 
than in healthy subjects (Kamel et al., 1994). 
MacLeay et al. (2004) studied the effect of dietary induced metabolic acidosis and 
ovariectomy on bone mineral density and bone turnover in ewes, and found that body 
weights, serum bone alkaline phosphatase and urinary deoxypyridinoline were not 
influenced by either diet or ovariectomy. Mullins and Sinning, (2005) concluded that 
high resistance training and subsequent maintenance of a high protein intake for 10 
days have no effect on bone metabolism. Strength, lean tissue and deoxypyridinoline 
increased significantly after a time in the trained group and the high protein group, 
whereas bone alkaline phosphatase decreased. No significant changes were found 
in osteocalcin. Arjmandi et al. (2002), treated postmenopausal women who were not 
on hormone replacement therapy, with dried plums and dried apples for three 
months, both of which contain similar amounts of calories, fat, carbohydrates and 
fibres. Dried plums caused an increase in insulin-like growth factor-I and bone 
alkaline phosphatase activity. Serum and urinary markers of bone resorption were 
not affected by this dietary regime.  
 
Literature 
 38
Exercise 
 
Karlsson et al. (2003) studied the effect of exercise as a regulator of bone turnover. 
There were no differences in remodelling markers within the three groups of active 
soccer players. The active groups had higher bone markers than the controls. Former 
players had no differences in bone remodelling markers compared to matched 
controls. In this study it seemed as if the bone turnover, which was evaluated by 
serum bone remodelling markers, adapted to the current activity needed to maintain 
bone strength. Duration of exercise above that level seemed to confer no additional 
benefits.     
Weight bearing and physical activity are important stimuli to bone growth and 
metabolism. Kim et al. (2000) indicated that bed rest immobilisation may influence 
the circadian rhythm due to no mechanical loading with the loss of daily activity. The 
study, however, showed that immobilisation on day 14 does not disrupt the basic 
diurnal rhythm of bone resorption. 
Some studies confirm that exercise increases markers of collagen formation.  The 
effect of whole body vibration training on hip density muscle strength and postural 
control was studied in postmenopausal women by Verschueren et al. (2004). The 
vibration training increased BMD significantly in the hip. This suggests that this may 
be useful for the prevention of osteoporosis. 
Maimoun et al. (2004) determined the effect of physical activities (cycling swimming, 
triathlon), that induced moderate external loading on the skeleton, on bone 
remodelling. Osteocalcin was higher in swimmers and triathletes, whereas urinary 
type I collagen C-telopeptide was only higher in swimmers. Bone alkaline 
phosphatase was lower in cyclists than in other groups. An osteogenic effect was 
only found at bone sites under higher mechanical stress. This may suggest that bone 
turnover is sport dependent. Giangregorio et al. (2005) found that body-weight- 
supported treadmill training did not alter the expected pattern of change in bone 
biochemical markers over time. Maimoun et al. (2006) found an increase in 
osteocalcin and type I.-C telopeptid breakdown products in response to exercise 
performed above ventilatory threshold. Bone alkaline phosphatase increased both 
under the ventilatory threshold and above the ventilatory threshold. All markers of 
bone turnover returned to initial values during recovery. Shibata et al. (2003) 
examined the influences of long-term walking, and walking and jumping training on 
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bone mineral density and bone metabolism and found no significant differences in 
osteocalcin, parathyroid hormone and type I collagen cross-linked N-telopeptide. 
Bone alkaline phosphatase increased significantly after one year. The increase rate 
of this marker was greater in the walking and jumping group. The conclusion was that 
long-term walking training is beneficial for the promotion of bone formation. Yamazaki 
et al. (2004), demonstrated that moderate walking exercise in postmenopausal 
women with osteopenia/osteoporosis suppresses bone turnover and that an early 
change of cross-linked N terminal telopeptide of type I collagen may be a useful 
predictor of long term response to exercise.   
The effect of prolonged immobilisation was investigated by Fiore et al. (1999). The 
results showed that an imbalance between bone formation and resorption occurred 
during bed rest. A significant increase in the markers of resorption, urinary 
pyridinoline, deoxypyridinoline and serum type I collagen cross-linked C-telopeptide 
was observed. The positive correlation between resorption marker increase and 
length of immobilisation suggests that the resorption rate did not decrease with time. 
This was confirmed in Sato´s study (Sato et al., 2001). Smith et al. (2005) 
demonstrated that bone loss is of significant concern for astronauts on long duration 
missions. The study confirmed that after longer duration in space, bone resorption 
was increased with an increase in urinary calcium concentrations, and an increase in 
collagen cross-links (N-telopeptide, pyridinoline and desoxypyridinoline). Formation 
markers were unchanged at landing, but two to three weeks later bone alkaline 
phosphatase and osteocalcin increased significantly above pre-flight values.  
Donahue et al. (2003) state that bone loss also occurs during hibernation. The study 
consisted of the analysis of serum bone markers of five black bears. It was shown 
that the resorption markers remained elevated throughout the entire hibernation 
period compared to the period before hibernation. Bone formation was not affected 
by hibernation, but was accelerated after hibernation.  
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Marker correction 
  
Bone markers can be measured in urine or in serum. Urine provides a higher 
concentration of analyses and has a less complex matrix, due to the fact that serum 
constituents are filtered in the kidney. The filtration or modulation of the kidney may 
change the concentrations of conjugated cross-links compared to free cross-links. 
Urine values require correction for dilution using creatinine. Many life style and 
pathological conditions, such as exercise, stress, menstrual cycle or renal 
insufficiency may influence the creatinine concentrations (Gowans and Fraser, 1987). 
Serum values however do not require correction. 
 
Storage 
 
A lot of markers are very unstable, particularly proteins (Delmas et al., 2000). Levels 
of urine deoxypyridinoline and urine N-telopeptide of type I collagen have been 
reported to change during storage (Schober et al., 2002; Schneider et al., 2002). 
Qvist et al. (2004) confirmed the stability of C-telopeptides of type I collagen in serum 
and plasma samples for up to 3 years. Due to the stability at elevated room 
temperature in EDTA plasma, this might be the preferred matrix.  
 
Intact osteocalcin is only stable for a few hours at room temperature. Specimens 
should, therefore, be frozen within an hour after collection (Noonan et al., 1996). 
Serum storage at room temperature caused no significant loss of osteocalcin during 
the first six hours. After longer storage at room temperature, osteocalcin decrease 
depends on which test kit is used and which fragment of osteocalcin is measured (C-
terminal fragments are more susceptible to enzyme cleavage, N-mid fragments are 
more stable, see 2.4.1.2) (Knapen et al., 1996).  
 
Analytical factors 
 
This can be described in terms of coefficient variation. It can be determined from 
replicate analyses of specimens. Quality control materials are however used more 
often, to determine the acceptability of an analysis. 
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Different tests have been developed for the same bone marker e.g. osteocalcin, 
where different antibodies and method have been used. This leads to 
misinterpretation of results (Diaz Diego et al., 1994). Different antibodies may be 
directed against different epitopes of the analyte and therefore different analyte 
measurements may be obtained.   
Manufacturers inform users that the analytical variability ranges from approximately 
10%-3%. The analytical performances of bone markers are often focused within 
standardised laboratory settings. Inter-laboratory variation must be taken into 
account. The source of the analytical variation is relevant, when the results of an 
analyte are provided from different laboratories (Seibel et al., 2001; Kleerekoper, 
2001; Vesper et al., 2001). 
 
How to avoid pre-analytical variability  
 
Keeping in mind that the bone markers fluctuate in a diurnal rhythm, and bone 
markers are highest in the morning, one should collect specimens (serum, plasma, 
urine) at the same time each day of collection.  
The replicate collection, e.g. collecting of multiple samples over 3-5 days, should 
have more effect than replicate analyses on analytical variability. 
 
Factors affecting creatinine excretion should be identified and excluded.  
Schober et al. (2002) found that urinary NTX and creatinine concentrations 
decreased significantly respectively after storage at -20°C, whereas 
deoxypyridinoline and deoxypyridinoline/creatinine increased after storage at -20°C. 
It was concluded that storage at such low temperatures frees deoxypyridinoline and 
the epitope used for quantification of NTX is denaturated. These changes are often 
masked through centrifugation. In this process the free deoxypyridinolines are 
removed. It is suggested that an additional quotient deoxypyridinoline/NTX should be 
evaluated as an alternative to normalising via creatinine excretion. 
   
The use of serum assays minimises the variability occurring in urine markers. 
Samples should be analysed shortly after collection. If not, they should be stored 
correctly (Bernardi et al., 2004). Pre-analytical variables, such as the use of 
anticoagulants and protease inhibitors could decrease the instability of osteocalcin. 
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Minimal changes were found in heparin-treated plasma with or without aprotinin, 
stored at -20°C or -70°C for up to 90 days (Noonan et al., 1996). If no appropriate 
storage is available, then the analysis of more stable regions of osteocalcin should 
be chosen. Rosenquist et al. (1995) found that mean serum concentrations of intact 
osteocalcin decreased by 63% after 7 days at 4°C, whereas N-mid osteocalcin was 
only reduced by 10%. 
 
 
2.5 Animal models used to study osteoporosis 
 
Animal models make a contribution to the enhanced knowledge of the aetiology of 
osteoporosis. The preclinical evaluation of efficiency and safety of interventions that 
should prevent or reverse bone fragility can be studied. The FDA, Food and Drug 
Administration, “Guidelines for preclinical and clinical evaluation of agents used in the 
treatment or prevention of osteoporosis (1994)”, recommends two preclinical animal 
models, the ovariectomised (OVX) rat and a second non-rodent model, to 
demonstrate the efficiency and safety of new agents for osteoporosis therapy 
(Thompson et al., 1995). 
The goal of an animal model is to replicate the human condition as closely as 
possible. This has proved to be difficult. Fracture risk has not been reproduced in 
animals. Other questions such as the investigation of the degree of correspondence 
between mechanisms, which lead to bone changes in animals and in humans, have 
proved to be difficult. Species differences in cellular and biochemical levels influence 
the usefulness negatively (Turner et al., 2001). 
There are many things that influence bone mass and these vary in different species. 
It is, however, possible to evaluate an animal model objectively. This can be done by 
evaluating to what extent similar events, such as hormone deficiency or aging, lead 
to similar metabolic, cellular and architectural changes in humans and in animals 
(Turner et al., 2001). 
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2.5.1 Small animal models 
2.5.1.1 Rodents 
 
Rodents provide the most commonly used model for the study osteoporosis. They 
have many advantages. They are inexpensive, easy to house and genetically specific 
strains can be acquired easily. The short life span enables studies on the effect of 
age on the bone. Rodents, however, do not experience natural menopause, but an 
ovariectomy can produce an artificial menopause (Wronski et al., 1985). OVX 
(ovariectomy) results in significant bone loss, but the use of this model has 
limitations, because young rats have limited naturally occurring Bone Mineral Unit 
based remodelling.  Older rats, however, have a Haversian system and laminar bone 
(fine fibred), trabecular remodelling and secondary osteonal remodelling. Rats are 
therefore poor models for the effect of ovariectomy on cortical bone, because of the 
lack of a Haversian system and the absence of osteoblast activity in the late stages 
of estrogen deficiency (Wronski and Yen, 1991). Egrise et al. (1999) suggests that 
the extracellular fluid of bone marrow, which is also a medium surrounding the 
osteobasts and their precursor cells, may negatively regulate osteogenic cells and 
may contribute to the fact that older animals are unable to supply osteoblasts to the 
bone in proportion to demand. Barry et al. (2002) found that older rats have bone 
mineral which is less soluble and more crystalline than the bone mineral of younger 
rats. Aronson et al. (2001) suggests that 24-month old rats have a relative deficit in 
endosteal bone formation which may not be related to cell proliferation but rather to 
cell organisation. Chen et al. (2003) concluded that with an increase in age, the 
ability of osteogenesis of rat marrow stromal cells decreases. 
Findings of different investigators are not always consistent. This may be due to 
differences in the age of animals at ovariectomy, and time after ovariectomy 
(Yamazaki and Yamaguchi, 1989).  Patlas et al. (2000), oophorectomised rats at 
different ages, compared the histomorphometric findings (bone size, bone trabecular, 
and cartilage volume in different areas) and found that younger, rapidly growing rats 
exerted significant changes after oophorectomy. No significant changes were found 
in older 10 month old rats after oophorectomy. Fukuda and Iida (2004) found that 
total bone mineral density of metaphysic and diaphysis of long bones in rats 
increased until 12 months and decreased after 15-24 months. Cortical and trabecular 
bone mineral density were not always similar to total bone mineral density. 
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2.5.2 Large animal models 
2.5.2.1 Dogs 
 
The dog has not been widely used as a model to study osteoporosis. Some 
investigators detected bone loss after ovariectomy, while others detected no changes 
(Turner et al., 1994). Kern, (2000) studied the influence of phytoöstrogens, 
polyunsaturated fatty acids, vitamin D and K on bone metabolism and micro 
architecture of bone, in intact and ovariohysterectomised beagles, and found that 
these substances caused a prophylactic increase in bone mineral content. Bone 
turnover increased significantly after ovariohysterectomy, but bone microarchitecture 
was only altered to a small extent.  Faugere et al. (1990) also did a study with 
ovariohysterectomised beagles and found cancellous bone volume, trabecular 
density and wall thickness decreased after ovariohysterectomy. Ovariectomy 
produced no significant changes in bone composition or loss of cortical area, but a 
significant bone loss occurred in the spine (Martin et al., 1987). Boyce et al. (1990) 
describe the increase in bone remodelling after ovariohysterectomy as transient and 
add that at no time after the intervention was a reduction of bone volume detected. 
Wilson et al. (1998) demonstrated that rib cortical bone is a responsive site for the 
effects of ovariectomy in aged female dogs. A transient increase in cortical bone 
formation occurred with a six fold increase over sham-operated dogs at 4 months 
after the intervention. Fukuda and Iida, (2000) orchidectomised male beagles and 
studied the effects it had on the bone metabolism. 1-6 months after the intervention 
osteocalcin, alkaline phosphatase total calcium and parathyroid hormone values 
increased, indicating a high bone turnover. Mean trabecular thickness increased 
significantly 3 months after orchidectomy. These results argue for an appropriate 
model to study osteoporosis.   
The insensitivity and inconsistency of response of the dog’s skeleton may be due to 
the six month interval between periods of luteal activity. The large size and the long 
life span of a dog, make it less useful as a model. Costs for the maintenance of the 
animal and for the administration of larger amounts of chemicals would be a 
consequence of longer experimental periods (Turner et al., 2001). Not only has the 
effect of hormone deficiency been evaluated in dogs, but also the effect of 
alendronate therapy in healthy male dogs. Biphosphonate treatment does not 
weaken the properties of bone. The trends indicate a slight positive overall effect on 
the mechanical properties of healthy canine bone (Fischer et al., 2006). 
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2.5.2.2 Sheep 
 
Sheep are livestock. They are food animals, and society may tolerate the use of such 
animals as models more than that of dogs or cats. Sheep are docile and therefore 
easier to handle. They are flock animals and are less stressed when they are housed 
outdoors, with minimal supervision. Other advantages are the similarities of hormone 
profiles of ewes to those of women. Sheep have a seasonal polyestrous cycle. Cycle 
varies with breed and amount of light. Sheep, like rats, do not have a natural 
menopause that is characterised by bone loss (Newman et al., 1995).  A 
disadvantage of this model is the gastrointestinal tract. In studies where there is an 
interest in the absorption of drugs in the gastrointestinal system, a surgical insertion 
of an abomasel fistela is required to bypass the micro flora.  
Turner et al. (1995a) studied the bone density in the calcaneus and the distal radius 
of ovariectomised sheep and a control group. No differences were found between 
both groups. A further study was done by Turner et al. (1995b), where the bone 
mineral density was measured twelve months after ovariectomy. No differences were 
found between control group and operated group. Schorlemmer (2002) showed that 
a combination of ovariectomy and glucocorticoid therapy, led to osteopenia in sheep. 
Newton et al. (2004) determined the effects of ovariectomy on the trabeculae of ovine 
ilac bone. One year after the operation the trabecular volume decreased and the 
trabecular separation increased. Osteocalcin and urinary deoxypyridinoline were 
significantly higher at the end of the experiment than at the beginning. Chavassieux 
et al. (2001) studied the effect of a new selective estrogen receptor modulator (MDL) 
in comparison with ovariectomised ewes and ovariectomised ewes associated with 
Lentaron, on bone remodelling in ewes. MDL reduced bone turnover and increased 
bone mineral density, whereas ovariectomy increased bone turnover. Lantaron 
tended to amplify the effect of ovariectomy. MDL could therefore be an effective 
agent to prevent postmenopausal bone loss. Lill et al. (2001) did a pilot study 
comparing four groups of sheep; control group; ovariectomised, vitamin D/calcium 
restricted; ovariectomised, glucocorticoid treated and ovariectomised vitamin 
D/calcium restricted and glucocorticoid treated. The largest decrease in bone mineral 
density was seen in the ovariectomised vitamin D/calcium restricted and 
glucocorticoid treated group. Structural changes in the vertebral body were 
pronounced. These changes were less pronounced in the femoral head. The study 
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showed that the combined therapy group was the most effective model for inducing 
osteoporosis. 
2.5.2.3 Primates (non -human) 
 
Non-human primates, such as macaques and baboons, demonstrate many 
advantages. Their organ systems such as gastrointestinal tract, endocrine system 
and bone metabolism resemble those of humans. Female macaque monkeys have a 
monthly cycle and have hormonal patterns similar to those of humans (Hodgen et al., 
1977). A response to ovariectomy is a significant reduction in vertebral cancellous 
bone volume (Miller et al., 1986). Jerome et al. (1986) demonstrated that bone 
turnover is increased following ovariectomy in the baboon. The seemingly parallel 
endocrine system of primates and human is a notable advantage. Female primates 
must be of sufficient age, because the extent of osteoporosis is not only linked to 
rapid bone loss, but also to a sufficient peak bone mass (Rigotti et al., 1991). An 
important feature of the non-human primate is the presence of harverian osteonal 
remodelling in the cortical bone (as observed in humans) (Burr, 1992).  
In cynomolgus monkeys, the peak bone mass is not reached until 9 years of age 
(Champ et al., 1996). Many studies, however, have used ovariectomised monkeys 
aged 4-7 years (Jerome et al., 1993). The ovariectomy of skeletally immature 
monkeys therefore seems to be an inappropriate model.  
 
To acquire such aged female primates is difficult and costly. Furthermore, once 
acquired, the handling of such animals is an issue of concern. Aggression can be 
controlled by skilled technicians.  
It was frequently the case, that primates used in studies were captured in the wild. 
These monkeys were potential reservoirs of zoonotic diseases such as Marburg virus 
disease, Eloda virus disease, viral hepatitis (Herpesvirus simiae), and tuberculosis. 
For these reasons and because of legal requirements related to how these animals 
must be housed and kept; there is public resistance to their use as models. These 
days, however primates are especially breed and reared under laboratory conditions 
for the use in studies.  
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2.5.2.4 Pigs 
 
A commercial farm pig weighs approximately 150kg which limits its use as a research 
model. Minipigs have eliminated this problem. They weigh up to 60kg when mature 
and are therefore better to handle and less housing space is required. The 
reproductive cycle of the pig is similar in duration to that of the human (18-21 days). 
Like humans the cycle in pigs is continuous. Furthermore, pigs, like humans are 
omnivore and the anatomy of the gastrointestinal tract is very similar.  
Bourchard et al. (1995) found that Sinclair minipigs possess a definable peak bone 
mass at the age of 2.5 to 3 years. Tsutsumi et al. (2004b) obtained standardised 
data, established a relationship between growth and bone metabolism in female 
Göttinger minipigs and observed that the point of peak bone mass was not reached 
until 76 months of age. Mosekilde et al. (1993a, 1993b), discovered that pigs have a 
much higher bone mass and a denser trabecular network than humans. They also 
discovered that they have a different loading pattern of the skeleton. The combined 
effects of ovariectomy and a mild dietary calcium restriction (0.75%) resulted in 
excessive resorptive cell function at the level of the remodelling unit, which resulted 
in vertebral cancellous osteopenia and a reduced biochemical competence of the 
vertebral cancellous bone. The reduction of the cancellous bone appeared to be due 
to the trabecular perforation (Mosekilde et al., 1993a, 1993b). These findings suggest 
that the ovariectomised, calcium-restricted (0, 75%) Sinclair S1 minipig has potential 
as a model to study bone remodelling in humans and perimenapausal bone loss in 
women. 
Boyce et al. (1995) did an unbiased estimation of vertebral trabecular connectivity in 
calcium-restricted ovariectomised minipigs. The connectivity density was increased 
twofold when compared with sham-operated minipigs fed a standard diet. The results 
of this study suggested that in calcium-restricted ovariectomised minipigs, trabecular 
plates are transformed into rods by perforation. The changes in topography appeared 
to be due to the excessive resorptive cell function at the level of the bone remodelling 
unit. This data suggests that calcium-restricted ovariectomised Sinclair minipigs may 
be a useful model of cancellous osteopenia and trabecular plate perforation, 
remodelling, 3D architecture and strength in response to estrogen deficiency. 
 
Minipigs are large enough to receive prosthetic implants and withstand repetitive 
bone biopsies and large volumes of blood sampling. Bone removal and manipulation 
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or disposition of trabecular and cortical bone occurs at a rate comparable to that of 
humans and pigs possess laminar bone (Mosekilde et al., 1987).   
Bone metabolism, estrous cycle and gastrointestinal functions of swine are features 
commending them as animal models. There are, however, also negative factors. The 
acquisition costs are high and in some areas these animals are rare. Larger farm pigs 
require more space and handling is more difficult. Regardless of breed, pigs are loud 
and can be aggressive. This makes them inconvenient in the use of projects, which 
require a large amount of handling and interaction (Turner, 2001). 
 
 
2.6 Induction and simulation of post- menopausal osteoporosis 
 
The post-menopausal condition is caused by the absence of sexual hormones. To  
simulate the absence of these hormones different procedures can be performed.  
2.6.1 Oophorectomy, ovariohysterectomy 
 
The removal of the ovaries (oophorectomy) may be required to facilitate research or 
for pet pigs, such as miniature pigs. The miniature pig is increasingly being kept 
indoors, as a house pet. This has caused problems with female pigs when they 
become sexually mature. They tend to become sexually hyperactive. The 
hyperactivity is expressed through urinating and sometimes aggressiveness. Many 
pet owners have tried to treat the unwanted urinating with vasopressin, but have not 
been happy with the results. A method of treating this hyperactivity is to 
ovariectomise or ovariohysterectomise these animals. 
The removal of the ovaries alone is easier and faster, and the risk of fatal 
haemorrhaging is less than with the ovariohysterectomy. The blood vessels of the 
broad ligaments of the uterus require ligation when ovariohysterectomised. Ovaries 
may be removed from the paralumbar flank, ventrolateral, paramedian or the ventral 
midline. The ventral midline and the paralumbar access to the abdomen are often 
preferred because the risk of post- operative infection and complications, such as 
herniation is less. After the ovary removal an uterus atrophy is expected (St-Jean and 
Anderson, 1999). 
In pet pigs it is recommended to perform this procedure before the normal estrus 
cycle has begun. 
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 In sexually mature pigs, an ovariohysterectomy is recommended, due to the risk of 
pyometra. The uterus and the ovaries may also be removed via paralumar, 
ventrolateral, paramedian or ventral midline incision. Like the ovariectomy, it is 
preferred to remove the uterus and ovaries via the ventral midline or paralumbar (St-
Jean and Anderson, 1999). 
 
2.6.2 Immunocastration 
 
Immunocastration refers to a vaccination, which stimulates the development of 
sufficient antibodies to block the actions of hormones that are necessary for a 
successful reproduction. Delves (2004), differentiates between immunocontraception 
and immunocastration. Thus the sexually mature individuals become infertile, as long 
as certain antibody titres are maintained (immunocontraception). Immunisation to 
prevent the development of hormones that are needed to reach sexual maturity can 
be seen as immunocastration. 
The target hormone for immunocastration and immunocontraception is gonadotropin 
releasing hormone (GnRH).As well as this hormone, follicle stimulating hormone 
(FSH) and human chorionic gonadotropin (hCG) can also be targets for 
immunocontraception. Immunisation against FSH would suppress the 
spermatogenesis, whilst not interfering with the libido (LH being responsible for the 
induction of testosterone, which is necessary for the libido), only producing anti-FSH 
antibodies. Westhoff et al. (1996), show that, when whole FSH is used for 
vaccination, in addition to biological activity against FSH, anti-LH activity is also 
induced.  
 
GnRH, a decapeptid hormone, is produced in the hypothalamus. It consists of 10 
amino acids, which have a uniform sequence in mammals. When released, it 
simulates the anterior pituitary to secrete FSH and luteinizing hormone (LH). In male 
individuals these two gonadotropines act upon the gonads to stimulate testis growth 
and steroidogenisis. Testicular steroids such as testosterone are then released into 
the circulation where they perform certain functions and a feedback regulation of 
GnRH. Another steroid, androstenon, which is not androgenic, is stored in fat tissue 
and is in part responsible for the unpleasant boar taint. The immunisation against 
GnRH, therefore, will disrupt the hypothalamic-pituitary gonad axis and inhibit testis 
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growth and subsequently reduce boar odour, this being the reason why the 
immunisation has been used in male pigs. 
 
Bonneau et al. (1994) studied the effect of a vaccination against luteinizing hormone-
releasing hormone (LHRH), on performance of sexual development and levels of 
boar taint related compounds. Male pigs were allocated to three groups: a group of 
castrates, a group of intact males and an immunised group. Growth performance and 
carcass traits did not differ significantly between immunised and intact males. Genital 
tract weight was decreased by immunisation. Testosterone concentration was 
seventimes lower than that of the intact controls. Fat androstenone levels were 
reduced in those immunised, compared to the intact controls. Fat skatole, however, 
did not differ significantly in all three groups. The immunisation had limited effect on 
performance, but reduced androstenone, a boar taint-related compound, which is 
unwanted at slaughter. 
 
The effect of immunocastration in gilts has been studied only in few cases. 
Esbenshade and Britt (1985) studied the effects of the immunisation on gonadotropin 
secretion, reproductive functions and response to gonadotropin-releasing agonists. 
Zeng et al. (2002a) studied the effect on serum LH, Inhibin A and the sexual 
development and growth rate in Chinese female pigs and found that out of 12 
immunocastrated female pigs two did not respond to the immunisation. Ovarian and 
uterus weights of the immunocastrates were lower than intact controls. Non-
responders and intact controls had similar ovarian and uterus weights. Antibody titres 
were significantly lower in non-responders than in immunocastrates. No follicular 
structures were found in ovaries of immunocastrated, while large follicles and corpora 
lutea were found in the ovaries of controls and nonresponders. These results showed 
that immunocastration can be used as an alternative to surgical castration.  
 
The GnRH molecule in its physiological occurrence is small and is not able to induce 
antibody formation. A substance needs the size of over 5kDa, to have antigenic 
character. The GnRH-vaccination has been developed in recent years. At first the 
complete Freund´s aduvant was used, to obtain an immunological response, which 
was not very high (Talwar, 1985). This is a very effective adjuvant, but it causes 
unwanted tissue reactions (Thompson, 2000). 
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Good antibody titres were achieved when the GnRH molecule was linked to a large 
carrier protein molecule. This linkage can occur at the C-and N-terminals of the 
GnRH molecule and at the Ser4 or Tyr5 hydroxyl groups (Talwar, 1985). 
 
 
(pyro) Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
 
Amino acid sequence of GnRH in mammals (Metz, 2003) 
 
The linkage should not, however, obstruct the immunogenic structures of the 
molecule, which would decrease the antigenity. Many sequences of the GnRH 
molecule have been said to be antigenic epitops. Talwar´s, (1985) hypothesis 
preposed the amid form at the C-terminal (Gly10-NH2) as a binding position for 
specific antibodies.  
An additional improvement of the immune reaction was achieved by conjugating two 
GnRH molecules (Tandem) (Meloen et al., 1994). The use of the Freund´s adjuvant 
was necessary here for the first immunization. Oonk et al. (1998) managed to 
develop a GnRH-tandem-dimer with incomplete Freund´s adjuvant and achieved 
good results. In further studies, the structure of the GnRH molecule was modified and 
the function of each amino acid as an antigen was evaluated. G6k-GnRH-Tandem-
Dimer (Lys6 instead of Gly6) could still bind a carrier, ovalbumin, at the ε-amino group 
of lysine and showed good immunisation results in a mild oily adjuvant. Turkstra et al. 
(2002) found that four (pGly1, Ser4, Arg8, Gly10) out of nine amino acids can be 
replaced by alanine, without negatively effecting the immunocastration efficiency. If 
Tyr5, Leu7 and Pro9 were replaced, a partial decrease in efficiency occurred, while the 
replacement of His2 and Trp3 completely negated immunocastration activity. The 
conclusion was that two positions in the basic unit of G6k-GnRH-Tandem-Dimer do 
not allow substitution by alanine, indicating that effective immunocastration can be 
achieved with modified GnRH peptides.  
Zeng et al. (2002b) demonstrated that synthetic lipoproteins as self-adjuvanting 
immunocontraceptives can be highly immunogenic. Peptides used consisted of a 
collinear CD4+T helper cell epitope from the L-chain of influenza hemagglutanin and 
LHRH. LHRH had B cell epitopes but no T cell epitopes in its sequence. Lipides were 
attached to the N-terminus or between T cell epitope and LHRH. The solubilities and 
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immunological properties of the lipoproteins depended on the lipid content and the 
position of attachment of the lipids. The most effective vaccinations were highly 
soluble and had a lipid attached at the centre of the molecule. 
Fromme et al. (2003) investigated the immunological reaction caused by retro-
inverse Gonadotropin-Releasing Hormone. They found that retro-inverse GnRH 
conjugated to ovalbumin as well as unconjugated retro-inverse GnRH elicited high 
anti-GnRH antibodies in rabbits and mice. The immunisation of mice occurred without 
Freund´s complete adjuvant. Retro-inverse peptides are resistant to cleavage of 
proteolytic enzymes and are potentially orally active, which is a positive aspect for the 
future application in animals. 
 
There are vaccinations available commercially: Vaxstrate® (Arther Webster Pty Ltd, 
Australia) (Hoskinson et al. 1990) and Improvac® (CSL Animal Health, Victoria, 
Australia) (Dunshea et al. 2001). Vanxtrate® is used in cattle, while Improvac® is 
authorized for the use in boars.  
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3 Material and Methods 
 
3.1 Animals used in this experiment 
 
16 Dresdner miniature pigs were penned in separate stalls in a Danish system. Each 
animal had eye contact with the neighbouring animal. This enabled a feed ration 
control. Each animal received the same ration of feed allocated to each specific 
experimental group, which enabled steady weight gain. The enclosures allowed an 
individual observation of health status. During the first weeks after arrival animals 
were weighed regularly.  
 
3.1.1 Animals care during the experiment 
 
Pigs were fed twice a day. The daily ration increased with age. The feed consisted of 
a commercially obtainable miniature pig pellet feed from Firma Zimmererwerke, 
Landshut, Germany. 
Two different diets were fed. The control group received a diet with a 0.99% calcium 
concentration. The rest of the pigs received 0.7% calcium in the diet. 
 
3.1.1.1 Feed ration  
 
Table 3:  Age and daily feed ration of all three test groups 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
 
- 9 months 
 
9 months – 
10  months 
 
10 months-end of 
trial 
 
Ration per 
day 
 
 
440g 
 
500g 
 
550g 
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3.1.1.2 Energy ration  
 
The energy content of both feed types was determined with a bomb calorimeter (C 
2000 Basic, IKA, Staufen). This method measures the heat involved or absorbed 
during a chemical or physical process. The principle of this apparatus is the burning 
of a hydrocarbon in high pressure oxygen in a stainless steel container, maintaining a 
constant volume. The stainless steel container is surrounded with water. The heat 
produced by the reaction is absorbed by the surrounding water. By measuring the 
temperature changes in the water, the heat measured for the burned sample can be 
determined. This is the change in internal energy from the initial to the final states.  
 
Sample preparation: 
The net weight of a small plastic sample bag is determined. The scale should be 
tarred with the sample bag on it and then 0.270 grams of grinded feed is weighed 
and placed into the plastic bag. The energy content of the plastic sample bag should 
be taken into account before feed is bombed.  Feed sample in the plastic bag is then 
fixated to the small piece of fuse wire and placed into an ignition cup in the bomb. 
This should be done with great care; to be sure the sample will ignite when the 
bombing process is started. The net weight of the feed sample and the plastic bag is 
to be recorded in the digital apparatus. The bomb should then be sealed by screwing 
the cap on and then filled with high pressure oxygen. The electrical connections are 
made at the top of the bomb. The bomb is then lowered into a stainless steel bucket 
containing water.  A stirrer that is driven by a motor outside the calorimeter sticks in 
the water. A thermometer is also found in the water. This enables the water 
temperature to be monitored during the reaction. Two electrical leads connect the top 
of the bomb from the outside. These deliver the current that initiates the reaction. 
After approximately 15 minutes, the bombing process is completed and the energy 
content appears on the screen (MJ/kg).  
Table 4 represents the gross energy ration fed during the trial. Each group of animals 
received constant energy amounts throughout the trial.  
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Table 4:  Gross energy ration per kg feed measured by means of bomb calorimetery 
 
Feed I 0.99% calcium Feed II 0.7% calcium 
16.5 MJ/kg 15.6 MJ/kg 
 
 
3.2 Feed Analysis 
 
3.2.1 Weender Analysis 
 
To determine the nutritional content of feed used in this study, a Weender analysis 
was performed. Each analysis was performed in duplicate. Dry, homogenised feed 
samples were used for the analysis.  
 
• Determining crude dry substance  
 
The dry substance of each feed sample was determined by drying the sample in a 
cabinet desiccator type T12 Function Line, Firma Heraeus (Hanau, Germany) until a 
constant weight was reached. A defined amount of sample material was weighed in 
porcelain containers. This was placed in a cabinet desiccator, at 103°C for at least 4 
hours or more, until a constant weight was reached. This withdraws all crude water 
(pure water, volatile fatty acids and other substances that are volatile from samples. 
The samples are placed in an exiccator with silica gel to cool. This prevents samples 
absorbing air humidity. Dry samples are then weighed. The crude dry substance can 
be calculated as follows: 
 
  
   
Crude dry 
substance 
(%) 
= (Sample weight after drying/ sample weight before drying) x 
100 
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• Determining crude Water 
 
Crude water comprises all volatile substances at 103°C. It can be calculated as 
follows: 
 
Crude water (%) = sample weight - dry substance 
 
 
 
• Determining crude ash 
 
Feed samples are incinerated in the muffle furnace P 320, firma Nabertherm 
(Lilienthal. Germany). Defined amounts of samples are weighed in porcelain 
containers. These are placed in the muffle furnace for six hours to 3 days at 550°C, 
until completely incinerated. This process eliminates all organic constituents from 
samples. Only inorganic substances and mineral nutrients remain. The samples are 
left to cool in an exiccator and are weighed again. The percentage of crude ash in the 
samples can be calculated as follows: 
 
  
Crude ash = (sample weight after incineration / sample weight before 
incineration) X 100 
 
 
• Determining crude fat 
 
The crude fat concentration was determined by extracting samples with petroleum 
ether in a Soxhlet apparatus after an acidic pulping procedure. The appliance used 
was a Soxtec Avanti 2050, Firma FOSS (Höganäs, Sweden). 
After weighing 1-2g of sample, an acidic pulping was done with concentrated 
hydrochloric acid. Then an extraction or leaching with petroleum ether at 135° C was 
performed. The attained ether extract consists of neutral fats, lipoids and other ether 
soluble substances. Each sample was weighed after an hour´s drying in the cabinet 
desiccator. The amount of crude fat in % can be calculated as follows: 
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Crude fat (% dry 
substance) 
= (weight of extraction/ weight before extraction) X 100 
 
  
• Determining crude protein 
 
The crude protein analysis was conducted by means of the Kjeldahl technique. An 
automatic analysis apparatus was used, Kjeltec 2400, Firma FOSS (Höganäs, 
Sweden). 
0, 5-1g sample was weighed for the analysis. Firstly, samples were boiled with 
concentrated sulphuric acid in a digester. This caused the nitrogen to oxidate and 
form ammonium. Based on the Kjeldahl technique, the addition of sodium hydroxide 
solution causes the release of ammoniac. The nitrogen content in samples was then 
determined by means of titration. The concentration of crude protein in samples was 
calculated by multiplying the nitrogen concentration with the factor 6.25 because the 
average nitrogen concentration in proteins is 16%. Other substances containing 
nitrogen, besides proteins, are included in this analysis. 
 
• Determining crude fibre 
 
This analysis consisted of boiling the samples alternately in acids and bases in a 
Fibertec-Hotextractor, Firma FOSS (Höganäs, Sweden). Approximately 1 g of sample 
was boiled in 1. 25 % sulphuric acid and then washed in hot water. This was followed 
by boiling the samples in caustic potash solution for 30 minutes and renewed 
washing in hot water. Subsequently samples were washed with acetone. The residue 
was placed in the cabinet desiccator to dry at 103°C. The dry residue was then 
weighed. After weighing it was placed in the muffle furnace and weighed again. 
Crude fibre concentration can be calculated as follows: 
 
Crude fibre (% 
dry substance) 
= ((weight after muffle furnace - residue after drying)/sample 
weight) X 100 
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• Determining nitrogen free extract NfE 
 
This can be calculated as follows: 
 
NfE (% dry 
substance) 
= Dry substance - (crude ash + crude fat + crude fibre + crude 
protein) 
 
 
 
Table 5: Nutritional content of the 0.99% calcium diet and 0.7% calcium diet analysed with 
the Weender analysis. 0.99% calcium diet was allocated to the control group n=5. 
0.7% calcium diet was allocated to the OVX n=5 and second control groups n=6 
respectively. The nutritional content is displayed in % of the original substance 
(oS %) and % of the dry matter (dS)  
   
OVX 
n=5 
Second control  
n=6 Nutrients 
Control 
n=5 
0.99% Ca diet 0.7% Ca diet 
 oS % dS% oS% dS% 
Dry matter 89.2  89.2  
Humidity 10.8  10.8  
Rp 14.7 13.1 14.1 12.6 
Rfe 2.2 2 2.6 2.3 
Ra 8.1 7.2 8.3 7.4 
Rfa 12.1 10.8 12.4 11 
NfE 51.8 46.2 48.4 43.2 
 
3.2.2 Calcium and phosphorus determination 
 
Preparations for determining calcium and phosphorus concentration in feed 
 
To determine the calcium and phosphorus concentrations an ashing of the feed 
samples is required. Crude ash is the result of a 48 hour ashing at 550°C, (M 110 
thermicon P®, Heraeus, Hanau). This contains minerals (macro elements and trace 
elements) and other inorganic substances. To determine calcium and phosphorus 
concentrations it is necessary to mix crude ash with hydrochloric acid (37%), which 
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brings minerals into solution. This solution can be used directly to determine levels of 
calcium and phosphorus. 
 
• Calcium determination 
 
The calcium concentration in the prepared solution was determined with a flame 
photometer (Elex 6361, Eppendorf, Hamburg) at 622nm. If the measurements turned 
out too high, the solution was diluted. This was done with the help of a Duel Diluter 
(Diluter 5213, Eppendorf, Hamburg), with 1% Lithiumchloride solution. 
The principle of the flame photometer is as follows: the solution is drawn into the 
machine and distributed through pressure. It is then injected into a mixture of 
acetylene. A flame emerges, due to the stimulation of atoms. The strength of light 
produced is dependent on the number of atoms present. Through measuring the light 
intensity conclusions can therefore be drawn on the concentration of an element in a 
solution. The flame photometer reads the concentrations in mmol/l. A calculation is 
required, to determine the amount of calcium in grams per kilogram feed. The atomic 
weight of calcium is required for this calculation (40,08g/mol). 
  
  40.08[g/mol]*Reading[mmol/l]*Dilution 
gCa/kg = _________________________________________________ 
  1000 * weight of feed before ashing[g] 
 
 
• Phosphorus determination 
 
The phosphorus concentration in the prepared solution was determined by 
measuring a colour spectrum with a photometer (Spectral photometer, GENESYS 10 
UV, Thermo Spectronic, Rochester, New York, U.S.A). 
The prepared solution was mixed with trichlor acidric acid, molybdate and vanadate. 
Two blank values consisting of trichlor acidric acid, molybdate and vanadate and a 
standard solution, consisting of trichlor acidric acid, molybdate and vanadate and 
potassium hyrogenphosphate were prepared.  
Material and Methods 
 60
Photometry determines the translucence of a solution in monochromatic light that has 
a certain wavelength. Determining the blank values adjusts the translucence to 
100%. All readings were done at 366nm.  
A calculation is required to determine the amount of phosphorus in grams per 
kilogram feed. 
   
   
                X * 10.5 * Dilution 
g P/kg = ______________________________________________ 
  Factor * 100* weight of feed before ashing 
    Factor = 0. 34 
 
 
Table 6: Calcium and phosphorus concentrations in g/kg feed and percent (%) in feed I 
and II 
 
Feed I Feed II 
Calcium Phosphorus Calcium Phosphorus 
9.89 g/kg 7.01g/kg 6.98 g/kg 7.00 g/kg 
0.99% 0.7% 0.7% 0.7% 
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3.2 Design of the experiment 
 
This trial was authorised by the government of Bavaria (Regierung von Oberbayern). 
Animals were divided into three groups. The control group and the OVX group both 
consisted of 5 animals, while the second control group consisted of six animals.  
Blood samples were taken at intervals of seven weeks up until the first ovulation 
synchronisation, which occurred at a sexually mature age of one year and one 
month. The first blood samples were taken in week -65 followed by week -58 and -51. 
The first ovulation synchronisation ended in week -47. Blood samples were taken at 
this point of time, two weeks later (week -45) in the calculated diestrus cycle and one 
week after the calculated diestrus cycle (week -44). The same pattern of extraction 
followed in the following calculated cycle (week -42, week-41); week -42 being the 
calculated diestrus cycle stage in the following cycle and week -41 being the 
beginning of the third calculated cycle. The last two blood samples were taken in 
week -31 and week -19 pre-castration (diagram 2).   
A second synchronisation began seven weeks before the operation and ended four 
weeks before the operation. This was done as described in 3.3.1. 
Each animal in the OVX group received 2ml (8 mg) Altrenogest, Regumate®Janssen, 
Neuss orally two weeks before OVX, daily to suppress the estrus cycle stage. The 
animals in the OVX group were ovariohysterectomised at week 0. The control and 
second control group were not manipulated. Both OVX and second control group 
continued to receive 0.7% calcium diet until the end of the experiment, while the 
control group received a 0.99% calcium diet. Blood samples were drawn in all groups 
at week 0 followed by regular intervals of 2 weeks up until eight weeks post-
castration. The samples taken from the OVX group in week 0 were takewn before the 
operative intervention.   
 
3.3.1 Ovulation synchronisation 
 
In order to coordinate the animals´state of cycle, an ovulation synchronisation was 
performed. On days one to eighteen, 2ml (8 mg) Altrenogest, Regumate®Janssen, 
Neuss, synthetic progesterone was applied orally. 24 hours after the last Regumate®, 
Janssen, Neuss, application, 750 IU (3.7ml) Intergonan®, Intervet, Unterschleißheim, 
a horse serum Gonadotropine (PMSG), was injected im. in the m. brachiocephalicus. 
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78-80 hours after this application, 500 IU (1.6ml) Ovogest®, Intervet, 
Unterschleißheim, a choriongonadotropin, was applicated i.m. A day after the last 
hormone application, blood samples were drawn (“day one of the cycle”) (see 
diagram 1).  Two to three days after the last hormone application, animals were 
observed for estrus signs. Twelve days after first blood sampling, and nine days after 
the second blood sampling, further blood samples were taken. During the second 
cycle, the same procedure was repeated. Blood samples were drawn in the estrus, in 
diestrus and in estrus cycle stages (diagram 1). 
 
 
Diagram 1: Time schedule for the ovulation synchronisation and blood sampling. Day 1 
indicates the first application day of Regumate®  
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3.3.2 Ovariohysterectomy 
 
The uterus blood supply was minimised through estrus suppression with Regumate® 
Janssen, Neuss, which decreased the operation risk. 
3.3.2.1 Anaesthesia and preparation 
 
The ovariohysterectomy was performed in the clinic for pigs, Oberschleißheim, under 
the observation of Professor K. Heinritzi und Dr. M. Ritzmann.  
The animals fasted 24 hours before anaesthesia.  
Approximately 30 minutes before the operation began, an antibiotic, penicillin, 
(Procainpenecillin®, Animedica, Senden-Bösensell) 10000IU/kg, Meloxicam 
(Metacam® Boehringer, Ingelheim) 0.4mg/kg and Metamizol (Vetalgin®Intervet, 
Unterschleissheim), 20-50mg/kg were applied i.m. 
 
Premedication consisted of Azaparone (Stresnil®, Janssen, Neus), 2mg/kg and 
Ketaminhydrochlorid (UrsoKetamin®, Bernburg AG, Serumwerk), 10 mg/kg. The 
medications were applied simultaneously i.m. in M brachiocephalicus. This was 
followed by inhalation anaesthesia, Isofloran (Forene®, Abbott, Wiesbaden). 
 
An intra- venal catheter was laid in the ear vein, V. auricularis intermedia. During the 
operation the animals obtained an i.v. drip. 
During anaesthesia oxygen saturation and carbon dioxide expiration were controlled 
regularly. Reflexes (skin, eyelid, interdigital) were tested every ten minutes. Bulbus 
rotation was observed. 
Each animal was laid in dorsal recumbency. Ventral stomach bristle hair was 
removed. Skin was washed and disinfected. 
 
3.3.2.2 Operation 
 
After the disinfection with alcohol, a laparotomie in the linea Alba was performed. 
The incision started about 1cm caudal of the navel and ended 2 to 3 fingers cranial at 
the edge of the pubic bone. The incision could be widened in direction of the navel. 
Bleeding was stopped and the rest of the lig. Vesicae medianum was removed.  
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The uterus, uterus horns and ovaries were exteriorised out of the abdominal cavity. 
Ligatures were placed at both mesovars. Due to the strong blood supply in the 
ligamentum latum uteri in swine, two additional ligatures were needed to stop the 
blood supply. A further ligature was placed in the vaginal region. The uterus, uterus 
horns and ovaries were then removed through an incision caudal at the cervix, at the 
mesovars, freeing both ovaries, and at the ligatures that stopped the blood supply in 
the Ligamentum latum uteri. 
The uterus stump mucosa was removed and a diagonal ligation was placed on the 
stump. 
The closing of the abdominal cavity followed in layers. For the mesovar, ligamentum 
latum uteri, uterus stump ligatures and the inner layers of the abdominal cavity, 
absorbable sutures were utilised. The surgical skin suture was done with 
nonabsorbable thread. 
   
 
 
3.3.2.3 Postoperative care 
 
On the following two consecutive days, each ovariohysterectomised animal received 
10000 IU/kg penicillin, (Procainpenicllin®, AniMedica, Bösensell), and 20-50mg/kg 
Metamizol, (Vetalgin®, Intervet, Unterschleisheim).  Meloxicam 0.4mg/kg (Metacam®, 
Boehringer, Ingelheim) treatment was repeated one day after the operation. Sutures 
were removed ten days after the intervention. 
Despite the fact that each animal in the OVX group received 8mg (2ml) Regumate® 
Janssen, Neuss to suppress the cycle stage causing strong blood supply in the 
uterus and ligamentum latum uteri, one animal did not survive the intervention. The 
OVX group post operation therefore consisted of four animals.  
 
3.4 Collection of blood samples 
 
Fixation occurred with the help of a pig catcher. Blood was drawn from the v. 
jugularis with monovettes (Monnovette®, Sarstedt, Nümbrecht). Samples were 
directly centrifuged, serum separated and frozen at -80°C.  
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3.5 Analysing blood samples 
3.5.1 Determining progesterone concentrations   
 
The progesterone concentrations were determined with a commercial 
radioimmunoassay, (Coat- A-Count, progesterone kit, Diagnostic Products 
Corporation, Los Angeles, CA.) validated for the use as a direct assay with porcine 
plasma and serum (Novak et al., 2003; Smith et al., 1992). 
This is a solid phase radioimmunoassay, where progesterone labelled with  125 I 
competes with progesterone in the patient’s sample, for a certain amount of time. The 
antibody is immobilised through fixation to the wall of a polypropylene tube. Simple 
decantation allows a termination of the competition and an isolation of antibody- 
bound, labelled progesterone. Counting is done with the aid of a gamma counter. A 
number is yielded and converted, with the help of a calibration curve, to measure 
progesterone present in the patient sample.  
Before use, all test components are to have room temperature (15-28°C). Four 
uncoated polypropylene tubes are to be labelled. Two with T (total counts) and two 
NSB (non specific binding) 
The tubes coated with antibodies are labelled A to G in duplicate, followed by the 
same coated tubes for the patient’s samples in duplicate. 100µl of zero calibrator is 
placed into tubes A and NSB. The rest of the calibrators B to G are placed into the 
corresponding tubes. 100µl of serum from each patient are pipetted into the coated 
tubes for each patient. 
1mL of 125 I Progesterone is now placed into each tube and mixed. After an 
incubation period of 3 hours, the contents of all tubes, except the T tubes, are 
decanted thoroughly. The gamma counter should be programmed according to the 
calibrator concentrations. Tubes are then placed into the gamma counter. The 
progesterone concentrations are read from the gamma counter. Each reading lasts a 
minute per tube. 
3.5.2 Determining estradiol concentrations 
 
Serum estradiol concentrations are determined with the Elecsys® and estradiol 
reagents, calibrators and controls (Fa. Seidel medipool, Buchendorf). The Elecsys® 
1010 analyser is a fully automatic analyser system for determination of 
immunological tests, using an electrochemiluminescent process. The 
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chemiluminescent reactions that lead to the emission of light are initiated 
electronically, rather than chemically, which enables the precise control over the 
entire reaction. Serum samples are transferred into bar-coded sample tubes which 
are recognised by the machine. Reagents are also bar-coded and recognised. All 
components, samples and reagents for routine analysis are integrated in the 
analyser. Calibration occurs before each test run. The test runs automatically.  
 
3.5.3 Determining bone markers 
 
Each test was performed with the help of the epMotion 5070®, Eppendorf, Hamburg. 
The epMotion 5070® enables performing dispensing processes automatically. The 
fluid is taken up in pipette tips (epT.I.P.S.Motion), transported and then discharged 
from these at the dispensing position (destination). To perform the dispensing 
process, it is necessary to program each test, which is to be performed, step by step. 
Processes are performed according to programming, with tips, as well as tubs (30ml 
and 100ml, for wash solution, enzyme conjugate, substrate solution, antibody 
solution, reagents, stop solution, waste etc.) or tubes (for samples, standards and 
controls) in racks and plates with 6, 12, 24, 96, or 384 wells. These are placed in four 
positions of the area and three external positions. It is possible to exchange the tips, 
cups, tubs and tubes from external to internal positions and within internal positions, 
according to program. A waste box must also be installed. The required dispensing 
tool is set in place manually (50 µl, 300 µl, 300 µl- 8 channel tool). The 50 µl tool has 
a volume ranging from 1-50 µl and 300 µl tools have volumes ranging from 20-300 µl. 
The dispensing tools function as piston stroke pipettes with an air cushion. 
Dispensing tools can be used with or without filter. This is to be determined in the 
program. These tools are coded, so they are recognised by the workstation. If 
necessary the optical sensor checks for the correct selection and positioning of the 
tubes, the supply of tips in the tip racks and also the filling of the tubs and tubes.  
 
3.5.3.1 C-terminal telopeptides of collagen type I  
 
Serum Crosslaps® ELISA (Nordic Bioscience Diagnostics, Herlev, Denmark) is an 
enzyme immunologic test, which quantifies the dismantling products of C-terminal 
telopeptides of type I collagen in serum and plasma of humans. Allen (2003) confirms 
Material and Methods 
 67
the cross-reactivity in this test for the following animals: dogs, horses, sheep and 
pigs. 
Serum Crosslaps® ELISA is based on two highly specific monoclonal antibodies 
which target the amino acid sequence EKAHD-β-GGR. Two amino acid chains with 
this sequence must be cross-linked to one another, to enable the serum Crosslaps® 
ELISA to measure a specific signal. 
Before beginning with the test procedure, all solutions and test components should 
have reached room temperature. The antibody solution should be prepared 
approximately 30 minutes before test beginning.  
Test procedure begins with the addition of standards, controls and samples into the 
provided microtitre wells. This is followed by pippetting the prepared antibody solution 
into the mictrotitre wells. A complex is formed between the Crosslaps® antigen, and 
antibodies, which bind to the surface of the wells after an incubation period of 120 
minutes. The wells are then decanted and washed five times. Subsequently 
chomogen substrate solution is added and the colour reaction is stopped with a stop 
solution. The absorption is measured at 450 nm, with a reference of 650nm.  
 
3.5.3.2 Osteocalcin  
 
Metra Osteocalcin immunoassay (Metra Osteocalcin EIA®) (Quidel Corpartion, San 
Diego, CA, USA), allows a quantitative measurement of intact (de novo) osteocalcin 
in serum. This is a competitive immunoassay, which uses osteocalcin- coated strips, 
a mouse anti-osteocalcin antibody, an anti-mouse IgG-alkaline phosphatase 
conjugate and a (p-Nitrophenyl phosphate) pNPP substrate to quantify the 
osteocalcin in serum. Due to the high concentration of osteocalin in porcine serum, it 
was necessary to dilute the samples (1:10) with 1x wash buffer. Allen, (2003) 
confirms the cross-reactivity of this test for pigs. The cross-reactivity has been 
validated (Allen, 2003). Standards and controls are to be dissolved with 1x wash 
buffer, within an hour of use. Enzyme conjugate should be prepared within two hours 
of use. Each required vial is reconstituted with 10ml of 1x wash buffer. Working 
substrate solution should be prepared within an hour of use. One substrate tablet is 
placed into each required bottle and left to dissolve. The test procedure begins with 
the addition of 25 µl standards, controls and samples into each well of the coated 
strips. This is followed by 125 µl of anti osteocalcin and an incubation period of 2 
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hours (+/- 10 minutes) at 20-25°C. After a washing step consisting of a total of three 
washes and vigorous blotting on dry paper towels, 150 µl of enzyme conjugate is 
added to each well. This is followed by an incubation period of 60 minutes. A second 
washing step is now required. After three washes, coated strips are again vigorously 
blotted dry on paper towels. Before the last incubation period, 35-40 minutes at 20-
25°C, starts, 150 µl of working substrate solution are added to each well. The last 
step consists of the addition of 50 µl of stop solution. The test should be read at an 
optical density of 405 nm.  
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4 Results 
 
 
4.1 Weight gain prior to castration  
 
 
During the first sixteen weeks after arrival of pigs and study began, weight remained 
constant in all three groups, ranging from 9.0kg to11.1kg. After this time a steady 
weight gain proceeded, reaching 27.0kg±1.8, 27.0±1.7 and 28.5kg±3.5 in the control, 
OVX and second control groups respectively. No significant differences were found at 
the different weighing times. No significant differences were found between the 
groups (table 7).  
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Table 7:  Weight development of miniature pigs over a period of 70 weeks in control n=5, 
OVX n=5 and second control n=6 groups in kilograms; mean ± standard 
deviation 
 
0.99% Ca ration 0.7% Ca ration 
Weighing time 
point in weeks 
Control Group  
n=5 
weight in kg 
OVX 
n=5 
weight in kg 
Second control 
group 
n=6 
weight in kg 
0 9.0±1.6 8.4±1.3 8.7±1.5 
3 9.2±1.7 8.7±1.3 9.1±1.7 
8 9.2±1.6 8.7±1.4 9.1±1.6 
10 9.2±1.7 8.7±1.4 9.1±1.6 
11 9.4±1.6 8.8±1.2 9.2±1.6 
12 9.5±1.6 9.2±0.9 9.5±1.6 
14 10.3±1.5 9.9±0.8 10.3±1.8 
16 10.7±1.5 10.8±0.9 11.1±1.8 
22 14.5±1.9 14.5±1.2 14.1±2.7 
25 17.5±1.6 17.9±1.6 17.7±2.5 
29 19.4±1.2 19.7±1.6 19.8±2.6 
33 20.7±1.2 20.7±1.5 20.4±2.2 
35 21.3±1.3 22.4±1.9 21.9±1.9 
39 23.2±1.4 22.3±1.5 22.5±2.2 
49 26.7±0.7 25.5±1.7 25.7±2.2 
61 26.1±1.6 25.7±2.2 26.7±4.2 
70 27.0±1.8 27.0±1.7 28.5±3.5 
Different letters a,  b  characterise the significant differences (p < 0,05) between different blood sampling points of 
time   
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Study procedures 
 
The pre-castration period consisted of a period of 65 weeks. During this time 10 
blood samples were extracted and two ovulation synchronisations were performed, 
the first synchronisation beginning in week -50 and ending in week -47. The second 
synchronisation was performed shortly before the castration period, beginning in 
week -7 and ending in week -4. The post-castration period began at week 0, at 
ovariohysterectomy. This period consisted of 5 blood sample extractions, each with 
an interval of 2 weeks (diagram 2).  
 
 
 
 
 
Diagram 2: schematic diagram of procedures during the experiment; 10 blood samples were    
taken pre-castration (week -65,-58,-51,-47,-45,-44,-42,-41,-31,-19); 5 blood samples 
were taken post-castration (0, 2, 4, 6, 8); 0 being at OVX  
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4.2 Pre-castration period 
 
4.2.1 Bone marker progression  
 
At the beginning of the study: blood samples were drawn every seven weeks. Each 
extraction took place in the morning, at 9:00am. Samples were centrifuged directly 
and frozen at -80°C.  For each week of extraction pre-castration and post-castration 
see diagram 2. 
4.2.1.1 Osteocalcin  
 
The osteocalcin concentration development was very similar in all three experimental 
groups during the pre-castration period. All three groups started with low 
concentrations at study begin (80.2±25.7ng/mg in control group, 89.4±33.1 ng/mg in 
OVX group and 93.7±38.4 ng/mg in the second control group). This was followed by 
a peak in both the control groups. The OVX group reached a maximum seven weeks 
after both control groups. All further concentrations in the OVX group decreased 
constantly.  In both control groups one slight increase can be seen in the descending 
concentrations, this being 31 weeks pre-castration in the control group and 41 weeks 
pre-castration in the second control group. Minimal concentrations were measured at 
the last blood analysis before castration.  
No statistical differences were found among the experimental groups pre-castration 
(p=0,684), considering the area under the curve. The statistical significances within 
the different groups at various sampling periods for the osteocalcin concentrations 
are displayed in table 8.  
 
 
 
 
 
 
 
 
 
 
Results 
 73
Table 8: Osteocalcin concentrations (ng/ml) pre-castration, in control n=5, OVX n=5 and 
second control n=6 groups at certain blood sampling points of time; mean 
values ± SD   
 
Osteocalcin concentrations ng/ml 
0.99 %Ca ration 0.7% Ca ration 
Blood sampling   
periods in weeks 
before castration 
Control 
n=5 
OVX 
n=5 
Second control 
group 
n=6 
-65 80.2±25.7  bc 89.4±33.1  ab 93.7±38.4  ab 
-58 169.6±38.8  a 151.5±39.4  ab 176.0±65.3  a 
-51 154.9±18.4  ab 184.7±149  ab 170.5±44  a 
-44 140.1±54  ab 171.1±57.4  b 122.3±20.2  ab 
-41 95.9±48.5  bc 112.7±19.6  ab 127.0±40.4  ab 
-31 106.5±40.9  b 98.7±22.6  ab 99.8±18.3  ab 
-19 60.3±20.3  bc 71.6±10.6  a 84.6±28.7  b 
 
Different letters a,  b  characterise the significant differences (p < 0,05) between different blood sampling points of 
time   
 
 
 
Table 9: Comparing osteocalcin concentrations among the experimental groups control 
n=5, OVX n=5 and second control n=6 pre-castration using area under the curve. 
Mean area under the curve ± SD is represented for each group  
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=5 
Second control group 
n=6 
1069.3±247.2 1209.8±230.4 1168.9±303.9 
 
The significance between the three groups was p=0.684  
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4.2.1.2 Crosslaps  
 
Each group had similar concentration progression during the pre-castration period. 
All groups reached peak concentrations seven weeks after the first analysis. This 
was followed by a simultaneous decrease. The OVX increased after this, while both 
control groups declined further. In week -41 the second control group showed an 
increase in concentrations. The trend that followed was a decrease in concentrations, 
followed by an increase reaching the last peak nineteen weeks before castration.  
Considering the area under the curve, no statistical differences were found among 
the experimental groups (p=0.866). The significances within the groups at the 
demonstrated sampling times, for the crosslaps concentrations can be seen in table 
10. No statistically significant differences were found in the OVX group at 
demonstrated sampling times pre-castration (p=0.292).  
 
Table 10:  Crosslaps concentrations (pg/ml) pre-castration, in control n=5, OVX n=5 and 
second control n=6 groups at certain blood sampling points of time; mean 
values ± SD 
 
Crosslaps 
concentrations pg/ml 
0.99% Ca ration 0.7% Ca ration 
Blood sampling 
periods in weeks 
before castration 
Control 
n=5 
OVX 
n=5  
Second control 
group 
n=6 
-65 164.5±118.3 a 435.4±261.6   209.8±123.99 b  
-58 590.4±245.9 b  448.2±244.3   483.02±204.4  a 
-51 398.6±119.4  ab     333.8±129.1 419.3±253.8  ab 
-44 364.7±63.7  ab 436.3±118.6       310.96±149.5  ab 
-41 310.3±154.0 ab  324.2±128.4  345.8±105.7  ab 
-31 338.3±226.8 ab   371.5±145.5     360.7±98.5  ab  
-19 546.3±281.2  b  544.9±188.9     411.9±247.8  ab   
 
Different letters a, b   characterise the significant differences (p < 0. 05) between different blood sampling points of 
time   
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Table 11:   Comparing crosslaps concentrations among the experimental groups control 
n=5, OVX n=5 and second control n=6 pre-castration using area under the curve. 
Mean area under the curve ± SD is represented for each group  
 
Area under the curve 
0.99%Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=5 
Second control group 
n=6 
3450.2±992.8 3665.6±896.5 3419.6±828.6 
 
The significance between the three groups was p=0.866 
 
 
4.2.2 Hormone analysis 
4.2.2.1 Progesterone concentrations   
 
Blood sample collection in the pre-castration period stretched over a period of 65 
weeks or calculating with the first drawn blood sample as day one, 315 days. 
Calculating with a 21 day cycle of a pig, this period could contain approximately 15 
cycles. Three clear progesterone peaks were demonstrated, in the control group, in 
the total analysis time pre-castration, (the first being in week -45 and the second in 
week -42). This is an interval of 21 days. Taking an approximate deviation of two to 
three days in a cycle into account, the high progesterone concentrations in week -42 
seem to indicate the following cycle in this analysis period. The third peak was found 
in week -31, 77 days after the second peak. This is an interval of approximately three 
cycles, again taking a two to three day cycle fluctuation into account. The OVX and 
the second control group also showed a definite peak in week -45.The second peak 
was reached in week -42 in the OVX group, whereas the second control group 
reached the second peak in week -41. Progesterone concentrations started 
increasing in week -42 in the second control group. Taking a two to three day cycle 
fluctuation into account, these two groups could be in approximately the same stage 
of cycle. The peak found in week -31 could not clearly be represented. These two 
groups reached higher progesterone concentrations in week -19, 84 days later, which 
would be the equivalent of four cycles later.  
The significant differences between the three groups were calculated using the area 
under the curve (p=0.274). The differences in the median values among the  groups 
is greater than would be expected to occur randomly when comparing the delta 
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values between the three groups (p=0.045) at sampling time point -41 and -31.  The 
significance in the groups at the different sampling points of time is demonstrated in 
table 12.  
 
 
Table 12:  Progesterone concentrations in ng/ml in control n=5, OVX n=5 and second 
control n=6 groups mean ± SD. Blood sampling time points are demonstrated in 
weeks and days in the pre-castration period; progesterone peaks are coloured 
grey 
 
Progesterone ng/ml 
0.99% Ca  ration 0.7% Ca ration Blood 
sampling 
time 
point in 
days 
Blood 
sampling 
time 
point in 
weeks 
Control  
n=5 
OVX 
n=5 
Second control 
group 
n=6 
1 -65 0.1±0.1  b     0.2±0.1  ab 0.2±0.1  b 
49 -58 0.1±0.02  b  0.1±0.04  b 0.2±0.1  b 
98 -51 0.2±0.1  ab 0.5±1.0  ab 7.4±18.0  b 
126 -47 3.5±2.3  ab 4.8±4.9  ab 2.5±1.7  ab 
140 -45 116.0±70.9 a 35.5±47.4ab 31.7±60.1  ab 
147 -44 0.2±0.1  ab 1.0±1.7  ab 4.7±8.0  ab 
154 -42 28.2±18.3  ab 27.6±27.6  ab 5.1±12.0  ab 
161 -41 3.7±7.6  ab 5.0±7.4  ab 15.3±6.8  ab 
231 -31 19.8±22.1  ab 15.0±14.8  ab 7.9±11.3  ab 
315 -19 0.8±0.6  ab 34.9±32.2  a 38.8±34.7  a 
 
Different letters a, b   characterise the significant differences (p < 0.05) between different blood sampling points of 
time   
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Table 13:  Comparing progesterone concentrations in control n=5, OVX n=5 and second 
control n=6 groups pre-castration using area under the curve. Mean area under 
the curve ± SD is represented for each group  
 
Area under the curve 
0.99%Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=5 
Second control group 
n=6 
172.1±72.2 107.0±72.8 101.7±99.4 
 
The significance between the three groups was p=0.274 
 
 
4.2.2.2 Estradiol concentrations  
 
The estradiol concentration development in the analysed weeks -47,-45,-44,-41 was 
very similar in each group. The first measured concentrations were minimal 
concentrations of 22.0±4.1pg/ml, 16.5±5.3 pg/ml and 26.7±8.1 pg/ml respectively in 
control, OVX and second control group. These concentrations increased in week -45 
and reached peak concentrations in week -44. Thereafter concentrations decreased.  
The significance in the groups for estradiol concentrations at certain analysis points 
of time pre-castration are displayed in table 14. No significant differences were found 
in the OVX group and the control group pre-castration. The statistical significance 
between the groups for estradiol calculated using the area under the curve is shown 
in table 15. p=0.125 which characterises a trend between the groups.    
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Table 14: Estradiol concentrations (pg/ml) measured in week -47,-45,-44 and -41 pre-
castration in control n=5, OVX n=5 and second control groups n=6; mean ± SD 
 
Estradiol 
concentrations pg/ml 
0.99% Ca ration 0.7% Ca ration 
Blood sampling 
periods in weeks 
before castration 
Control 
n=5 
OVX 
n=5  
Second control 
group 
n=6 
-47 22.0±4.1   16.5±5.3 26.7±8.1  b 
-45 30.3±1.2   19.5±13.6 29.0±7.6  b 
-44 33.8±20.9   29.2±19.1 38.5±7.1  a 
-41 23.4±3.1   21.0±6.3 31.9±11.7  ab 
 
Different letters a, b   characterise the significant differences (p < 0.05) between different blood sampling points of 
time   
 
 
 
Table 15:  Comparing estradiol concentrations in control n=5, OVX n=5 and second control 
n=6 groups pre-castration using area under the curve. Mean area under the curve 
± SD is represented for each group  
 
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=5 
Second control group 
n=6 
98.4±22.1 77.9±29.4 113.6±29.0 
 
The significance between the three groups was p=0.125 
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4.3 Post- castration period 
 
Osteocalcin and crosslaps concentrations were determined from the blood samples 
drawn at ovariohysterectomy and 2,4,6,8 weeks after the operation.  
4.3.1 Bone marker progression 
4.3.1.1 Osteocalcin 
 
The concentration development of osteocalcin at castration and two weeks after 
castration was very similar in all three groups. These concentrations increased in the 
OVX group four weeks after the ovariohysterectomy, and stayed higher until eight 
weeks post-castration, when comparing concentrations with the two control groups. 
The post-castration statistical differences within the various groups at different points 
of sampling time can be seen in table 16. No significant differences were found in the 
second control and the OVX group post-castration. A comparison of osteocalcin 
concentrations post-castration among the experimental groups, surveying the area 
under the curve, is displayed in table 17. There were no statistically significant 
differences found in this analysis (p=0.93). 
 
 
 
 
Table 16:  Osteocalcin concentrations (ng/ml), at castration and after castration in control 
n=5, OVX n=4 and second control n=6 groups; blood sampling periods displayed 
in weeks; mean values ± SD 
 
Osteocalcin concentrations ng/ml 
0.99% Ca ration 0.7% Ca ration Blood sampling   
periods at 
castration and 
weeks after 
castration 
Control 
n=5 
OVX 
n=4 
Second control 
group 
n=6 
0 75.6±39.9  a 79.6±31.0   86.6±12.4  
2 86.8±42.6  ab 84.5±25.6  88.6±21.2  
4 84.3±22.2  ab 142.5±11.9   90.0±23.6   
6 86.4±26.6  ab 141.6±16.3   89.3±26.7   
8 113.6±53.1  b 139.4±13.4   115.1±13.3   
 
Different letters a,  b characterise the significant differences (p < 0,05) between different blood sampling points of 
time   
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Table 17: Comparing osteocalcin concentrations among the experimental groups control 
n=5, OVX n=4 and second control n=6 at castration and after castration using 
area under the curve. Mean area under the curve ± SD is represented for each 
group  
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=4 
Second control group 
n=6 
409.3±156.8 446.3±234.2 410.8±43.7 
 
The significance between the three groups was p=0.93  
 
 
4.3.1.2 Crosslaps 
 
All groups had similar concentration development post-castration. The OVX and the 
control groups had increased concentrations two weeks after ovariohysterectomy. 
This increase was followed by a peak in the fourth week post- operation in the OVX 
group. The control group and the second control group reached a peak two weeks 
later in the sixth week post-operation. Eight weeks after the intervention all 
concentrations in all groups decreased.  
The statistical significances for the post-operative period of eight weeks during the 
different sampling periods are displayed in table 18 for each group. No statistically 
significant differences were found in the second control group (p=0.308). The area 
under the curve for each group is shown in table 19. No statistically significant 
differences were found between the three groups in this analysis (p=0.916). A 
statistical significance was found when comparing the delta values of each group with 
one another. The delta values calculated from the 6th and 8th week post-operation 
gave a significant difference of p=0,016 between the OVX and the control group.   
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Table 18:  Crosslaps concentrations (pg/ml), at castration and after castration in control 
n=5, OVX n=4 and second control n=6 groups; blood sampling periods displayed 
in weeks; mean values ± SD 
 
Crosslaps 
concentrations pg/ml 
0.99% Ca ration 0.7% Ca ration Blood sampling 
periods in weeks 
at castration and 
after castration 
Control 
n=5 
OVX 
n=4  
Second control 
group 
n=6 
0 492.4±62.1  a 640.8±183.1  b   587.6±210.3 
2 584.9±236.2  ab 727.7±321.7  ab 536.4±177.6 
4 588.5±123.5  ab 1037.0±253.9  a 574.8±202.9 
6 965.1±364.7  a 809.3±120.4  ab 702.5±282.7 
8 539.2±279.5  b/y 715.6±331.0  ab/x 633.8±175.6  xy 
 
Different letters a, b   characterise the significant differences (p < 0.05) between different blood sampling points of 
time  
Different letters xy  characterise the ∆ values of each group which show the significant differences(p<0.05) 
between the groups 
 
 
 
 
Table 19:  Comparing crosslaps concentrations among the experimental groups control 
n=5, OVX n=4 and second control n=6 at castration and after castration, using 
area under the curve. Mean area under the curve ± SD is represented for each 
group  
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=4 
Second control group 
n=6 
2923.9±921.6 2952.1±1708.4 2692.3±604.7 
 
The significance between the three groups was p=0.916 
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4.3.2 Hormone analysis 
 
Blood samples from each sampling point of time at castration and after castration 
were used to determine progesterone concentrations. The estradiol concentrations 
were determined from samples up until and including the 6th week post-castration.  
4.3.2.1 Progesterone concentrations 
 
At ovariohysterectomy progesterone concentrations in the OVX group were at 31.4 
±0.7 ng/ml. These reached a peak two weeks later. Thereafter the concentrations 
decreased (11.4 ±0.3 ng/ml) and stayed almost constant in the last four weeks of the 
examination period. Both control groups, however, showed high concentrations in 
week 0. The concentrations in both groups decreased two weeks later. In the 4th 
week the second control group increased, while the control group declined. In week 
six, the second control group reached a second peak. Minimum concentrations were 
found in the control group at this time. In the last examination week, the control group 
reached a second peak, while the second control group declined (table 20).  
No significant differences were found between the sampling times in the control 
group (p=0.549). In the OVX group the differences in the mean values among the 
sampling periods was greater than expected randomly (p=0.031). No significant 
differences were found in the paired multiple comparisons in this group. No 
significant differences were found in the second control group between the different 
sampling periods in the post-castration period.  
All groups were compared with one another, surveying the area under the curve. No 
significant differences were found between the groups (p=0.502) (table 21). The delta 
values calculated from the different blood sampling time points were compared 
between the three groups. No significant differences were found between the groups 
when examining this value.  
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Table 20:  Progesterone concentrations (ng/ml), at castration and after castration in control 
n=5, OVX n=4 and second control n=6 groups; blood sampling periods displayed 
in weeks; mean values ± SD 
 
Progesterone 
concentrations ng/ml 
0.99% Ca ration 0.7% Ca ration Blood sampling 
periods in weeks 
at castration and 
after castration 
Control 
n=5 
OVX 
n=4  
Second control 
group 
n=6 
0 36.21±1.4   31.4±0.7   23.8±1.2 
2 21.0±0.5   34.3±1.1   11.6±0.3 
4 19.6±0.2   11.4±0.3 23.9±0.9 
6 8.9±0.3   15.5±0.4 57.1±0.6 
8 30.8 ±1.4 14.7±0.3 43.1±1.4 
 
Different letters a, b   characterise the significant differences (p < 0.05) between different blood sampling points of 
time   
 
Table 21:  Comparing progesterone concentrations among the experimental groups control 
n=5, OVX n=4 and second control n=6 at castration and after castration, using 
area under the curve. Mean area under the curve ± SD is represented for each 
group  
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=4 
Second control group 
n=6 
82.1±52.5 63.6±64.7 78.8±88.6 
 
Different letters a, b   characterise the significant differences (p<0.05) between the experimental groups 
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4.3.2.2 Estradiol concentrations 
 
 
Both control groups have similar concentration gradient development 0, 2, 4 weeks 
after castration. In the sixth week after ovariohysterectomy the control group estradiol 
concentrations decrease, while the concentrations in the second control group 
increase. The OVX group has higher concentrations at castration. These decrease 
39% after the operation and stay more or less constant there after.  
No significant differences were found in control, OVX and second control groups in 
the post-castration period when comparing the blood sampling time points. A 
statistical significance was found between the groups using the area under the curve 
p<0.001 (table 23). A significant difference of p<0.001 was found when comparing 
the area under the curve in the second control group with the OVX group p<0.05 
when comparing the control and OVX group. No significant difference was found 
between second control group and the control group. Comparing the delta values 
between the groups, statistical significances were found in the first calculated delta 
value post-operation; a statistical significance was found when comparing the control 
group with the OVX group (p<0.01) and when comparing the second control group 
and the OVX group (p<0.05). No significances were found between both the control 
groups for this delta value.   
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Table 22:  Estradiol concentrations (pg/ml) measured in week 0, 2, 4 and 6 during the post- 
castration period in control n=5, OVX n=4 and second control groups n=6; mean 
± SD 
 
 
Estradiol 
concentrations pg/ml 
0.99% Ca ration 0.7% Ca ration Blood sampling 
periods in weeks 
at castration and 
after castration 
Control 
n=5 
OVX 
n=4  
Second control 
group 
n=6 
0 19.2±3.9 38.2±16.9 30.2±19.9 
2 36.9±14.3  x 14.7±16.7  y 35.3±8.1  x 
4 26.7±14.7 16.6±3.2 34.2±14.6 
6 20.6±3.2 15.3±0.4 40.6±10.9 
 
Different letters a, b   characterise the significant differences (p < 0.05) between different blood sampling points of 
time   
Different letters xy  characterise the ∆ values of each group which show the significant differences(p<0.05) 
between the groups 
 
 
 
 
Table 23:  Comparing estradiol concentrations among the experimental groups control n=5, 
OVX n=4 and second control n=6 at castration and after castration, using area 
under the curve. Mean area under the curve ± SD is represented for each group  
 
 
Area under the curve 
0.99% Ca  ration 0.7% Ca ration 
Control 
n=5 
OVX 
n=4 
Second control group 
n=6 
93.7±15.6  b 56.3±25.6  a 130.0±21.6  b 
 
Different letters a, b   characterise the significant differences (p<0.05) between the experimental groups (control, 
OVX and second control groups).  The significance between the three groups was p<0.001 
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4.4 Comparing cycle stage, calculated cycle day, progesterone and estradiol 
concentrations in all three groups 
 
One day after synchronisation and hCG application, the estrus cycle stage was 
reached. Calculating with a time span of three days in the estrus cycle stage, each 
group reached the diestrus cycle stage two weeks later. The progesterone 
concentrations reached higher concentrations in this cycle stage in all groups. In 
week -31 and -19 the calculated day of cycle was day 9, the diestraus cycle stage. 
No samples were extracted on day one of these two cycles during these extraction 
times.  Estradiol concentrations were not measured in week -31 and -19.  
4.4.1 Pre-castration 
4.4.1.1 Control group  
 
Progesterone and osteocalcin concentration parameters reacted inversely in the 
control group. Where progesterone concentrations were at a minimum, osteocalcin 
concentrations were at a maximum (week -58 and -51). In week -47 osteocalcin 
concentrations decreased to 137.7ng/mg, while progesterone still had low 
concentrations of 3.5ng/ml. In week -45, the calculated day 14 of the cycle, diestrus, 
progesterone concentrations reached a peak. Simultaneously osteocalcin 
concentrations decreased. The same pattern was found in the following calculated 
estrus and diestrus cycle stages. Osteocalcin reaching higher concentrations in the 
estrus cycle stage (week -44) and lower concentrations in the diestrus cycle stages 
(week -43) (table 24). 
This inverse behaviour was not clearly seen when comparing the crosslaps and 
progesterone concentration development. Crosslaps had low concentrations on the 
first day of analysis (164.5 ±118.3 pg/ml) when progesterone concentrations were low 
(0.1 ±0.01 ng/ml) in week -65. An increase in the crosslaps concentrations was seen 
when viewing week -58. A steady decrease was seen until week -45, where 
progesterone concentrations peaked in the calculated diestrus cycle stage. This 
inverse behaviour was not followed up at the second progesterone peak in week -42, 
where crosslaps concentrations increased (441.5 ±286.6 pg/ml). Each parameter had 
similar development thereafter up until week-19. Here progesterone again had lower 
concentrations 0.8 ±0.6 ng/ml, while crosslaps seemed to reach a third peak.  
Osteocalcin and crosslaps had similar development during most of the pre-castration 
analysis. The only difference in concentration behaviour was seen in week -42 and  
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-19, where osteocalcin decreased while crosslaps increased. 
Comparing estradiol and progesterone concentrations, estradiol concentrations 
increased at the calculated day one of the cycle in week -44, where progesterone 
concentrations were low (0.2 ±0.1ng/ml). This increase was not clearly seen in week 
-47 and -41 where progesterone concentrations were also low, but not at a minimum 
(table 24). Both crosslaps and osteocalcin concentrations increased in week -44, 
where estradiol had high concentrations.  
 
 
 
Table 24: Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/mg and crossLaps in pg/mg in the control group n=5 pre-
castration 
 
Blood 
sampling 
time point 
in weeks  
Calculated 
day of 
cycle 
Estradiol
pg/ml 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
 
Crosslaps 
pg/ml 
-65   0.1±0.1   80.2±25.7 164.5±118.3   
-58   0.1±0.02    169.6±38.8 590.4±245.9   
-51   0.2±0.1   154.9±18.4 398.6±119.4   
-47 1 22.0±4.1  3.5±2.3  137.7±27.1 388.6±214.7 
-45 14 30.3±1.2   116.0±70.9 81.7±30.6 262.4±133.4 
-44 1 33.8±20.9  0.2±0.1  140.1±54 364.7±63.7   
-42 15  28.2±18.3  112.7±29.2 441.5±286.6 
-41 1 23.4±3.1   3.7±7.6  95.9±48.5 310.3±154.0   
-31 9  19.8±22.1  106.5±40.9 338.3±226.8   
-19 9  0.8±0.6  60.3±20.3 546.3±281.2  
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4.4.1.2 OVX group  
 
As in the control group, progesterone and osteocalcin concentration development in 
the OVX group also reacted inversely.  
Comparing crosslaps and progesterone, the concentration development was similar 
to that of the control group. At the beginning of the analysis, both parameters reacted 
inversely. Progesterone peaked in week -45 and crosslaps reached a minimum. The 
opposite behaviour continued until week -41. The following concentration course was 
similar. 
 
Comparing week -65 and -58, osteocalcin and crosslaps concentrations had the 
same concentration development. This was followed by an inverse reaction of 
osteocalcin and crosslaps in week -57 and -47. Both parameters analysed in the 
weeks that followed reacted in the same way. During the last analysed weeks -31 
and -19 parameters reacted inversely. 
Similar to the estradiol concentrations in the control group, estradiol reached high 
concentrations in week -44 on the first calculated day of cycle. Here progesterone 
concentrations are low (1.0 ±1.7 ng/ml). On both the other calculated day one of the 
cycle, week -47 and -41, estradiol peaks were not seen. Progesterone 
concentrations, however, are not at a minimum at these analysis times. Both 
osteocalcin and crosslaps increased their concentrations in week -44 (see table 25).  
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Table 25: Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/ml and crosslaps in pg/ml in the OVX group n=5 pre-castration 
 
Blood 
sampling 
time point 
weeks 
and days 
Calculated 
day of 
cycle 
Estradiol
pg/ml 
 
 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
Crosslaps 
pg/ml 
-65   0.2±0.1   89,4±33,1 435.4±261.6 
-58   0.1±0.04   151.5±39.4 448.2±244.3 
-51   0.5±1.0   184.7±149 333.8±129.1 
-47 1 16.5±5.3 4.8±4.9   207.7±77.6 315.98±115.2
-45 14 19.5±13.6 35.5±47.4 88.5±32.0 283.6±32.8 
-44 1 29.2±19.1 1.0±1.7   171.1±57.4 436.3±118.6 
-42 15  27.6±27.6   114.5±14.7 336.9±114.6 
-41 1 21.0±6.3 5.0±7.4   112.7±19.6 324.2±128.4 
-31 9  15.0±14.8   98.7±22.6 371.5±145.5 
-19 9  34.9±32.2   71.6±10.6 544.9±188.9 
 
 
4.4.1.3 Second control group  
 
Like the control group and the OVX group, the second control group showed the 
opposite behaviour of osteocalcin and progesterone at many time points in the 
analyses. 
Comparing the concentration gradient development of crosslaps and progesterone, 
up until week -44 these parameters reacted oppositely. Thereafter each parameter 
increases simultaneously with exception of week- 41.  
Crosslaps and osteocalcin concentrations reacted the same way up until week -44. 
After this they reacted inversely.  
As in the control and OVX groups analysed, estradiol concentrations were highest in 
week -44.  Both osteocalcin and crosslaps concentrations had increased in week -44.  
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Table 26:  Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/ml and crosslaps in pg/ml in the second control group n=6 pre-
castration 
 
Blood 
sampling 
time point 
weeks 
and days 
Calculated 
day of 
cycle 
Estradiol
pg/ml 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
Crosslaps 
pg/ml 
-65   0.2±0.1   93.7±38.4 209.8±123.99
-58   0.2±0.1   176.0±65.3 483.02±204.4
-51   7.4±18.0   170.5±44 419.3±253.8 
-47 1 26.7±8.1   2.5±1.7    334.8±208.2 
-45 14 29.0±7.6   31.7±60.1   104.7±50 287.5±196.95
-44 1 38.5±7.1   4.7±8.0   122.3±20.2 310.96±149.5
-42 15  5.1±12.0   120.2±43.1 414.3±58.2 
-41 1 31.9±11.7  15.3±6.8   127.0±40.4 345.8±105.7 
-31 9  7.9±11.3   99.8±18.3 360.7±98.5 
-19 9  38.8±34.7   84.6±28.7 411.9±247.8 
 
 
 
 
4.4.2 Post-castration 
4.4.2.1 Control group 
 
The osteocalcin concentrations reacted inversely with the progesterone 
concentrations in week 0, 2 and week 6. An opposite behaviour was not seen in 
week 4, concentrations decreased in both parameters, and in week 8, concentrations 
increased in both parameters.  
Comparing crosslaps and progesterone at each analysis point in time, concentration 
development was opposite in each week. One parameter increased while the other 
decreased.  
Both crosslaps and osteocalcin concentrations increased from week 0 to week 2 
post-castration. In week 4 crosslaps reached a peak, while osteocalcin decreased. 
Both parameters showed increases in week 6. Osteocalcin reached peak 
concentrations in week 8, while crosslaps´ concentrations fell. 
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The calculated day of cycle was day 14, at ovariohysterectomy. This would be the 
diestrus cycle stage. Progesterone concentrations peaked at this time, while estradiol 
concentrations were at a minimum. Two weeks later, the calculated day 5 of the 
cycle, metestrus, estradiol concentrations peaked, while progesterone concentrations 
decreased in comparison to previous concentrations. In week 4 progesterone 
concentrations had decreased further. Estradiol concentrations were at 26.7pg/ml on 
the 21st day of cycle (last day of cycle, proestrus). In week 6, day 14, diestrus, 
progesterone concentrations were at a minimum. Estradiol decreased to 20.6pg/ml.  
In week 2 estradiol concentrations peaked, osteocalcin and crosslaps concentrations 
increased in this week. Week 4 showed a decrease in estradiol concentrations, while 
osteocalcin decreased slightly, and crosslaps increased slightly. Week 6 showed 
another decrease in estradiol concentrations, whereas crosslaps and osteocalcin 
increased (see table 27).  
   
 
 
 
 
 
Table 27: Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/mg and crosslaps in pg/mg in the control group n=5 at 
castration and after castration 
 
Blood 
sampling 
time point 
in weeks  
Calculated 
day of 
cycle 
Estradiol 
pg/ml 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
 
Crosslaps 
pg/ml 
0 14 19.2±3.9 36.2±1.4 75.6±36.9 492.4±62.1 
2 5 36.9±14.3 21.0±0.5 86.8±42.6 584.9±236.2
4 21 26.7±14.7 19.6±0.2 84.3±22.2 588.5±123.5
6 14 20.6±3.2 8.9±0.3 86.8±26.6 965.1±364.7
8 5  30.8±1.4 113.6±53.1 539.2±279.5
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4.4.2.2 OVX group 
 
Osteocalcin and progesterone concentrations increased simultaneously from week 0 
to week 2. Week 4 and 6 showed an inverse pattern of these parameters. Each 
parameter decreased simultaneously from week 6 to week 8. 
Comparing crosslaps and progesterone, crosslaps showed the same parameter 
development as osteocalcin.  
Osteocalcin and crosslaps had similar concentration development at all analysis 
times. 
Estradiol concentrations peaked at ovariohysterectomy (38.2 ±16.9 pg/ml). Week 0 
also showed high progesterone concentrations 31.4ng/ml. Two weeks later estradiol 
concentrations decreased to 14.7pg/ml and stayed almost constant at the rest of the 
analysis points. Progesterone, however, reached a peak 2 weeks after 
ovariohysterectomy. This parameter also declined, 4 weeks after the operation 
(11.4ng/ml). Week 6 and 8 showed almost constant progesterone concentrations.  
Where estradiol concentrations were high in week 0, both markers showed the lowest 
concentrations. In week 2, 4, 6 where estradiol concentrations were almost constant, 
both markers reached maximum values in week 4. These decreased in week 6 (table 
28) 
 
Table 28:  Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/ml and crosslaps in pg/ml in the OVX group n=5 at and after 
castration 
 
Blood 
sampling 
time point 
in weeks  
Calculated 
day of 
cycle 
Estradiol 
pg/ml 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
 
Crosslaps 
pg/ml 
0 14 38.2±16.9 31.4±0.7 75.6±31.0 640.8±183.1 
2 5 14.7±1.68 34.3±1.1 84.5±25.6 727.7±321.7 
4 21 16.6±3.2 11.4±0.3 142.5±11.9 1036.9±253.9
6 14 15.3±0.41 15.5±0.4 141.6±16.3 809.3±120.4 
8 5  14.7±0.3 139.4±13.4 715.6±331.1 
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4.4.2.3 Second control group 
 
Osteocalcin and progesterone concentrations developed inversely in week 0, 2, 6, 8. 
Week 4 showed the same concentration development in both parameters.  
Both crosslaps and progesterone showed the same behaviour in concentrations at all 
analysis times.  
Osteocalcin and crosslaps concentrations had inverse development at all times other 
than week 4. Here both parameters increased simultaneously. 
On the calculated day 14 of the cycle estradiol concentrations were low, compared to 
the other concentrations measured in this group. Progesterone concentrations were 
at 23.8 ±1.2 ng/ml. Cycle day 5, metestrus showed higher estradiol concentrations. 
On this day progesterone showed minimum concentrations. Week 4, day 21 of the 
cycle estradiol concentrations were at 34.2 ±14.6 pg/ml, while progesterone was at 
23.9 ±0.9 ng/ml. Week 6 showed a progesterone peak. Estradiol also showed high 
concentrations at this time 40.6±10.8 pg/ml (table 29).  
 
 
Table 29:  Blood sampling point of time displayed in weeks; calculated day of cycle in a 21 
day cycle of a pig; mean± SD of estradiol in pg/ml, progesterone in ng/ml, 
osteocalcin in ng/ml and crosslaps in pg/ml in the second control group n=6 at 
castration and after castration 
 
 
Blood 
sampling 
time point 
in weeks 
Calculated 
day of 
cycle 
Estradiol 
pg/ml 
Progesterone 
ng/ml 
Osteocalcin 
ng/ml 
 
Crosslaps 
pg/ml 
0 14 30.2±19.9 23.8±1.2 86.6±12.4 587.6±210.3
2 5 35.3±8.1 11.6±0.3 88.6±21.2 536.4±177.6
4 21 34.2±14.6 23.9±0.9 90.0±23.6 574.8±202.9
6 14 40.6±10.8 57.1±0.6 89.3±26.7 702.5±282.7
8 5  43.1±1.4 115.1±13.3 633.8±175.6
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4.5  Correlations 
4.5.1 Pre-castration 
 
During the pre-castration period a total of 50 variables for each parameter 
(osteocalcin, crosslaps and progesterone) were analysed in the control and OVX 
group and 60 in the second control group. Due to the fact that estradiol was only 
analysed at four sampling points of time, only 20 variables (control and OVX group; 
24 variables in the second control group) were analysed for this parameter. The 
correlations between osteocalcin, crosslaps and progesterone could therefore be 
examined with 50 variables (60 in the second control group). The correlations for 
these three parameters and estradiol were examined with 20 variables (24 in the 
second control group). Each correlation was performed with Pearson’s correlation. 
4.5.1.1 Correlations in the control group  
 
A positive significant connection was found between osteocalcin and crosslaps with a 
correlation coefficient of 0.373 (see table 30). No other significant correlations were 
found in this analysis. 
 
Table 30: Correlations for the parameters crosslaps, osteocalcin, progesterone and 
estradiol at all blood sampling points of time in the control group pre-castration 
(correlation coefficient R; significance p; n=number of samples analysed) 
  
 Osteocalcin Progesterone Estradiol 
 
Crosslaps 
0.373 
p<0.01 
n=50 
-0.173 
p=0.231 
n=50 
-0.187 
p=0.429 
n=20 
 
Osteocalcin  
 -0.235 
p=0.101 
n=50 
-0.701 
p=0.769 
n=20 
 
Progesterone 
  0.128 
p=0.592 
n=20 
 
 
Due to the fact that no definite correlations were found when analysing all blood 
sampling time points together, each sampling time was analysed separately and the 
following correlations were found; in week -42 a correlation was found between 
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osteocalcin and progesterone, with a significant negative correlation coefficient. One 
variable increased while the other decreased. In weeks -47 and -41 significant 
correlations (p<0.05 and p<0.01) were found between osteocalcin and crosslaps. 
The correlation coefficients for week -47 and -41 were 0.917 and 0.965 respectively. 
In week -41 a significant correlation was also found between estradiol and 
osteocalcin. In the same week a correlation was also found between estradiol and 
crosslaps. A negative correlation coefficient was found for each parameter. In this 
week one variable seemed to decrease while the other increased. A significant 
(p<0.001) correlation was found for crosslaps and progesterone in week -42 with a 
correlation coefficient of -0.886 (table 31). No correlations were found between 
estradiol and progesterone at the analysed blood sampling points of time.  
 
 
Table 31:  correlations for osteocalcin, crosslaps, progesterone and estradiol at certain 
blood sampling time points during the pre-castration period in the control group 
(correlation coefficient R; significance p; sampling time point in weeks) 
 
 Osteocalcin Progesterone Estradiol 
 
 
Crosslaps 
 
0.917 
p<0.05 
week-47 
 
0.965 
p<0.01 
week-41 
 
 
 
-0.886 
p<0.01 
week-42 
 
 
-0.971 
p<0.001 
week-41 
 
Osteocalcin 
 -0.934 
p<0.05 
 week -42 
-0.905 
p<0.05 
week-41 
Progesterone   - 
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4.5.1.2 Correlations in the OVX group 
 
No correlations were found for the pre-castration period when all parameters were 
analysed together at all blood sampling time points. 
At separate analysis of each blood sampling time point the following correlations 
were found; a significant (p<0.05) positive correlation coefficient (0.892) was found 
between osteocalcin and crosslaps in week -58; there was a significant negative 
correlation between crosslaps and progesterone in week -44 (table 32); a negative 
correlation coefficient was calculated in week -47 for estradiol and crosslaps  
 
 
 
Table 32:  correlations for osteocalcin, crosslaps, progesterone and estradiol at certain 
blood sampling time points in the pre-castration period in the OVX group 
(correlation coefficient R; significance p; sampling time point in weeks) 
 
 Osteocalcin Progesterone Estradiol 
 
Crosslaps 
0.892 
p<0.05 
week-58 
-0.881 
p<0.05 
week-44 
-0.879 
p<0.05 
week-47 
Osteocalcin  - - 
Progesterone -  - 
 
 
 
4.5.1.3 Correlations in the second control group  
 
A significant connection (p<0.05) was found between osteocalcin and crosslaps in 
this group, when analysing all blood sampling points of time (table 33). The 
correlation coefficient for these two parameters was R=0.290. No correlations were 
found for any of the parameters in this analysis.  
 No correlations were found in this group for any of the parameters at different blood 
sampling points of time in the pre-castration period.  
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Table 33:  Correlations for the parameters crosslaps, osteocalcin, progesterone and 
estradiol at all blood sampling points of time in the second control group pre-
castration (correlation coefficient R; significance p; n=number of samples 
analysed) 
 
 Osteocalcin Progesterone Estradiol 
Crosslaps 0.290 
p<0.05 
n=60 
0.0296 
p=0.825 
n=60 
0.318 
p=0.130 
n=24 
Osteocalcin   -0.0936 
p=0.481 
n=60 
-0.0811 
p=0.706 
n=24 
Progesterone   -0.277 
p=0.190 
n=24 
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4.5.2 Post-castration 
 
During the post-castration period 25 variables for each parameter osteocalcin, 
crosslaps and progesterone were analysed in the control group. In the second control 
group, which consisted of six animals, at five blood sampling points of time, a total of 
30 variables were used to calculate the correlations for these three parameters. 
Estradiol, however, was only analysed at four extraction times, therefore 20 variables 
were used in the control group and 24 variables in the second control group. The 
OVX group had one animal less (n=4) two weeks after the ovariohysterectomy and at 
the rest of the analysis time, therefore only 21 variables for osteocalcin, progesterone 
and crosslaps and 17 variables for the estradiol were included in the correlations 
tests.  
 
4.5.2.1 Correlations in the control group 
 
No significant correlations were found in this group between the different parameters 
at all sampling time points.   
Due to the fact that no correlations were found when analysing all blood sampling 
time points together, each extraction time was analysed separately. No correlations 
were found for any of the analysis time points in the control group post-castration.  
 
4.5.2.2 Correlations in the OVX group 
 
A positive weak significant connection was found between the parameters 
osteocalcin and crosslaps(R: 0.449; p<0.05). Estradiol and crosslaps showed a 
negative weak significant connection (R:-0.522; p<0.05).  No other significant 
connections or correlations were found in this analysis (table 34) 
 
 
 
 
 
 
 
 
Results 
 99
 
Table 34:  Correlations for the parameters crosslaps, osteocalcin, progesterone and 
estradiol at all blood sampling points of time in the OVX group in the post-
castration period (correlation coefficient R; significance p; n=number of samples 
analysed) 
 
 Osteocalcin Progesterone Estradiol 
 
Crosslaps 
0.449 
p<0.05 
n=21 
-0.428 
p=0.0529 
n=21 
-0.522 
p<0.05 
n=17 
 
Osteocalcin  
 -0.268 
p=0.239 
n=21 
-0.357 
p=0.160 
n=17 
 
Progesterone 
  0.293 
p=0.254 
n=17 
 
 
Each blood sampling point of time was analysed separately for correlations in the 
OVX group. A strong negative significant connection was found between estradiol 
and crosslaps in week 0 (R: -0.935; p<0.05). This strong negative significant 
correlation was found again in week 2 (R:-0.957; p<0.05). No other significant 
correlations were found at any analysis time points (table 35). 
 
   
Table 35: correlations for osteocalcin, crosslaps, progesterone and estradiol at certain 
blood sampling time points in the post-castration period in the OVX group 
(correlation coefficient R; significance p; sampling time point in weeks) 
 
 Osteocalcin Progesterone Estradiol 
 
 
Crosslaps 
 
 
- 
 
 
- 
-0.935 
p<0.05 
week 0 
-0.957 
p<0.05 
week 2 
Osteocalcin  - - 
Progesterone   - 
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4.5.2.3 Correlations in the second control group 
 
 
No significant connections were found between any of the analysed parameters at all 
sampling points of time in this group post-castration.  
A significant negative correlation was found in the second control group for estradiol 
and progesterone in week 4 post-castration. No other connections or correlations 
were found between any of the parameters in this group (table 36).  
 
 
Table 36:  correlations for osteocalcin, crosslaps, progesterone and estradiol at certain 
blood sampling time points in the post-castration period in the second control 
group (correlation coefficient R; significance p; sampling time point in weeks) 
 
 Osteocalcin Progesterone Estradiol 
Crosslaps - - - 
Osteocalcin  - - 
Progesterone   -0.959 
p<0.05 
week 4 
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5 Discussion 
 
The objective of this study was to examine the dependence of bone marker activity 
(osteocalcin and crosslaps) on the estrous cycle of the miniature pig. This was done 
by comparing the development of marker concentrations with progesterone and 
estradiol concentrations in the respective cycle stages of each pig after 
synchronisation and at particular sampling points of time.  
Furthermore the behaviour of biochemical markers, osteocalcin and crosslaps were 
examined at and after ovariohysterectomy to determine the effect of OVX on these 
specific bone markers in the miniature pig.  A further purpose of this thesis was to 
determine the influence of a calcium deprived feed ration on bone metabolism before 
and after castration.  
This was a pilot study, which should reduce uncertainties in, and gather data for 
future studies in this area; therefore the animal numbers were very small.  
Sixteen animals were divided into three groups, namely control, second control and 
OVX group. The control group received a 0.99% calcium ration in the feed, while the 
OVX and the second control group received a 0.7% calcium ration.  
The experiment consisted of two periods; the pre-castration period, lasting 
approximately 65 weeks and a post-castration period lasting 8 weeks. Blood samples 
were drawn and analysed at selected time points. 
 
5.1 Weight gain during the experiment 
 
Weight control was practised from the arrival of the pigs up until 70 weeks after 
arrival. Weight showed a constant gain until peaking and levelling at 70 weeks. This 
corresponded to age and growth of the animals. The weight controlling was done to 
avoid over- weight or under-weight animals. Over-weight could have been followed 
by weight loss, which influences markers of bone metabolism during the estrous 
cycle pre-castration and post-castration. Thus far no consistent abnormal findings 
have been described with regard to bone remodelling markers in obese persons 
(Seibel, 2002). There is, however, evidence that weight loss is associated with 
changes in BMD and bone remodelling. Ricci et al. (2001) suggested that the 
reduction of body fat mass was directly associated with a decrease in serum 
oestrone, and therefore estrogen is a major determinant of high bone turnover during 
weight loss. Adipocytes produce Interleukin 6. 30% of the circulating cytokines 
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derrive from fat cells (Mohamend et al. 1997). Factors such as interleukin 1 and 
interleukin 6 are known to play an important role in bone resorption (Cannon and 
Dinarello, 1985; Angstwurm et al., 1997). Adipocyte- produced cytokines are the 
pathogenic link between obesity and its metabolic consequences, such as bone 
resorption (Friebe and Peters, 2005). Further weight development was not followed in 
the present study. The reason for this was because each animal was in a steady 
state of health and remained constant in weight, so there was no risk of weight loss 
or weight gain.  
 
5.2 Parameter determination, test validation, sample extraction and sample handling 
 
Biochemical measures of bone formation and resorption allow the assessment of 
bone turnover. These may assist in the study of the pathophysiological growth of the 
skeleton and in the study of diseases such as osteoporosis, which are characterised 
by disorders in bone mass and may cause disturbances in both formation and 
resorption. The most common example of loss in bone balance (formation and 
resorption are balanced during remodelling) occurs after menopause when estrogen 
loss leads to increased bone resorption with low bone mass as a consequence of this 
(Allen, 2003). At least one formation and one resorption parameter should be 
measured to determine the status of bone metabolism. Most of the tests for these 
parameters found on the market are human specific. The use of these tests in 
animals is possible if a validated cross reactivity for the specific parameter exists.  
  
Osteocalcin is a sensitive and specific marker of bone formation (Szulc et al., 2000). 
Concentrations were determined with the Metra Osteocalcin immunoassay (Metra 
Osteocalcin EIA® Quidel Corpartion, San Diego, CA, USA).  This assay measures 
quantitative intact osteocalcin in serum. It is a competitive immunoassay, which uses 
osteocalcin coated strips, a mouse anti-osteocalcin antibody, an anti-mouse IgG-
alkaline phosphatase conjugate and a (p-Nitrophenyl phosphate) pNPP substrate to 
quantify the osteocalcin in serum. Allen (2003) confirms the cross reactivity of this 
test for pigs and a number of other animals, which has been validated. The serum 
concentrations of osteocalcin, however, are lower in humans than in pigs; therefore 
porcine serum had to be diluted 1:10.  This test could be used in the present study 
due to the validation. The degree of dilution was considered when calculating the 
final osteocalcin concentrations.    
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Serum crosslaps is a marker of bone resorption. The breakdown of collagen type I is 
mediated by osteoclast- derived acid proteases. This leads to a release of free 
peptide- bound metabolites of collagen type I molecules (amino terminal telopeptides 
or carboxy terminal telopeptides) (Coleman, 2002). Serum Crosslaps® ELISA (Nordic 
Bioscience Diagnostics, Herlev, Denmark) is an enzyme immunologic test, which 
quantifies the dismantling products of C-terminal telopeptides of type I collagen in 
serum and plasma of humans. Allen (2003) confirms the cross- reactivity in this test 
for the following animals: dogs, horses, sheep and pigs. Serum Crosslaps® ELISA is 
based on two highly specific monoclonal antibodies which target a certain amino acid 
sequence. Two amino acid chains with this sequence must be cross-linked to one 
another, to enable the serum Crosslaps® ELISA to measure a specific signal. It was 
not necessary to dilute porcine serum samples in this test. This test was easy to 
perform and the cross reactivity and validation for pigs made it useful for the present 
study. 
The formation marker, osteocalcin and the resorption marker, crosslaps showed 
changes that were due to age, cycle and ovariohysterectomy. These markers are 
therefore parameters that can be used in further studies on bone metabolism in 
minipigs.     
To determine the dependence of bone marker activity on the estrous cycle of the pig, 
hormone concentrations (progesterone and estradiol) were measured. These 
parameters assisted in the approximate cycle stage classification of each animal. The 
progesterone concentrations were measured with a commercial radioimmunoassay, 
(Coat- A-Count, progesterone kit, Diagnostic Products Corporation, Los Angeles, 
CA.) validated for the use as a direct assay with porcine plasma and serum (Novak et 
al., 2003; Smith et al., 1992). This is a solid phase radioimmunoassay, where 
progesterone labelled with  125 I competes with progesterone in the patient’s sample, 
for a certain amount of time. The antibody is immobilised through fixation to the wall 
of a polypropylene tube. Simple decantation allows a termination of the competition 
and an isolation of antibody bound, labelled progesterone. Counting was done with 
the aid of a gamma counter. Again the validation for porcine serum and plasma made 
this test useful for the present study. Progesterone concentrations showed the 
expected peaks in the appropriate calculated cycle stages, which was of assistance 
in determining the cycle dependence of the bone markers in minipigs. 
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Serum estradiol concentrations were determined with the Elecsys® and estradiol 
reagents, calibrators and controls (Fa. Seidel medipool, Buchendorf). This test is a 
test for humans and is not specifically validated for porcine serum. The 
concentrations measured in the experiment were an aid and support to the measured 
progesterone concentrations for the cycle stage determination. The course of the 
hormonal concentration development can be determined from these test results. No 
statement can be made about each single hormone concentration at each point in 
the analysis time. This test was, however, used in the present study. The course of 
parameter development was used together with the progesterone concentrations to 
determine the approximate cycle stage of each animal and group. Estradiol did show 
high concentrations as expected at calculated ovulation or follicular cycle stages. 
This test, therefore, can be used as a backup in determining the cycle stage of 
minipigs. Determining two hormonal parameters allows precise cycle stage 
determination.   
Each blood sample was centrifuged directly after extraction, serum separated and 
frozen at -80°C to prevent further degradation of parameters. The samples were kept 
frozen until all specimens from one trial period (pre-castration or post-castration) 
were complete. Only then were they thawed for the use in different ELISAs and the 
RIA. This was done to prevent degradation of bone markers such as intact 
osteocalcin. 
Levels of urine deoxypyridinoline and urine N-telopeptide of type I collagen have 
been reported to change during storage (Schober et al., 2002; Schneider et al., 
2002). Osteocalcin degradation occurs rapidly at room temperature therefore if the 
analysis of intact osteocalcin is wanted specimens should be frozen soon after 
collection (Blumsohn et al., 1995). Lee et al. (2000) state that samples should be 
collected on ice, plasma and serum stored at -20°C for short term storage and at 
 -70°C for long term storage. Furthermore samples should only be thawed once to 
prevent degradation and degeneration of osteocalcin fragments. If parameter 
degradation in serum specimens of minipigs was the same as in humans, the 
handling of these specimens would have excluded larger degradation of osteocalcin 
and crosslaps.   
Biochemical markers are known to have diurnal variations. Studies in human 
medicine have concluded that osteocalcin concentrations peak in the early morning 
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0400h (Grundberg et al., 1985; Tracy et al., 1990). In humans bone alkaline 
phosphatase has been showed to increase in the morning to the afternoon. 
Osteocalcin increases at night (Nielson et al., 1990a). NTX, Pyd, Dpd increase at 
midnight (Schlemmer et al., 1994). Osteocalcin and bone alkaline phosphatase 
showed the same patterns in miniature pigs as in humans (Tsutsumi et al., 2004a). 
To avoid diurnal variations in the present study, all samples were extracted at the 
same time of day at 9 a.m.  
Qvist et al. (2002) examined the diurnal variation in serum crosslaps and found 
maximum levels in the morning at 5 a.m. and minimum levels in the afternoon at 2 
p.m. The study showed that the only parameter which had a pronounced influence on 
the circadien variation was fasting, which reduced the circardian variation to about 
one fourth. All animals in the present study fasted before sample extraction. 
Tsutsumi et al. (2004a) found highest values for osteocalcin in miniature pigs at 
18:00h and the lowest were found at 06:00h. In the present study bone formation 
marker, osteocalcin, therefore did not have maximum concentrations at extraction 
times. Tsutsumi et al. (2004a) found different results for resorption parameters in 
pigs, in comparison to those of humans. In this study, however, the parameter NTX 
was measured. If serum crosslaps react the same way in pigs as they do in humans, 
concentrations were also not at a maximum at extraction time in this study. The 
present study did not determine the diurnal variations of each analysed parameter. 
The constant extraction times in the morning, would have excluded the variation of 
each marker, so if both markers were not at maximum concentrations at each 
extraction time, they were never at a maximum at any point of extraction, which 
would indicate a uniform concentration analysis, which was welcome in the present 
study. The errors in concentration deviation caused by diurnal variations were 
therefore avoided by keeping each extraction time at the same time of day. 
 
 
 
 
 
 
 
 
Discussion 
 106
5.3 Development of biochemical markers in the pre-castration period 
 
5.3.1 Osteocalcin 
 
Osteocalcin age-related 
 
The first blood samples were drawn at an approximate age of 9 months. The samples 
that followed were collected approximately at monthly intervals. Osteocalcin 
concentrations increased from 9 to 13 months and decreased at 14 months (diagram 
3). The increase in osteocalcin concentrations at the beginning of the study was age-
related. Both male and female miniature pigs reach sexual maturity at 4-6 months of 
age (Panepinto and Phillips, 1986). This would be the equivalent of the beginning of 
human puberty. Tsutsumi et al. (2004a) investigated the age-related changes in 
female Göttinger minipigs where the pubertal stage was estimated at 3-11 months. 
So, calculating with Tsutsumi´s age estimations, 12 months would be the 
approximate age of an adult miniature pig. As a result of measuring vertebral 
diameter, Inui et al. (2004) found that skeletal growth ended at about 20 months in 
male miniature pigs and at the age of 25 months in female miniature pigs. This, 
however, is restricted to the vertebral bone development. Bone markers stabilise their 
activity in pre-pubertal children and increase at the beginning of the pubertal growth 
spurt. After a final height is reached marker levels decrease to the levels seen in 
adulthood (Szulc et al., 2000). Tsutsumi et al. (2004a) confirm that the changes in 
osteocalcin concentrations in minipigs at this age are the same as in humans. The 
prepubertal stage was not included in the present study, so there is no evidence that 
the miniature pig has the same marker development at this age as they do in humans 
at the same age. At puberty it was, however, clear that osteocalcin increased by 
91%. Puberty is characterised by noticeable changes in linear growth, modifications 
in body composition and reproductive capacity, which are regulated by changes in 
the endocrine milieu. Growth hormone increases two-fold during puberty and insulin-
like growth factor I and its binding protein also increase during puberty. The rises in 
sex steroids, growth hormone and insulin-like growth factor I are crucial for linear 
growth, bone mass and muscle bulk (Federico et al., 2003; Mauras, 2001). Baroncelli 
et al. (2000) observed that growth hormone treatment caused the increase of 
osteobalst and osteoclast activity. The osteocalcin activity at puberty in minipigs 
could, therefore, be due to increased growth hormone concentrations and a rise in 
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sex hormones at this age. Fares et al. (2003) confirmed that all markers of bone 
turnover, which included osteocalcin, increased in girls during puberty and decreased 
toward adult levels in the last Tanner stage. A large increase from 9 to 10 months 
was seen in the present study, followed by an increase of 1.4% and then 1.5% at 12 
and 13 months. If 10 months is seen as a late Tanner stage in the minipig, 
osteocalcin reacts more slowely than it does in humans because concentrations are 
still high at this time. High osteocalcin concentrations are found in the second and 
third Tanner stages in girls (mid-puberty), while boys showed a higher marker at the 
beginning of puberty (Fares et al., 2003). Assuming that female minipigs in the 
present study can be compared with female humans during puberty, the present 
study shows that osteocalcin concentrations are still high at late puberty, unlike those 
in humans, which are high at midpuberty.  
At 12 and 13 months concentrations were still high. If the age assumption of 
Tsutsumi et al. (2004) is correct this would be early adulthood.  In humans, however, 
after a final height is reached marker levels decrease to the levels seen in adulthood 
(Szulc et al., 2000). The levels did not decrease in the equivalently aged minipigs. 
Osteocalcin stayed at high concentration at 12 and 13 months and decreased 47% in 
the 14th month. This study shows that osteocalcin concentrations are still high in early 
adulthood, if age estimations are correct. It could, however, be possible that the 
Göttinger minipig used in Tsutsumi´s study had an earlier growth development 
compared to the minipigs used in the present study. If this is the case, the 
osteocalcin concentration development in Dresdner minipigs is equivalent to the 
concentration development in humans.   
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Diagram 3: osteocalcin concentrations (ng/ml) represented in mean and SD calculated from 
mean and SD of control, OVX and second control group at 9, 10, 12, 13 and 14 
months of age  
 
 
Osteocalcin estrous cycle-related 
 
The pig typically has an estrous cycle duration of 21 days. This can vary from 17-25 
days. The cycle can be divided into four phases: estrus (sexual receptivity; ovulation; 
day 1-3)), metestrus (end of ovulation and beginning of the luteal phase; days 4-7), 
diestrus (luteal phase; day 8-17) and proestrus (follicular phase; day 18-21). Knox et 
al. (2003) measured plasma progesterone during the estrous cycle and found 
baseline concentrations 3 days after the LH peak (LH peak = estrus). Progesterone 
concentrations increased, reaching a peak on day 10 and remained elevated until 
day 14 (mid-late diestrus). Progesterone concentrations decline to a base line over a 
period of 2 days, at luteolysis. Knox et al. (2003) also measured estradiol 
concentrations in pigs. A base line was found during the progesterone elevated 
period. Concentrations increased 5 days before estrus, at estrus and a day after 
estrus. 
All sixteen animals included in this experiment were synchronised during the pre-
castration period. After synchronisation the pigs were all approximately in the same 
stage of cycle which eased working conditions. Blood samples were drawn a day 
after the last hCG application, in the assumed diestrus cycle two weeks later, 
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followed by another extraction a week after this (estrus). The same pattern was 
followed in the following cycle: one extraction in the diestrus cycle stage and one in 
the estrus cycle stage. This pattern of sample extraction was selected to determine 
the cyclic changes of sex hormones (progesterone and estradiol) during the estrous 
cycle of the pig and to determine related changes in bone formation and resorption. 
 
These samples showed that osteocalcin was cycle stage dependant in minipigs. 
Progesterone and osteocalcin concentrations reacted inversely for four extractions 
after the first synchronisation (see diagram 4 and 5).  
 
Diestrus 
 
Week -45 represented the calculated diestrus cycle stage with high progesterone 
concentrations in all three groups (116.0ng/ml, 35.5ng/ml, and 31.7ng/ml). 
Osteocalcin had lower concentrations at this time of extraction in all three groups 
(81.7ng/ml, 88.5 ng/ml and 104.7ng/ml). Week -42 again represented the calculated 
diestrus cycle stage, with high progesterone concentrations in control and the OVX 
groups (28.2ng/ml and 27.6ng/ml). At this extraction time, osteocalcin concentrations 
were again low in all three groups compared to the previous concentrations 
(112.7ng/ml, 114.5ng/ml and 120.2ng/ml) (diagram 4 and 5). 
 
Estrus 
 
Week -47 showed high osteocalcin concentrations in control and OVX groups 
(137.7ng/ml and 207.7ng/ml) where progesterone concentrations had low levels in 
conrol, OVX and second control groups respectively ( 3.5 ng/ml, 4.8ng/ml and 
2.5ng/ml). 
Week -44 represented the estrus cycle stage, again with low progesterone 
concentrations (0.2ng/ml, 1.0ng/ml, and 4.7ng/ml) and higher osteocalcin 
concentrations in all groups (140.1ng/ml, 171.1ng/ml, and 122.3ng/ml) (diagram 4 
and 5).  
 Estradiol and osteocalcin had the same concentration development in the first cycle 
after syncronisation (diestrus) and in the following estrus cycle stage in all three 
groups (see diagram 4 and 6). Week -45 represented the first calculated day of cycle 
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where higher estradiol concentrations were expected. This was not the case here 
(22.0pg/ml, 16.5pg/ml, and 26.7pg/ml). Week -45 and -44, diestrus and estrus 
respectively showed the expected concentration development, high concentrations in 
the estrus cycle stage (33.8pg/ml, 29.2pg/ml, and 38.5pg/ml ) and lower 
concentrations in the diestrus cycle stages (30.3pg/ml, 19.5pg/ml, and 29.0pg/ml).  
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Diagram 4: mean osteocalcin concentrations (ng/ml) in control, OVX and second control, 
pre-castration, sample extraction time in weeks 
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Diagram 5: mean progesterone concentrations (ng/ml) in control, OVX and second control, 
pre-castration, sample extraction time in weeks 
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Diagram 6: mean estradiol concentrations (pg/ml) in control, OVX and second control, pre-
castration, sample extraction time in weeks 
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Chiu et al. (1999) found that osteocalcin did not vary substantially across the cycle in 
humans. No significant correlations were found for estradiol and progesterone with 
osteocalcin in this study. Schlemmer et al. (1993) observed no cyclic changes in 
urinary parameters of resorption or in biochemical markers of bone formation, which 
included osteocalcin. This could not be confirmed in the present study. Osteocalcin 
showed steady cycle fluctuations in the miniature pig (diagram 4, 5, and 6). These 
studies, however, may be contraversial, because other studies have confirmed the 
opposite in humans. Studies have been performed to confirm that markers of bone 
metabolism vary during the menstrual cycle.  De Souze et al. (1997) discovered that 
disturbances in the progesterone production as a result of exercise are not 
associated with a decrease in bone mass. Long follicular phases, are associated with 
decreased estrogen production in the early follicular phase, which are both 
associated with a decline in bone mass. Bone mass was not determined in this study, 
but according to the development of the formation marker osteocalcin, during the 
estrous cycle, an increase in concentrations seemed to be dependent on the 
estradiol concentrations. In the present study no correlations were found for 
osteocalcin and estradiol in the OVX and in the second control group. This could be 
due to the small number of animals included in this study. The control group, 
however, showed an inverse significant correlation in week -41 for osteocalcin and 
estradiol (R=-0.905; p<0.05). This correlation shows that osteocalcin concentrations 
increased, where estradiol concentrations decreased. Each osteocalcin concentration 
measurement is a snapshot of the actual bone metabolism at extraction time. 
Osteocalcin may have been on the verge of decreasing, and was measured exactly 
during the process, whereas estradiol had already reached lower concentrations. 
This could be an explanation for such a correlation. Week -41 represented the 
calculated day 1 of the estrous cycle, which was not mirrored in the estradiol 
concentrations, whereas progesterone concentrations showed low concentrations, 
which may represent the estrus stage or the late metestrus early diestrus cycle stage, 
where estradiol may have slightly higher concentrations. It is therefore possible that 
the animals in this group were in the metestrus cycle stage and the estradiol 
concentrations were not high enough to influence the osteocalcin concentrations.   
Progesterone concentrations showed distinct inverse development with osteocalcin 
(see table 4 and 5). However no correlations were found for osteocalcin and 
progesterone in the OVX and in the second control group. This could also be due to 
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the small animal number included this study. Osteocalcin and progesterone however 
showed a definite significant inverse correlation in week -42 in the control group (R=-
0.934; p<0.05). Haruyama et al. (2002) found a significant positive correlation 
between progesterone and osteocalcin, which suggested that bone forming activity 
also varies depending on the progesterone level during the estrous cycle in rats. 
Although the presence of progesterone receptors and the anabolic effects of 
progesterone have been demonstrated in cells of osteoblastic linage (Eriksen et al., 
1988; Scheven et al., 1992), the role of this sex hormone in bone metabolism is less 
clear than that of estrogen. The present study, however, shows inverse correlations 
between progesterone and osteocalcin, which does not indicate that progesterone, is 
needed for an increase in bone formation. Rats have a different sexual cycle 
compared to that of pigs and the importance of age and bone metabolism in the rat 
should not be forgotten. Haruyama´s study used 10 week old rats. The formation 
marker development during the experimental period could have been due to bone 
growth activity and not due to cycle dependency. This would explain the 
simultaneous high osteocalcin concentrations with high progesterone concentrations.    
 
Unlike the results found in the present study Nielsen et al. (1990c) found the highest 
osteocalcin levels in the luteal period of the menstrual cycle and a significant 
variance of osteocalcin in the menstrual cycle in humans. Hotchkiss and Brommage, 
(2000) however found osteocalcin peaks in the early follicular phase in cynomlgus 
monkeys. 
In the present study the highest osteocalcin concentration were found in the estrus 
cycle stage or in the late follicular period, which confirm the effect of estradiol on 
bone metabolism. Estradiol increases osteoblast activity. 
The high osteocalcin concentrations in week -47 and week -44 (calculated estrus; 
ovulation period or late follicular period) are due to the high estradiol concentrations 
at these times. Hughes et al. (1996) also showed that estrogen causes apoptosis in 
osteoclasts. In the presence of estrogen, osteoblasts produce transforming growth 
factor-beta 1 (TGF-beta). Anti TGF-beta antibody inhibited TGF-beta and estrogen. 
This may indicate that TGF-beta might mediate osteoclast apoptosis. The presence 
of estradiol allows an increased osteoblast activity. These high concentrations may 
be a result of a direct effect of estradiol on bone formation. The production of 
collagen type I extra-cellular matrix occurs primarily within the first 10 days of the 
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osteoblast development sequence (Stein et al., 1990). Because osteoblasts exhibit 
estrogen receptors and estrogens are able to enhance collagen synthesis (Komm et 
al., 1988; Eriksen et al., 1988), high osteocalcin concentrations may be due to the 
direct effect of estrogen on bone formation. Zitterman et al. (2000) confirmed that the 
normal menstrual cycle in young women is associated with monthly fluctuations of 
bone turnover which are most probably estradiol related.  
 
The estradiol concentration in week -47 could have been higher in all three groups. 
The reason for its not reaching the expected peak could be the fact that the sample 
extraction in week -47 was the first, directly after the last hormone application at 
synchronisation. Estradiol peaks could have been reached two to three days later. 
For more precise hormone concentration development samples should have been 
extracted at lesser intervals. 
Week -45 and -42 each represent a clear progesterone peak in the control and OVX 
group (diestrus) (see diagram 5). These confirm the cycle course during the 
experiment. The second progesterone peak in the second control group was found a 
week later. This could be due to cycle fluctuations after synchronisation. Each animal 
can deviate approximately 2 to 3 days from one another. The longer the interval after 
the last the hormone application, the greater the cycle deviation between the 
animals. 
Taking this into consideration, the last three extractions showed clear inverse 
behaviour between osteocalcin and progesterone in the OVX and the second control 
group. The cycle-related changes for osteocalcin are maintained even though the 
extraction intervals were not as regular and had longer intervals compared to the 
weeks before. The concentration development of the control group during this time 
cannot be explained. 
These results confirm that osteocalcin concentrations increase with an increase in 
estradiol concentrations, so estradiol stimulates formation in miniature pigs.  
The bone formation marker osteocalcin has age-related changes and cycle-related 
changes in miniature pigs. This should be considered in further studies which include 
measuring the bone metabolism marker osteocalcin in the miniature pig. Bone 
turnover is higher at a younger age (puberty, 3-11) and decreases in adulthood, 
which was the equivalent of 14 months in this study. Additional fluctuations of this 
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marker occur during puberty and adulthood. Fluctuations during adulthood are cycle- 
stage dependant 
 
5.3.2 Crosslaps 
 
Age-related changes 
 
In the pre-castration period of the present study an increase in the crosslaps 
concentrations was found between the ages of 9 and 10 months (puberty). At the age 
of 12 months these high concentrations decreased and stayed at low concentrations 
in all three groups (see diagram 7).  
Many studies in humans have confirmed that the marker crosslaps, a bone resorption 
marker has age-related changes; Van der Sluis et al. (2002) found significant 
differences between three pubertal stages for cross-linked telopeptides of type I 
collagen in humans. The concentrations were higher in the earlier Tanner stages 
than they were here in the equivalently aged miniature pigs. Peichl et al. (2001) 
found rather poor associations between age of patients and markers of bone 
turnover, which include serum crosslaps. This could have been due to the fact that 
most of the patients included in the study were adults with fully developed bones. 
Gajewska et al. (2005) found peak concentrations for serum crosslaps and bone 
specific alkaline phosphatase in Polish children during puberty. After puberty a 
gradual lowering in both markers was observed. The data collected in this study 
confirms that the miniature pig also shows age-related changes for the resorption 
marker crosslaps. Crosslaps increased up until the age of 10 months and then 
showed a constant decrease in concentrations (see diagram 7). To determine the 
status of the bone, however, it is necessary to determine formation markers with 
resorption markers. Formation and resorption are coupled processes in the bone 
metabolism. If osteocalcin and crosslaps are determined at the same time, as they 
were in this study, it is conspicuous that osteocalcin and crosslaps have shifted 
responses to age. Osteocalcin had a lethargic reaction and stayed at higher 
concentrations for a longer period of time (12 to 13 months), while crosslaps 
decreased rather quickly at the third extraction at the age of 12 months. The 
decrease in concentrations for this marker at this point of time were very clear 
(diagram 7), whereas osteocalcin concentrations showed only slight increases at 12 
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and 13 months (diagram 3). Normally, a temporal and spatial coupling exists between 
resorption and formation in the skeleton, with resorption preceding formation during 
the remodelling sequence (Parfitt, 1982). The increase in bone formation can 
therefore be caused by an increase in bone resorption. 
Limitations in serum markers such as tissue specificity should, however, be kept in 
mind. Type I collagen is not only present in bone, but it is also found in skin, 
ligaments, cartilage and synovia. Cross-linked telopeptides of type I collagen is 
released when collagen type I undergoes degradation. This could be a product 
deriving from sources other than bone. Huber et al. (2003) compared the established 
urine marker deoxypyridinoline, related to creatinine with plasma cross-linked 
telopeptides of type I collagen and found that if plasma was extracted from fasting 
patients in the morning, cross-linked telopeptides of type I collagen seemed to 
indicate bone resorption in women on hormone replacement therapy correctly to 
normal. According to these results plasma (or serum) seemed to be preferable. The 
test used in this study was validated for porcine serum and results showed 
fluctuations expected. This could indicate that serum as a medium for examination 
and crosslaps as a parameter for bone resorption are useful to express features of 
the bone metabolism in miniature pigs. 
Almost all bone markers show diurnal variation. Qvist et al. (2002) examined the 
diurnal variation in serum crosslaps and found maximum levels in the morning at 5 
a.m. and minimum levels in the afternoon at 2 p.m. The study showed that the only 
parameter which had a pronounced influence on the circadian variation was fasting, 
which reduced the circadian variation to about one fourth. This was taken into 
account in this study. During the present study, all animals fasted before sample 
extraction. Each extraction was performed at 9 a.m. in the morning, so the maximum 
levels in the diurnal rhythm were not expected, if the diurnal rhythm of the miniature 
pig were the same as that in humans. Each extraction was performed at the same 
time of day. If there was a definite diurnal rhythm in the miniature pig for this marker, 
concentration differences due to this circadian rhythm would have been excluded, 
due to the constant pattern of extraction. A circadian rhythm for cross-linked 
telopeptides of type I collagen was not only found in humans but also in dogs 
(Ladlow et al., 2002). If other animals have a circadian rhythm for this marker, the 
possibility exists that miniature pigs could also have a circadian rhythm. To determine 
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this, further studies have to be done with the minipig. Blood samples should be taken 
in repeated hourly intervals and daily to determine a rhythm of this marker.   
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Diagram 7: crosslaps concentrations (pg/ml) represented in mean and SD calculated from 
mean and SD of control, OVX and second control group at 9, 10, 12, 13 and 14 
months of age  
 
 
Crosslaps estrous cycle-related 
 
Crosslaps concentrations decreased from week -47 to week -45 in all groups. These 
increased two weeks later in week -44 (see diagram 8, 9, and 10).  Like osteocalcin, 
crosslaps concentration development was opposite to that of progesterone at these 
extraction times.  
The first synchronisation ended in week -47. The expected high estradiol 
concentrations in the estrus cycle stage were not found in week -47 in any of the 
groups. The reason for not reaching the expected peak could be due to the fact that 
the sample extraction in week -47 was the first, directly after the last hormone 
application at synchronisation. Estradiol peaks could have been reached two to three 
days later. For more precise hormone concentration development, samples should 
have been extracted in smaller intervals. The sample extraction in very short intervals 
was not possible, due to the fact that so many samples had already been extracted 
during this trial. Each extraction was done directly from the V. jugularis, which caused 
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haemorrhaging after each extraction and difficulty at the next extraction, when 
intervals were too short.  
 
 
Estrus 
 
With these missing high estradiol concentrations in week -47 (diagram 10), higher 
resorption markers (diagram 8) were expected if the resorption marker, crosslaps has 
the same cyclic fluctuations in the minipig as other resorption markers have in 
humans. Chiu et al. (1999) stated that deoxypyridinoline, a resorption marker, has 
higher concentrations in the follicular phase of the cycle. This could also be the case 
with crosslaps concentrations. Week -47 was the calculated day one of the estrous 
cycle. Cycle fluctuations of two to three days should be taken into account. High 
crosslaps concentrations could, therefore, occur at the end of the follicular phase or 
the beginning of ovulation in minipigs. This behaviour was confirmed in the following 
calculated cycle stages in week -44, calculated day 1 of the cycle (ovulation or with 
cycle fluctuations late follicular stage), low progesterone concentrations and high 
estradiol concentrations, with higher crosslaps concentrations (diagram 8, 9, 10) 
 
Diestrus 
 
Low crosslaps concentrations were found in week -45 in the diestrus cycle stage 
(calculated day 14). Progesterone concentrations were high at this time in all three 
groups (see diagrams 8, 9, and 10). This confirmed the calculated cycle stage. Gorai 
et al. (1995) found low concentrations of urinary resorption marker N-telopeptide in 
the luteal phase in humans. This was confirmed in this study using minipigs. Day 14 
represents the beginning of the corpus luteum degradation period in the cycle of the 
pig where progesterone concentrations are still high. The estradiol concentrations 
however also seemed to be high at this time, but did not peak (see diagram10). 
These can be high at approximately day 7-9 of the diestrus cycle of a pig. This data 
confirms the early luteal phase. Crosslaps concentrations are therefore low in the 
luteal phase in pigs. Week -42 diestrus calculated day 15, luteal phase, with a 
decrease in crosslaps concentrations in the OVX group and simultaneous high 
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progesterone concentrations (see diagram 8, 9 and 10). Serum crosslaps therefore 
do have cyclic fluctuations in minipigs.  
Osteocalcin and crosslaps seem to have cyclic fluctuations at the same time. It is 
important to remember that bone formation rate changes follow changes in bone 
resorption, due to the coupling of formation and resorption in bone remodelling units. 
As seen in the age-related change, crosslaps is a marker that reacts rather promptly 
to changes, whereas osteocalcin reacts lethargically. Keeping this in mind and the 
fact that samples were taken in weekly and larger intervals, it could be possible that 
osteocalcin peaks represented in this study were not final peaks. The osteocalcin 
concentrations could have reached higher concentrations after or between the 
examined blood sampling points of time, which were not represented in this study. To 
confirm this further studies are needed, with shorter intervals between extraction 
times.  
Hughes et al. (1996) showed that estrogen causes apoptosis in osteoclasts. In the 
presence of estrogen, osteoblasts produce transforming growth factor-beta 1 (TGF-
beta). Anti TGF-beta antibody inhibited TGF-beta and estrogen. This may indicate 
that TGF-beta might mediate osteoclast apoptosis. Marie et al. (2000) state that 
soluble factors, which include bone morphometric proteins, leptin and TGF-beta, can 
modulate differentiation of mesenchymal stem cells to osteoblasts, chondrocytes or 
adipocytes. This would be one of the reasons why formation and resorption would not 
occur at the same time.  
Other factors such as interleukin 1 and interleukin 6 are known to play an important 
role in bone resorption. These factors also fluctuate during the menstrual cycle in 
humans (Cannon and Dinarello, 1985; Angstwurm et al., 1997). Interleukin 1 is 
known to stimulate bone resorption and perhaps formation. Pacifici et al. (1987) 
found that monocytes in postmenopausal osteoporotic patients (estrogen 
concentrations are low) produced more interleukin-1 than subjects in the control 
group. This could also be possible in minipigs. Interleukin 1 and 6 were not analysed 
in this study, but this would be an interesting prospect to evaluate in further studies. 
 
Week -47 showed inverse correlations for crosslaps and estradiol in the OVX group 
(R= -0.879; p<0.05). Zittermann et al. (2000) demonstrated that resorption marker 
deoxypyridinoline was inversely associated with estradiol, especially when estradiol 
was in the lower physiological range. Uebelhart et al. (1991) demonstrated that 
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estrogen had profound effects on collagen cross-link excretion. Pyridinoline and 
deoxypyridinoline concentrations in postmenopausal women returned to 
premenopausal values after 6 months of estrogen containing hormone replacement 
therapy. This may also be the case in minipigs, but definite evidence in not displayed 
in the present study. The estradiol concentrations in week -47 were expected to be 
high after synchronisation. The estradiol test used in this study was a test for human 
serum and was not validated for porcine serum and results should be evaluated with 
caution. The animals in the OVX group could have reached the expected higher 
estradiol concentrations two to three days later. To confirm the inverse correlation of 
these two parameters, further studies are needed, with larger animal numbers, and 
smaller intervals between extraction times, to demonstrate the resorption processes 
in bone metabolism and its relationship to estradiol concentrations in the minipig. 
Week -44 showed significant inverse correlations in the OVX group for crosslaps and 
progesterone (R=-0.881; p<0.05). This was the calculated day 1 of the estrous cycle. 
Progesterone concentrations were low, with simultaneous high crosslaps 
concentrations. If progesterone has a definite function in bone resorption, it is not 
clear. The question of whether progesterone stimulates formation as a result of 
increased resorption must be evaluated further in follow up studies. 
 
The lower progesterone concentrations in week -42 (diagram 9) in the second control 
group could indicate the beginning of the follicular stage, which would explain the 
high crosslaps concentrations. Simultaneous high crosslaps and high progesterone 
concentrations in the control group could be due to the representation in mean 
concentrations. The standard deviation in this group at this extraction time was very 
high for crosslaps.  
The last three extraction weeks in the pre-castration period showed that the 
crosslaps and progesterone seemed to have the same concentration development in 
the OVX and the second control group. Week -41 showed a decrease in estradiol 
concentrations with progesterone concentrations that did not peak. This was also 
calculated as day 1 of the estrous cycle. The hormone concentrations however 
indicate the metestrus stage (approximate day 3-4) or day 16-18, the end of the 
diestrus beginning of the proestrus cycle stage (late luteal phase or beginning of the 
follicular phase). At this extraction time in the control group, estradiol and crosslaps 
showed a significant inverse correlation (R= -0.971; p<0.001). Crosslaps 
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concentrations were between 300-400 pg/ml. Comparing these concentrations to the 
previous concentrations, no definite conclusion can be made about cycle-related 
concentration changes.  The last two extraction points of time were very far apart. 
This could cause imprecise cycle stage assumption without estradiol concentration 
backup. In week -19 progesterone peaks in OVX and second control group suggest 
that these groups were in the diestrus cycle stage. Crosslaps concentrations seemed 
to be at a peak. To interpret definite cycle fluctuations in markers, extraction times 
should be closer to one another and more frequent.  
This study showed that crosslaps had cyclic fluctuations in minipigs. High crosslaps 
concentrations were found in the estrus cycle stage or late follicular cycle stage; 
whereas low crosslaps were found in the luteal phase. This study did not 
demonstrate a chronological difference between formation and resorption marker 
cyclic fluctuations. Remodelling is a temporal and spatially constrained process in 
which bone is subsequently removed and then replaced by new bone. In skeletally 
mature animals, bone resorption and bone formation are balanced during 
remodelling so there is no net change in bone mass (Allen, 2003). The data of this 
study does not show a precise separation of remodelling and formation processes. 
This could be due to the large intervals between sample extractions and the reactivity 
of each marker measured. The formation and resorption processes, however do 
seem to be balanced, which was expected in adult animals.  
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Diagram 8: mean crosslaps concentrations (pg/ml) in control, OVX and second control 
groups pre-castration, sample extraction time in weeks 
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Diagram 9: mean progesterone concentrations (ng/ml) in control, OVX and second control 
groups pre-castration, sample extraction time in weeks 
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Diagram 10: mean estradiol concentrations (pg/ml) in control, OVX and second control pre-
castration, sample extraction time in weeks 
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Correlations between crosslaps and osteocalcin in the pre-castration period 
 
Peichel et al. (2001) found correlations between osteocalcin and crosslaps in 
humans. Analysing correlations over all groups for all extraction times, these 
correlations were not found. Analysing correlations in each group for each extraction 
time, a significant positive connection was found in the control (p<0.001; R=0.373) 
and second control groups (p<0.05; R=0.290) during the pre-castration period. These 
results confirm that the formation and resorption processes are coupled processes, 
which are balanced in the physiological bone metabolism. This was expected in 
healthy adult minipigs. Further correlation analysis was done at each extraction time 
and additional connections were found for these two parameters. The control group 
showed significant correlations in week -47 and -41 respectively (p<0.05; R=0.917); 
(p<0.01; R=0.96) and the OVX group in week -58 (p<0.05; R=0.892). The reason 
why the correlations between these parameters were only found at these specific 
times could be;  the fact that the crosslaps and osteocalcin concentrations measured 
at each extraction time are a snapshot of the actual bone metabolism at the particular 
time of extraction. Formation and resorption processes continued changing during 
extraction between each animal.   
 
 
5.4 Development of biochemical markers in the post-castration period 
5.4.1 Osteocalcin 
 
The biochemical marker, osteocalcin was examined at and after ovariohysterectomy 
to determine the effect of ovariohysterectomy on this marker.  Blood samples were 
extracted at ovariohysterectomy and at two week intervals up to and including eight 
weeks after operation in all groups. The osteocalcin concentrations showed an 
increase 4 weeks after the intervention in the OVX group. These high concentrations 
stayed constant up until 8 weeks (diagram 11). The osteocalcin concentrations in the 
control and second control groups stayed almost constant from week 0 to week 6. 
Week 8 showed a slight increase in both groups, which did not exceed the 
concentrations found in the OVX group. 
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Diagram 11: Osteocalcin concentrations ng/ml (mean and SD) at extraction times 0, 2, 4, 6, 8 
weeks; post-castration period in control, second control and OVX group 
 
Dresner-Pollak et al. (1996) found negative correlations between formation, 
resorption markers and bone mass. An increase in bone turnover in humans can 
cause a loss in bone mass. Conclusions can therefore be drawn from bone markers 
about bone density and fracture risk (Looker et al., 2000). 
Many studies have been done in humans and animals, which confirm the increase of 
bone turnover after ovariohysterectomy and ovariectomy; Peris et al. (1999) 
determined biochemical markers of bone metabolism after surgical menopause in 
humans. These markers included formation marker osteocalcin. Three months after 
the operation all formation and resorption markers determined in this study 
increased. Itoh et al. (2002) did a similar study with mature cynomolgus monkeys. 
These were ovariectomised and evaluated over a period of 16 months. Serum 
osteocalcin values increase 168% compared to sham operated animals. The 
ovariectomised cynomolgus monkey is a recognised animal model used as a model 
in the human osteoporosis research. Legrand et al. (2003) ovariectomised seven old 
cynomolgus monkey and used thirteen age matched sham controls to demonstrate 
that reliable biochemical parameters are available to determine formation and 
resorption activity in the bone. Osteocalcin correlated highly with a decrease in bone 
mineral density induced by ovariectomy. Newton et al. (2004) determined the effects 
of ovariectomy on the trabeculae of ovine iliac bone. Blood samples were draw at 
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ovariectomy and in three month intervals up until twelve months. Osteocalcin 
concentrations were significantly higher in the OVX groups compared to the controls. 
Lukacs et al. (2006) demonstrated that women in early menopause years (40-52 
years) had elevated osteocalcin values.  
In this study the increase of the formation marker osteocalcin 4 weeks after 
ovariohysterectomy indicates that osteoblasts may have been activated, due to an 
imbalance in formation and resorption processes. The ovariohysterectomy caused an 
estrogen depletion (diagram 12), which triggered an increase in resorption and bone 
loss. This was followed by higher bone formation rates. The same scenario is found 
in the post menopausal osteoporosis.  
Diagram 12 shows a decrease in estadiol concentration two weeks post operation. 
This decrease was significant p< 0.05 for the delta values among the groups for the 
extraction time week 0 and week 2. The area under the curve in the OVX group 
showed a significant difference p< 0.001 compared to the control and the second 
control group. Estradiol concentrations stayed at a minimum after the 2nd week in the 
OVX group, which confirmed the effect of the intervention. The estradiol 
concentrations continued to alternate at higher concentrations in the control and 
second control groups. This showed that the rest of the animals continued their 
estrous cycle.  
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Diagram 12: estradiol concentrations (pg/ml) mean and SD at extraction times 0, 2, 4, 6, 8 
weeks in the post-castration period in control, second control and OVX groups 
 
Progesterone was a further parameter determined, which confirmed the effect of 
castration on the cycle of the animals (diagram 13). Two weeks after OVX 
progesterone concentrations still seemed to be high in the OVX group. This could be 
due to a slow breakdown of progesterone in pigs after anaesthesia. This could have 
been caused by the application of Regumate®, synthetic progesterone, in this group 
before castration, to suppress the estrus cycle stage. In the fourth week after 
operation, progesterone declined and stayed at low concentrations in this group, as 
expected. The control and second control group continued to show fluctuations in 
progesterone concentrations, which were also expected in the cyclic occurrences of 
the pig. 
 
-40
-20
0
20
40
60
80
100
120
140
0  week 2  week 4  week 6  week 8  week
extraction time
pr
og
es
te
ro
ne
 n
g/
m
l
control
second control
OVX
 
Diagram 13: progesterone concentrations (ng/ml) mean and SD at extraction times 0, 2, 4, 6, 8 
weeks in the post-castration period in control, second control and OVX groups 
 
There is an effect of OVX on osteocalcin in minipigs. The absence of significances 
between the two control groups and the OVX group for osteocalcin was due to the 
small number of animals included in this experiment. To determine the effect of 
ovariohysterectomy on the bone mineral density and bone quality, further studies 
have to be performed including other forms of analysis such as DXA and micro-CT.  
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5.4.2 Crosslaps 
 
Like osteocalcin, serum crosslaps were analysed at castration and in two week 
intervals after castration up to and including 8 weeks post-castration (diagram 14). 
Crosslaps concentrations increase 2 and 4 weeks post operation in the OVX group. 
Thereafter concentrations decreased in this group.  
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Diagram 14: Crosslaps concentrations pg/ml (mean and SD) at extraction times 0, 2, 4, 6, 8 
weeks; post-castration period in control, second control and OVX groups 
 
Gaumet et al. (1996) studied the influence of ovariectomy on bone metabolism in 
very old rats and found an increase in bone resorption markers pyridinoline and 
deoxypyridinoline seven weeks after OVX compared to the controls. These rats were 
mature, and therefore had slower bone growth (Patlas et al., 2000). The changes in 
crosslaps concentrations after OVX in the minipig were very prompt and clear in 
comparison to those of the resorption markers in the mentioned study using rats. The 
minipigs were at a mature age, which rules out a high bone turnover due to growth. 
This aspect makes the minipig a convenient model to study postmenopausal 
osteoporosis.  
The absence of estrogen caused an increase in osteoclast activity, post operation. 
Diseases characterized by disorders in bone mass may have disturbances in both 
formation and resorption. These circumstances cause the balance that typifies bone 
remodelling in adult animals to be lost. i.e. increased osteoclastic activity in post 
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menopausal osteoporosis may be accompanied by an increase, decrease or 
unchanged osteoblastic activity (Civitelli et al., 1988). This increase in osteoclast 
activity was portrayed by the increase in crosslaps activity after operation. This was 
accompanied by an increase of bone formation, osteoblast activity (osteocalcin 
concentrations increased 4 weeks after the intervention) (see diagram 11). Together 
these results show a higher bone turnover after ovariohysterectomy, which makes 
the minipig an interesting model for further studies on osteoporosis. 
 
5.5  The effect of calcium ration on bone metabolism markers 
 
 
To evaluate this effect both control groups were examined in the pre and post-
castration period. The control group received a calcium ration consisting of 0.99% 
calcium, while the second control group received a 0.7% calcium diet.  
The calcium metabolism is regulated by parathyroid hormone, calcitriol (vitamine D 
hormone) and calcitonin. Bone resorption and intestinal calcium absorption are 
regulated by calcitriol (vitamine D hormone) and parathyroid hormone. An increase in 
serum calcium concentrations would result in a decreased production of these two 
hormones and an increase in calcitonin. Calcitonin is the antagonist of parathyroid 
hormone in the bone, but acts synergistically with parathyroid hormone in the kidney, 
causing calcium resorption and phosphorus excretion. One would not expect that the 
calcium in the diet would change the serum calcium values; therefore calcium was 
not determined in the serum in the present study.  
 
In the 2, 4 and 6 week post operation period, serum crosslaps concentrations 
showed a tendency to higher concentrations in the control group, which received 
0.99% calcium diet. Assuming that higher calcium concentrations caused an increase 
in calcitonin concentrations and therefore stopping the effect of parathyroid hormone 
and calcitriol, which would have decreased resorption, which was not the case in 
week 2, 4, and 6. The resorption marker had increased concentrations (diagram 15).  
There was however a decrease in resorption in week 0 and week 8 in this group. No 
definite influence could be seen in the concentration development of this parameter 
in connection with the calcium ration when comparing crosslaps concentrations in 
both control groups in the pre-castration period. The feed was fed during the whole 
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experimental period, so the calcium ration had sufficient time to influence the bone 
metabolism.  
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Diagram 15: Crosslaps concentrations pg/ml (mean and SD) at extraction times 0, 2, 4, 6, 8 
weeks; post-castration period in control and second control groups 
 
Liesegang and Risteli, (2005) investigated the influence of different calcium diet in 
growing dairy goats and sheep. This study showed that serum crosslaps had the 
tendency towards lower concentrations in the groups of animals fed 17.7g calcium 
per day and 18.5g calcium per day. In the present study the control group received a 
0.99% calcium ration, which is equivalent to 9.89g/kg feed. Each animal received a 
daily ration of 550g of feed. The actual calcium ration in the control group was 5.49g 
per day and 3.84g in the second control group. These were very low concentrations 
in comparison to the study described above. This could be the reason for the missing 
or minimal reaction of the resorption markers during the present study.  
Liesegang et al. (1998) found reduced bone formation markers in a group of cows 
that were fed a low calcium diet. High calcium rations however had no effect on 
resorption markers in this study. In the present study osteocalcin showed slightly 
more activity in the second control group (0.7% calcium ration) (diagram 16). This 
was also the case, for the majority of the time in the pre-castration period. Lower 
calcium concentrations would increase in parathyroid hormone and cacitriol 
secretion. This would lead to an increase in bone resorption and intestinal calcium 
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absorption. An increase in formation markers does not indicate increased bone 
resorption. The slight increase in osteocalcin in the second control group could be a 
result that occurred by chance. The difference between the calcium concentrations in 
both control groups was very small. In future studies performed to demonstrate the 
effect of calcium rations on markers of bone metabolism, calcium ration differences 
between the groups should be greater to achieve the expected results.  
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Diagram 16: Osteocalcin concentrations ng/ml (mean and SD) at extraction times 0, 2, 4, 6, 8 
weeks; post-castration period in control and second control groups 
 
Studies such as Mosekilde´s show that calcium restriction in diets can cause bone 
loss; showed that the OVX-minipig on 0.75% calcium showed significant changes in 
remodelling parameters and lead to alterations in bone structure (Mosekilde et al. 
1993). In this study not only calcium restriction, but also the lack of estrogen post 
OVX caused bone loss. In the presented study the difference in calcium rations 
between the two control groups was too small to show a difference in effect on the 
bone markers between these groups, while the effect in the OVX group, who were 
fed the 0.7% ration, was very clear (diagram 11 and 14). 
Scholz-Ahrens et al. (1996) studied the effect of ovariectomy on bone metabolism in 
sows and fed a standard diet of 1.5% calcium. No significant differences were found 
between the OVX and control animals in bone chemical or histological analysis 
neither 12 nor 20 months post OVX in young sows. Multiparous sows had increased 
plasma parathyroid hormone and calcitriol 8 months after operation, while total and 
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bone alkaline phosphatase increased 12 months post OVX. Bone chemical or 
histiological analyses were not affected by OVX 12 and 20 months post OVX.  Due to 
the results of this study, it is clear that the changes after OVX with an ample amount 
of calcium in the daily diet, does not result in osteopenia/osteoporosis. In the present 
study bone markers do not show definite differences between the control group and 
the second control group fed with a calcium diet of 0.99% and 0.7% respectively. It is, 
however not clear if the structure of the bone had changed. No histological analysis 
or micro-CT was performed from the bone. To determine these changes further 
studies have to be performed with these calcium rations. The OVX group received a 
0.7% calcium diet. Resorption and formation markers showed changes post-
castration, which shows that this is a calcium ration that can be used in further 
studies where induced osteopenia is required. 
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6 Summary 
 
Brenda Babel: Investigations on bone metabolism in intact and 
ovariohysterectomised miniature pigs 
 
Biochemical markers of bone metabolism have become a common form of analysis 
for bone metabolism. A number of factors, however, cause fluctuations in these 
parameters such as day-to-day changes, seasonal changes and age. In women, 
studies have confirmed parameter fluctuations during the menstrual cycle (Zittermann 
et al., 2000). Up until now, the coherence hormone status and bone marker activity 
have been scanty in animal models. 
The objective of this study was to examine the dependence of bone marker activity 
on the estrous cycle in the Dresdner miniature pig. The present study included the 
bone formation marker osteocalcin, and bone resorption marker serum crosslaps. 
The estrous cycle dependency was determined by comparing the development of 
marker concentrations with progesterone and estradiol in the respective cycle stages 
of each pig after synchronisation and at particular sampling points of time. 
Furthermore the behaviour of biochemical markers, osteocalcin and crosslaps were 
examined at and after ovariohysterectomy (OVX) to determine the effect of OVX on 
these specific bone markers.  Another aspect of this study was to determine the 
influence of calcium content in the diet on bone metabolism before and after 
castration.  
Sixteen animals were divided into three groups, two control groups and a OVX group. 
One control group received a 0.99% calcium diet, while the OVX and the second 
control group received a 0.7% calcium diet. The animals in the OVX group were 
ovariohysterectomised, while the pigs in the control and the second control groups 
were not manipulated. The trial consisted of two periods; the pre-castration period, 
lasting 65 weeks and a post-castration period lasting 8 weeks. Blood samples were 
drawn and analysed at selected extraction times. 
The bone marker development pre-castration showed age-related and cycle-related 
changes. Osteocalcin showed definite increased concentrations, at the age of 9-13 
months. If 10 months were seen as a late prepubal stage (Tanner stage) in the 
minipig, osteocalcin reacts more slowly in minipigs as it does in humans. Assuming 
that female minipigs in the present study can be compared with female humans 
during puberty, the present study shows that osteocalcin concentrations are still high 
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at late puberty, unlike those in humans, which are high at midpuberty. Crosslaps 
increased up until the age of 10 months and then showed a constant decrease in 
concentrations. This would be the equivalent reaction of resorption markers in 
humans.  
Osteocalcin concentrations increased with an increase in estradiol concentrations, so 
estradiol stimulates bone formation in miniature pigs. The resorption marker serum 
crosslaps also showed cyclic fluctuations. High crosslaps concentrations were found 
in the estrus cycle stage or late follicular cycle stage; whereas low crosslaps were 
found in the luteal phase. 
As was often the case in other studies, the effect of a calcium reduced diet was not 
evident between the control and second control group. Resorption and formation 
markers showed changes post-castration in the OVX group, which shows that this is 
a calcium diet that can be used in further studies where induced osteopenia is 
required. 
Osteocalcin showed a definite concentration increase 4 weeks after castration. 
Serum crosslaps increased 2 weeks post operation. These increased concentrations 
were not significant, which could be due to the small animal numbers included in this 
study. Both markers reacted within a short time after ovariohysterectomy, which is a 
useful aspect for further osteoporosis research. 
This study portrayed the usefulness of the minipig as an animal model, not only for 
further studies on postmenopausal osteoporosis, but also verified the use of 
osteocalcin and serum crosslaps as biochemical parameters of bone metabolism in 
this species, to have age-related and cycle-related fluctuations, which should be 
considered in further studies.   
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7 Zusammenfassung 
 
Brenda Babel: Untersuchungen zum Knochenstoffwechsel am intakten und 
ovariohysterektomierten Miniaturschwein 
 
Die Bestimmung von biochemischen Markern des Knochenstoffwechsels stellt bei 
der Analyse des Knochenstoffwechsels eine weit verbreitete Methode dar. Eine 
Reihe von Faktoren, wie Tageszeit, Jahreszeit und Alter, beeinflussen dabei  diese 
Parameter. Bei Frauen konnte eine Abhängigkeit vom Menstruationszyklus 
nachgewiesen werden (Zittermann et al., 2000). Eine Beeinflussung der 
Knochenmarkeraktivität durch den Hormonstatus wurde für die verschiedenen 
Tiermodelle noch nicht ausreichend untersucht. 
Das Ziel der vorliegenden Arbeit war daher die Untersuchung der Zyklusabhängigkeit 
der Knochenmarkeraktivität an Dresdener Miniaturschweinen. Als Marker für die 
Knochenformation wurde Osteocalcin und als Marker für die Resorption wurden 
Crosslaps im Serum bestimmt. Die Zyklusabhängigkeit wurde durch den Vergleich 
der Veränderungen der Markerkonzentrationen mit der Progesteron- und 
Östradiolkonzentration, im zeitgleich gewonnenen Serum an unterschiedlichen 
Zyklustadien im Anschluss eine Zyklussynchronisation, bestimmt. Zusätzlich wurden 
Veränderungen der Konzentrationen von Osteocalcin und Crosslaps im Zeitraum 
nach Ovariohysterektomie (OVX), zur Ermittlung des Einflusses einer 
Ovariohysterektomie auf die Höhe der Knochenmarker, untersucht. Ein weiterer 
Aspekt der Arbeit war die Untersuchung der Auswirkung unterschiedlicher 
Calciumgehalte der Futterrationen auf den Knochenstoffwechsel vor und nach der 
Kastration. 
Sechzehn Tiere wurden in drei Gruppen, zwei Kontrollgruppen und eine OVX Gruppe 
aufgeteilt. Eine Kontrollgruppe wurde mit einer Futterration die 0.99% Kalzium 
enthielt, gefüttert, während der zweiten Kontrollgruppe und die OVX Gruppe eine 
Futterration mit einem Kalziumgehalt von 0.7% erhielten. Die Tiere der OVX Gruppe 
wurden ovariohysterektomiert, während die Tiere der beiden Kontrollgruppen keinem 
Eingriff unterzogen wurden. Die Untersuchungen wurden getrennt nach der 
Vorkastrationsperiode, die einen Zeitraum von 65 Wochen umfasste, und der 
Nachkastrationsperiode, die einen Zeitraum von 8 Wochen umfasste, ausgewertet. 
An bestimmten Zeitpunkten wurden Blutproben gewonnen und analysiert. 
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Die Knochenmarkerkonzentrationen zeigten während der Vorkastrationsperiode eine 
Alters- und Zyklusabhängigkeit. Die Osteocalcinkonzentration steigt bis zu einem 
Alter von 9-13 Monaten. Wenn eine Alter von 10 Monaten als spätes präpubertales 
Stadium (Tanner stage) des Miniaturschweines angesehen wird, scheinen sich die 
Osteocalcinkonzentrationen beim Miniaturschwein langsamer zu verändern als es 
beim Menschen beschrieben ist. Die Miniaturschweine in dieser Untersuchung 
können in ihrem Entwicklungstand mit Mädchen während der Pubertät verglichen 
werden. Unter dieser Annahme kann man davon ausgehen, dass die 
Konzentrationen von Osteocalcin beim Miniaturschwein, in der Spätpubertät noch 
hoch sind, während sie beim Menschen in der Mitte der Pubertät am höchsten sind 
und dann abfallen. Die Crosslapskonzentration im Serum nimmt bis zum Alter von 10 
Monaten zu, im Weiteren konnte dann aber ein konstanter Abfall der Konzentration 
nachgewiesen werden. Diese Konzentrationsentwicklung entspricht der die beim 
Menschen beschrieben ist.  
Die Osteocalcinkonzentration nimmt mit ansteigender Östradiolkonzentration zu, dies 
lässt darauf schließen, dass Östradiol die Knochenformation stimuliert. Die 
Knochenmarker Crosslaps zeigten ebenfalls zyklusabhängige Konzentrations-
veränderungen. Hohe Crosslapskonzentrationen konnten im Östrus oder im 
Proöstrus nachgewiesen werden, während in der Lutealphase niedrige 
Crosslapskonzentrationen im Serum festgestellt werden konnten.  
Wie schon in anderen Studien beschrieben, konnten keine Effekte einer 
kalziumreduzierten Futterration zwischen den beiden Kontrollgruppen festgestellt 
werden. Resorptions- und Formationsmarker reagieren in der Postkastrationsperiode 
in der OVX Gruppe sensitive. Dies zeigt, dass die gefütterte Ration mit einem 
Kalziumgehalt von 0.7% in Versuchen zur Erzeugung einer Osteoporose in 
Miniaturschweinen als Futterration geeignet erscheint.  
Die Osteocalcinkonzentration stieg in der vierten Woche nach der Kastration an. Die 
Serum Crosslapskonzentration stieg zwei Wochen nach der Kastration an. Diese 
Anstiege waren nicht signifikant, was mit der kleine Tierzahl in der vorliegenden 
Arbeit zusammenhängen könnte. Beide Marker reagierten in einem sehr kleinen 
Zeitabschnitt nach der Ovariohysterektomie, was für die Osteoporoseforschung sehr 
nützlich sein kann.  
Die vorliegende Arbeit zeigt auf, dass das Miniaturschwein ein geeignetes Modell zur 
postmenopausalen Osteoporoseforschung darstellt. Die Osteoclacin und 
Zusammenfassung 
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Crosslapskonzentration als Marker für den Knochenstoffwechsel folgt bei dieser 
Spezies einem alters- und zyklusabhängigen Verlauf. Dies muss bei weiterführenden 
Studien berücksichtigt werden. 
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